{"PMC7516365": [["Einleitung", [["Einleitung", "CHEMICAL", 0, 10], ["Einleitung", "CHEMICAL", 0, 10]]]], "PMC7429931": [["THE SITUATION THUS FARAs soon as the first local cases of coronavirus disease 2019 (COVID-19) were reported, the governments of the islands were quick to take decisive measures, choosing to close their airspace and implement the necessary mitigation measures.(3) As of now Bonaire has 2 positive cases (308 tested), Saba 3 positive cases (125 tested), and Statia 2 positive cases (17 tested).(4-5) All three pre-emptively closed off their borders, with the first case reported on April 16th, April 12th and March 31st respectively.", [["coronavirus disease", "DISEASE", 58, 77], ["coronavirus", "ORGANISM", 58, 69], ["airspace", "MULTI-TISSUE_STRUCTURE", 202, 210], ["coronavirus disease", "PROBLEM", 58, 77], ["COVID", "TEST", 84, 89], ["the necessary mitigation measures", "TREATMENT", 225, 258], ["Saba", "TEST", 316, 320], ["Statia", "TEST", 356, 362], ["coronavirus disease", "OBSERVATION", 58, 77], ["airspace", "OBSERVATION", 202, 210]]], ["Cura\u00e7ao, as of now, has 21 confirmed cases (1100 tested, 1 by death) since the first reported case on March 12th with most of these \u201cimported cases\u201d involving people who were visiting or residents who arrived from abroad.", [["death", "DISEASE", 62, 67], ["people", "ORGANISM", 159, 165], ["people", "SPECIES", 159, 165]]], ["In both St. Martin and Aruba, however, at one point the virus was spreading locally within the community with 77 (450 tested, 15 deaths) and 101 cases (2150 tested, 3 deaths) respectively registered since the first reported cases on the 1st and 13th of March 2020.(7-8) (Table 1)THE SITUATION THUS FARThe local governments took action before local transmission of the virus was confirmed on the islands and the chosen measures can be considered adequate for the benefit of public health and also courageous as the entire economy would be shut down as a result.", [["deaths", "DISEASE", 129, 135], ["deaths", "DISEASE", 167, 173], ["St. Martin", "ORGANISM", 8, 18], ["the virus", "PROBLEM", 52, 61], ["the virus", "PROBLEM", 364, 373], ["virus", "OBSERVATION", 56, 61], ["virus", "OBSERVATION", 368, 373]]], ["In contrast, during this same period soccer matches were still being played in Spain and Italy, and carnival was celebrated in the Netherlands despite news that the virus was present in Europe.", [["the virus", "PROBLEM", 161, 170], ["virus", "OBSERVATION", 165, 170]]], ["This dilemma between public health measures and the economy was observed in most countries, followed by unprecedented repercussions.", [["public health measures", "TREATMENT", 21, 43]]], ["The islands were no exceptions in this as the restrictive measures, while effective, also led to much chagrin among the population, requiring repeated press conferences by the local governments to explain the need for these measures.SCARCITY IN HEALTHCARE EQUIPMENT AND PERSONNELThe overriding aim is to ensure that the local healthcare capacity is not overburdened and specifically that there are never more patients that require ventilatory support than there are suitable intensive care unit (ICU) beds.(9) On average for Europe, Asia and the U.S., the number of these beds are respectively 0.12, 0.04 and 0.28 per 1,000 people, with considerable variations even between regions with the same World Bank classification.", [["patients", "ORGANISM", 409, 417], ["people", "ORGANISM", 624, 630], ["patients", "SPECIES", 409, 417], ["people", "SPECIES", 624, 630], ["these measures", "TREATMENT", 218, 232], ["ventilatory support", "TREATMENT", 431, 450], ["islands", "OBSERVATION", 4, 11], ["no exceptions", "UNCERTAINTY", 17, 30], ["restrictive", "OBSERVATION", 46, 57]]], ["Germany, for example, has 6.9 times more ICU beds than Portugal.(10,11) In comparison, on Cura\u00e7ao, Aruba, Bonaire, and St. Martin there are respectively 0.05, 0.12, 0.15, and 0.073 beds per 1,000 people.", [["St. Martin", "ORGANISM", 119, 129], ["people", "ORGANISM", 196, 202], ["people", "SPECIES", 196, 202]]], ["The two smaller islands have no ICU.SCARCITY IN HEALTHCARE EQUIPMENT AND PERSONNELWhile flattening the curve is the goal, many countries are also increasing their ICU capacity.", [["PERSONNELWhile flattening the curve", "PROBLEM", 73, 108], ["two", "OBSERVATION_MODIFIER", 4, 7], ["smaller", "OBSERVATION_MODIFIER", 8, 15], ["islands", "OBSERVATION", 16, 23], ["no", "UNCERTAINTY", 29, 31]]], ["While the islands can convert the respirators used in their operating rooms, they have no military or navy to provide additional ventilators and depend on external support to alleviate their scarcity of employees.", [["additional ventilators", "TREATMENT", 118, 140], ["external support", "TREATMENT", 155, 171], ["islands", "OBSERVATION", 10, 17]]], ["Twelve ICU unit beds, including ventilators, personal protective equipment (PPE), and personnel arrived in St. Martin in March, whereas the other islands will receive aid later if needed.SCARCITY IN HEALTHCARE EQUIPMENT AND PERSONNELThe minister of Health of Cura\u00e7ao announced that the Netherlands would be financing the wages of 102 medical personnel from the U.S. and Cuba if Cura\u00e7ao financed their stay.(12)SCARCITY IN HEALTHCARE EQUIPMENT AND PERSONNELThe question is, how big of a burden will the disease be on the islands if left unmitigated?", [["(12)SCARCITY", "CHEMICAL", 406, 418], ["ventilators", "TREATMENT", 32, 43], ["the disease", "PROBLEM", 498, 509], ["left", "ANATOMY_MODIFIER", 531, 535]]], ["The Imperial College reports a strong correlation between the gross domestic product (GDP) per capita of a country and its population\u2019s underlying demography.(10) They argue that HICs tend to have a bigger proportion of the population who are above 65 years of age and therefore, have a higher incidence of severe disease and hospitalization.", [["HICs", "CANCER", 179, 183], ["severe disease", "PROBLEM", 307, 321], ["severe", "OBSERVATION_MODIFIER", 307, 313], ["disease", "OBSERVATION", 314, 321]]], ["Although Aruba, Cura\u00e7ao and St. Martin are officially classified as HIC, there is a big difference between their respective GDP per capita (16,778 USD, 17751 USD, and 22,047 USD) and, for example other HICs such as the Netherlands (53,024 USD) or Italy (34,483 USD).(13,14) Despite this gap, between 13 to 17% of the population on each of these islands is >65 years old, only slightly lower than the Netherlands (19%) and Italy (23%).(15-19)SCARCITY IN HEALTHCARE EQUIPMENT AND PERSONNELBased on current data, older adults who have severe underlying medical conditions are at a higher risk for severe illness from COVID-19.(20,21) The most recent census on Cura\u00e7ao (2011) revealed that at least 27.4% of the residents have one or more chronic diseases and/or disorders.(22) According to the WHO STEPwise Approach Survey (STEPS) conducted in Aruba, obesity, hypertension and diabetes were the most common diseases reported, affecting 77.1%, 40.7% and 5.4%, respectively, of the population.(23) Non-communicable diseases (NCDs), primarily cardiovascular disease and cancer, are responsible for 79% of deaths in Cura\u00e7ao and 85% in Aruba.(24) With both an aging population and a high incidence of NCDs, the islands are at a high risk of large impact from COVID-19.AN ECONOMIC DISASTERThe economies of the islands are for a large part, if not solely, dependent on tourism.", [["cardiovascular", "ANATOMY", 1037, 1051], ["cancer", "ANATOMY", 1064, 1070], ["GDP", "CHEMICAL", 124, 127], ["illness", "DISEASE", 601, 608], ["chronic diseases", "DISEASE", 735, 751], ["obesity", "DISEASE", 848, 855], ["hypertension", "DISEASE", 857, 869], ["diabetes", "DISEASE", 874, 882], ["Non-communicable diseases", "DISEASE", 993, 1018], ["NCDs", "DISEASE", 1020, 1024], ["cardiovascular disease", "DISEASE", 1037, 1059], ["cancer", "DISEASE", 1064, 1070], ["deaths", "DISEASE", 1099, 1105], ["Cura\u00e7ao", "DISEASE", 1109, 1116], ["NCDs", "DISEASE", 1193, 1197], ["GDP", "CHEMICAL", 124, 127], ["St. Martin", "ORGANISM", 28, 38], ["GDP", "SIMPLE_CHEMICAL", 124, 127], ["adults", "ORGANISM", 516, 522], ["cancer", "CANCER", 1064, 1070], ["this gap", "PROBLEM", 282, 290], ["severe underlying medical conditions", "PROBLEM", 532, 568], ["severe illness", "PROBLEM", 594, 608], ["COVID", "TEST", 614, 619], ["more chronic diseases", "PROBLEM", 730, 751], ["disorders", "PROBLEM", 759, 768], ["obesity", "PROBLEM", 848, 855], ["hypertension", "PROBLEM", 857, 869], ["diabetes", "PROBLEM", 874, 882], ["the most common diseases", "PROBLEM", 888, 912], ["Non-communicable diseases", "PROBLEM", 993, 1018], ["primarily cardiovascular disease", "PROBLEM", 1027, 1059], ["cancer", "PROBLEM", 1064, 1070], ["Cura\u00e7ao", "TEST", 1109, 1116], ["NCDs", "PROBLEM", 1193, 1197], ["COVID", "TEST", 1251, 1256], ["slightly", "OBSERVATION_MODIFIER", 376, 384], ["lower", "OBSERVATION_MODIFIER", 385, 390], ["more", "OBSERVATION_MODIFIER", 730, 734], ["chronic", "OBSERVATION_MODIFIER", 735, 742], ["diseases", "OBSERVATION", 743, 751], ["obesity", "OBSERVATION", 848, 855], ["hypertension", "OBSERVATION", 857, 869], ["diabetes", "OBSERVATION", 874, 882], ["Non-communicable", "OBSERVATION_MODIFIER", 993, 1009], ["diseases", "OBSERVATION", 1010, 1018], ["cardiovascular disease", "OBSERVATION", 1037, 1059], ["cancer", "OBSERVATION", 1064, 1070], ["aging", "OBSERVATION", 1152, 1157], ["NCDs", "OBSERVATION", 1193, 1197], ["large", "OBSERVATION_MODIFIER", 1233, 1238], ["impact", "OBSERVATION", 1239, 1245], ["ECONOMIC", "OBSERVATION_MODIFIER", 1263, 1271], ["DISASTER", "OBSERVATION", 1272, 1280], ["economies", "OBSERVATION_MODIFIER", 1284, 1293], ["islands", "OBSERVATION", 1301, 1308]]], ["Emsley Tromp, former director of the Central Bank of Cura\u00e7ao and St. Martin, estimates that the GDP of the islands may contract by 15 to 25%.(25) The Minister of Finance, Economic Affairs, and Culture of Aruba, Ms. Xiomara Maduro, expects the GDP of the island to decline with 44,4%.", [["Central", "ANATOMY_MODIFIER", 37, 44]]], ["The stress scenario analysis of S&P Global puts Aruba and Cura\u00e7ao in respectively the 1st and 11th place of nations with the most affected GDP due to the loss of tourism as a result of the COVID-19-crisis.(26)AN ECONOMIC DISASTERFurthermore, other sectors and industries that are dependent on the import of supplies have also been affected.", [["GDP", "CHEMICAL", 139, 142], ["(26)AN", "CHEMICAL", 205, 211], ["GDP", "SIMPLE_CHEMICAL", 139, 142], ["The stress scenario analysis", "TEST", 0, 28], ["Aruba", "TEST", 48, 53], ["Cura\u00e7ao", "TEST", 58, 65], ["the most affected GDP", "PROBLEM", 121, 142], ["the loss of tourism", "PROBLEM", 150, 169], ["the COVID", "TEST", 185, 194], ["crisis", "PROBLEM", 198, 204], ["dependent", "OBSERVATION_MODIFIER", 280, 289]]], ["The Cura\u00e7ao business association (VBC) estimates that 45% of the population will lose their jobs, accounted for by the virtual stop of tourism-related industries.(27) To worsen matters, the majority of the islands were in a recession before the pandemic, with tourism being the only sector that was performing well.", [["islands", "OBSERVATION", 206, 213]]], ["The island of St. Martin is still struggling with the recovery following Hurricane Irma in 2017, with the damages caused by the hurricane being in the billions of U.S. dollars.", [["St. Martin", "ORGANISM", 14, 24], ["the damages", "PROBLEM", 102, 113], ["island", "OBSERVATION_MODIFIER", 4, 10], ["St. Martin", "OBSERVATION", 14, 24]]], ["Following the hurricane, both the French and Dutch governments provided much needed financial aid to the island, yet the challenges the governments face for reconstruction are particularly difficult.", [["Dutch governments", "TREATMENT", 45, 62], ["financial aid", "TREATMENT", 84, 97], ["reconstruction", "TREATMENT", 157, 171]]], ["Tahseen Sayed, the World Bank country director for the Caribbean, stated that because of the small size of the island (88 sq. km), almost every citizen was directly impacted.(28) Similarly, Cura\u00e7ao had been battling its own economic decline due to the closure of the local oil refinery, which led to an excessively high unemployment rate of 21%.(29) With this pandemic, it faces a worsening of an already weak economy.", [["Cura\u00e7ao", "CHEMICAL", 190, 197], ["oil", "ORGANISM_SUBSTANCE", 273, 276], ["an excessively high unemployment rate", "PROBLEM", 300, 337], ["this pandemic", "PROBLEM", 355, 368], ["small", "OBSERVATION_MODIFIER", 93, 98], ["size", "OBSERVATION_MODIFIER", 99, 103], ["impacted", "OBSERVATION", 165, 173], ["closure", "OBSERVATION", 252, 259], ["excessively", "OBSERVATION_MODIFIER", 303, 314], ["high", "OBSERVATION_MODIFIER", 315, 319], ["unemployment", "OBSERVATION", 320, 332], ["worsening", "OBSERVATION_MODIFIER", 381, 390], ["weak", "OBSERVATION_MODIFIER", 405, 409], ["economy", "OBSERVATION", 410, 417]]], ["SARS-CoV2 causing a massive global recession seems inevitable, and the six islands will be no exception.REGIONAL COMPARISONAll six islands in the Dutch Kingdom are performing well compared to other similarly sized and populated islands in the Caribbean region.", [["SARS", "DISEASE", 0, 4], ["a massive global recession", "PROBLEM", 18, 44], ["massive", "OBSERVATION_MODIFIER", 20, 27], ["global", "OBSERVATION_MODIFIER", 28, 34], ["recession", "OBSERVATION", 35, 44], ["COMPARISONAll", "OBSERVATION_MODIFIER", 113, 126], ["six", "OBSERVATION_MODIFIER", 127, 130], ["islands", "OBSERVATION_MODIFIER", 131, 138], ["Dutch Kingdom", "OBSERVATION", 146, 159], ["similarly", "OBSERVATION_MODIFIER", 198, 207], ["sized", "OBSERVATION_MODIFIER", 208, 213], ["populated", "OBSERVATION_MODIFIER", 218, 227], ["islands", "OBSERVATION", 228, 235], ["Caribbean", "ANATOMY_MODIFIER", 243, 252], ["region", "ANATOMY_MODIFIER", 253, 259]]], ["(Table 2) All islands in the region were spared the dramatic situation seen in countries such as China and Italy.", [["islands", "OBSERVATION", 14, 21], ["region", "ANATOMY_MODIFIER", 29, 35], ["dramatic", "OBSERVATION_MODIFIER", 52, 60]]], ["Most of the islands are now exploring the best ways to loosen the restrictions they imposed and reopen the economy safely.(30) Currently, a mandatory 14-day quarantine for incoming travelers has been implemented in many countries.", [["islands", "OBSERVATION", 12, 19]]], ["With no active cases reported, Aruba and Anguilla are examples of islands that are now allowing non-essential businesses to reopen, although tourism has not yet been reinstated.", [["Anguilla", "ORGANISM", 41, 49], ["active cases", "PROBLEM", 8, 20], ["no", "UNCERTAINTY", 5, 7], ["active", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20], ["Anguilla", "ANATOMY", 41, 49]]], ["In contrast, Antigua and Barbuda still have 25 confirmed cases and planned to reopen commercial flights in June, provided that incoming tourists have been tested negative to COVID-19 on arrival.", [["tourists", "ORGANISM", 136, 144]]], ["For noncitizens, however, an entry will be denied if they have traveled to high-risk countries.(30) In Suriname, all airports and land borders have been closed, and the country is currently experiencing a second wave of positive cases following the recent presidential election.", [["positive cases", "PROBLEM", 220, 234], ["closed", "OBSERVATION", 153, 159]]], ["With a new President after 10 years, the country is expected to encounter daring challenges in fixing its downfallen economy.", [["new", "OBSERVATION_MODIFIER", 7, 10]]], ["(40)REGIONAL COMPARISONThe Region of the Americas as a whole is now dealing with more than three million confirmed cases and has become the new epicenter for the disease.", [["(40)REGIONAL", "CHEMICAL", 0, 12], ["the disease", "PROBLEM", 158, 169], ["Americas", "OBSERVATION_MODIFIER", 41, 49], ["new", "OBSERVATION_MODIFIER", 140, 143], ["disease", "OBSERVATION", 162, 169]]], ["Dr. Carissa Etienne, director of the Pan American Health Organization (PAHO) has called for unity between countries in facing the epidemic, and the Organization has donated 3.4 million testing kits to laboratories in the region.Socio-economic measures ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSFrom a socio-economic perspective, it is clear that down the line, the public health approach for mitigating the impact on (the amount and complications of) COVID-19 patients will surely not suffice.", [["patients", "ORGANISM", 461, 469], ["patients", "SPECIES", 461, 469], ["complications of) COVID", "TREATMENT", 434, 457], ["region", "ANATOMY_MODIFIER", 221, 227]]], ["While suppression measures are maintained, vaccines and drugs are needed to influence the different phases of a global pandemic effectively.", [["suppression measures", "TREATMENT", 6, 26], ["vaccines", "TREATMENT", 43, 51], ["drugs", "TREATMENT", 56, 61]]], ["However, the Dutch Caribbean islands as SIDS have to date, demonstrated their ability to adequately and rapidly react and implement necessary safety measures for a pandemic.", [["SIDS", "DISEASE", 40, 44], ["safety measures", "TREATMENT", 142, 157], ["a pandemic", "PROBLEM", 162, 172]]], ["For example, if the ICUs are at maximum capacity, categorically excluding patients due to a shortage of ventilators may result in perceptions of unfairness within these societies.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["a shortage of ventilators", "TREATMENT", 90, 115], ["unfairness", "PROBLEM", 145, 155]]], ["Therefore, hospitals and governments need to acknowledge this plausible threat and establish and implement policies that fairly allocate these scarce resources.(32) In preparation for future epidemics, closer cooperation between the Dutch Caribbean islands and arguably other Caribbean SIDS would be needed.External cooperation ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSTo date, Spain and Italy, while having the highest death rates in Europe, have received little to no help in the form of personnel or ventilators from the EU, and were late to start the discussions regarding the provision of financial aid.(33) One may, therefore, question if the islands can genuinely rely on outside help.", [["SIDS", "DISEASE", 286, 290], ["death", "DISEASE", 422, 427], ["future epidemics", "PROBLEM", 184, 200], ["ventilators", "TREATMENT", 505, 516]]], ["The islands could benefit from their historical ties as previously constituting one country (the former Netherlands Antilles).", [["islands", "OBSERVATION", 4, 11]]], ["On a healthcare level, this has led to a unique situation where Aruba, Cura\u00e7ao, and St. Martin as independent countries currently provide general healthcare services locally and refer patients abroad to either nearby countries (mostly Colombia) or The Netherlands for specialized care.", [["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192]]], ["Providing some of this specialized care locally divided over the islands has turned out to be unfeasible financially and logistically as some islands stand to benefit more than others.External cooperation ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSA recent study has shown that the trends in life expectancy are more favorable in territories with less political autonomy such as Martinique, Guadeloupe, and the British Virgin Islands.", [["this specialized care", "TREATMENT", 18, 39], ["SIDSA recent study", "TEST", 244, 262], ["Virgin Islands", "OBSERVATION", 419, 433]]], ["However, this is not the case in territories with more political autonomy such as Puerto Rico, the US Virgin Islands, Aruba, and Cura\u00e7ao.(34) The islands are too small to each develop and maintain an adequate, high-quality healthcare system for themselves.", [["Virgin Islands", "OBSERVATION", 102, 116], ["too small to", "OBSERVATION_MODIFIER", 158, 170], ["adequate", "OBSERVATION", 200, 208]]], ["For a small population of up to 160,000 inhabitants for the largest island, there is insufficient demand for high-quality (tertiary) specialty care.", [["a small population", "PROBLEM", 4, 22], ["small", "OBSERVATION_MODIFIER", 6, 11], ["population", "OBSERVATION", 12, 22], ["largest", "OBSERVATION_MODIFIER", 60, 67], ["island", "OBSERVATION", 68, 74], ["insufficient", "OBSERVATION_MODIFIER", 85, 97], ["demand", "OBSERVATION_MODIFIER", 98, 104]]], ["Highly specialized care for such small numbers means higher health care expenses for the individual islands.(31) Closer cooperation and distributing care across the islands might, therefore, be a strategy to achieve stronger collaborations with Dutch (health) organizations.", [["such small numbers", "PROBLEM", 28, 46]]], ["However, this is not without its challenges financially, logistically, and ethically.", [["not without", "UNCERTAINTY", 17, 28]]], ["Logistically speaking, it would be a massive undertaking to fly-out patients regularly.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["It will also force several medical specialists to relocate and redesign their services if specific treatments are no longer feasible on their islands.", [["specific treatments", "TREATMENT", 90, 109]]], ["Furthermore, separating people from friends and family in their most vulnerable moment, because a decision has been made to discontinue the provision of specific services on their islands would result in moral and ethical dilemmas.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["moral and ethical dilemmas", "PROBLEM", 204, 230]]], ["This delicate balance between public health and the economy requires a scientific and ethical platform supported by data and models for decision making.Provision of medical resources ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSWhen we mirror the islands' current state of affairs on a larger scale, one may wonder what chance the smaller islands have in acquiring hospital equipment at a reasonable price.", [["a larger scale", "TREATMENT", 282, 296], ["smaller", "OBSERVATION_MODIFIER", 329, 336], ["islands", "OBSERVATION", 337, 344]]], ["As various states and the federal government in the US are in a bidding war for ventilators and PPE (35), many have advocated that countries will need to become more self-reliant to prevent future healthcare crises, for example, not being reliant on foreign production of PPE.", [["ventilators", "TREATMENT", 80, 91], ["PPE", "TREATMENT", 96, 99], ["future healthcare crises", "PROBLEM", 190, 214], ["PPE", "PROBLEM", 272, 275]]], ["For islands with such small populations in the hundred thousand or less, a regional manufacturing agreement or large supply reservoir could be a more manageable objective.Provision of medical resources ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSBeing individual municipalities of The Netherlands, the islands of Bonaire, Statia, and Saba can consistently expect help from the Dutch government directly.", [["such small populations", "PROBLEM", 17, 39], ["large supply reservoir", "PROBLEM", 111, 133], ["small", "OBSERVATION_MODIFIER", 22, 27], ["populations", "OBSERVATION_MODIFIER", 28, 39], ["less", "OBSERVATION_MODIFIER", 67, 71], ["large", "OBSERVATION_MODIFIER", 111, 116], ["supply reservoir", "OBSERVATION", 117, 133]]], ["The special municipalities are unable to treat the most seriously ill patients locally.", [["ill", "DISEASE", 66, 69], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["They and thus the Netherlands have requested for these patients to be transferred to the larger independent islands.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["islands", "OBSERVATION", 108, 115]]], ["Many students leave the islands for an education abroad, but only a few return.(36) Thus, a sizable number of indigenes from the islands are known to be working abroad (mostly in the Netherlands) in the healthcare industry.", [["sizable", "OBSERVATION_MODIFIER", 92, 99]]], ["The dire healthcare needs on the islands resulting from this crisis highlight the importance of why the healthcare professionals from the various islands must unite and find ways in which their assistance can quickly be called upon when needed.Workforce capacity ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSA good example to be less dependent on external help is an initiative by a group of young healthcare professionals from the various islands who, in 2017, formed an association to address this need.", [["this crisis", "PROBLEM", 56, 67]]], ["As of now, with approximately two hundred members in its database, the association was able to recruit 65 professionals to offer local support for the islands' health care services during the current pandemic.", [["local support", "TREATMENT", 129, 142]]], ["The islands should develop and implement a framework for transportation, housing, financing, and quick hospital familiarization for foreign medical personnel in times of crisis.", [["crisis", "PROBLEM", 170, 176], ["islands", "OBSERVATION", 4, 11]]], ["Thus, making it a less daunting step for foreign healthcare professionals.Communication measures ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSLack of clear communication on guidelines of care and the rise of fake news via social media increase levels of anxiety and stress, more so in groups with low levels of education who are not able to correctly interpret situation reports released by the government authorities or in groups within a non-medical field of expertise.", [["anxiety", "DISEASE", 252, 259], ["guidelines of care", "TREATMENT", 171, 189], ["anxiety", "PROBLEM", 252, 259], ["stress", "PROBLEM", 264, 270]]], ["The negativity bias is the phenomenon by which humans give greater psychological weight to bad experiences or news than good ones.", [["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["negativity bias", "OBSERVATION", 4, 19]]], ["When such biases and fallacies are not adequately managed or corrected, it can lead to a crisis.Communication measures ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSRisk communication should emerge long before a crisis occurs (preparedness), aiming to reduce the likelihood of a crisis event.", [["such biases and fallacies", "PROBLEM", 5, 30], ["a crisis", "PROBLEM", 87, 95], ["a crisis", "PROBLEM", 207, 215], ["a crisis event", "PROBLEM", 274, 288]]], ["However, there is a significant chance of miscommunication in risk communication.", [["significant", "OBSERVATION_MODIFIER", 20, 31], ["miscommunication", "OBSERVATION", 42, 58]]], ["Recently a study has been started at the University of Utrecht and University of Groningen, The Netherlands, to assess the social impact of COVID-19 risk communication on vulnerable groups (older adults, ethnic minorities, and refugees) in the Kingdom of the Netherlands, including the Caribbean islands.", [["a study", "TEST", 9, 16], ["COVID", "TREATMENT", 140, 145]]], ["This study will hopefully be used in guidelines for SIDS to inform better, prepare, manage, and cope with future pandemics.Financial (in)dependence ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSCurrently, the respective governments and central banks of Aruba and Cura\u00e7ao have estimated that both islands would need somewhere between 750 and 900 million euros to accommodate and recover from this pandemic.(37) The Dutch government has decided to provide financial aid to the islands, which will allow the islands to provide some financial relief to citizens and businesses.", [["SIDS", "DISEASE", 52, 56], ["This study", "TEST", 0, 10]]], ["The Dutch government, however, has put forth strict demands before the money can be given, such as a 12.5% salary cut for all civil servants, a salary cut of 25% for all ministers, and CEOs of government-owned companies can no longer earn more than 130% of the Prime Minister's salary.(38) This financial dependence on the Netherlands has long been an issue within the Kingdom.", [["This financial dependence", "PROBLEM", 290, 315]]], ["The goal has always been temporary (financial) aid, which should ultimately lead to the islands' self-reliance.", [["temporary (financial) aid", "TREATMENT", 25, 50]]], ["Despite the considerable political pressure from the Netherlands and many accompanying expert reports and plans, this goal is yet to be achieved.", [["considerable", "OBSERVATION_MODIFIER", 12, 24], ["political", "OBSERVATION_MODIFIER", 25, 34], ["pressure", "OBSERVATION_MODIFIER", 35, 43]]], ["Further, due to the scale of SIDS, it is questionable if this can ever be achieved.", [["SIDS", "DISEASE", 29, 33], ["SIDS", "PROBLEM", 29, 33]]], ["Historically the Dutch financial aid to the islands has been low, around a yearly 500 USD per capita.", [["low", "OBSERVATION_MODIFIER", 61, 64]]], ["In comparison, the French aid to their Caribbean territories is between 2,900-3,800 USD per capita, and the US spends around 2,500 USD and 1,000 USD per capita in Puerto Rico and the US Virgin Islands, respectively.(38)Financial (in)dependence ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSA suggested solution is to structurally embed these extra costs in institutions such as is already done with the 'Waddenfonds' for the Frisian islands, a North Sea archipelago directly off the coast of the Netherlands.(38) This could be difficult due to the autonomous status of Cura\u00e7ao, Aruba and St. Martin.", [["St. Martin", "ORGANISM", 585, 595], ["Virgin Islands", "OBSERVATION", 186, 200]]], ["Economic recovery following the pandemic will likely be slow as the local economies will only begin to recover when the economies in other countries have recovered, and traveling is restored to normal.", [["normal", "OBSERVATION", 194, 200]]], ["Dutch aid will once again be needed, but a longer, more sustainable situation needs to be created in the future.Financial (in)dependence ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSIt is a fact that these six Caribbean islands will suffer significant consequences from the COVID-19 crisis both financially and medically.", [["the COVID", "TEST", 268, 277]]], ["They are countries with economies driven by tourism and, therefore, long-term economic consequences will be catastrophic if not properly addressed.", [["catastrophic", "PROBLEM", 108, 120]]], ["It is admirable and, at the same time, exemplary of the islands to not have allowed economic pressure to affect their public health decisions while trying to limit the medical consequences of this crisis.", [["this crisis", "PROBLEM", 192, 203]]], ["The islands should, however, not forget to focus on cooperation with each other and adequately using their own native healthcare professionals living abroad.", [["islands", "OBSERVATION", 4, 11]]], ["Every country is currently encountering its battles and will be facing very tough medical and ethical choices while attempting to manage the acute and chronic phases of this pandemic.", [["the acute and chronic phases", "PROBLEM", 137, 165], ["this pandemic", "PROBLEM", 169, 182], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["chronic", "OBSERVATION_MODIFIER", 151, 158]]], ["However, as a global society, we should not neglect to draw attention to those countries that can bear the least.Disclaimer. ::: CHALLENGES AND RECOMMENDATIONS FOR SIDSAuthors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or the Pan American Health Organization.", [["the RPSP/PAJPH", "PROBLEM", 303, 317]]]], "PMC7322224": [["IntroductionWith the outbreak of a new coronavirus (COVID-2019) that has been rearing its ugly head for several weeks in China and worldwide [1\u20133], the international press and the Coalition for Epidemic Preparedness Innovations have already advocated the urgent need to develop an appropriate vaccine [4].", [["head", "ANATOMY", 95, 99], ["coronavirus", "DISEASE", 39, 50], ["coronavirus", "ORGANISM", 39, 50], ["head", "ORGANISM_SUBDIVISION", 95, 99], ["a new coronavirus", "PROBLEM", 33, 50]]], ["This request illustrates without a doubt that although current uptake of adult vaccines is still too low in Italy, and in Europe in general [5], vaccines have a powerful (if not magic) perceived efficacy for the general public.", [["adult vaccines", "TREATMENT", 73, 87], ["vaccines", "TREATMENT", 145, 153]]], ["Indeed, everyone seems to have understood that vaccines train the immune system to recognize and respond to a pathogen by mounting a rapid and effective immune defence, preventing the establishment of infection or disease, or decreasing the disease severity [6].IntroductionAs stressed in the paper by Antonelli Incalzi and colleagues in this issue [5], vaccine hesitancy is linked to \u201cthe constant flow of contradictory, distorted or plainly false news about vaccines in the media, and much of this information stems from sources that are not scientifically robust\u201d.", [["immune system", "ANATOMY", 66, 79], ["infection", "DISEASE", 201, 210], ["vaccines", "TREATMENT", 47, 55], ["a pathogen", "PROBLEM", 108, 118], ["a rapid and effective immune defence", "PROBLEM", 131, 167], ["infection", "PROBLEM", 201, 210], ["disease", "PROBLEM", 214, 221], ["the disease severity", "PROBLEM", 237, 257], ["vaccine", "TREATMENT", 354, 361], ["vaccines", "TREATMENT", 460, 468], ["infection", "OBSERVATION", 201, 210]]], ["Disinformation of the public about vaccination is not compensated for by medical and paramedical personnel, in whom there is a notable lack of training, and who are often not updated about the burden of vaccine preventable diseases (VPDs) [7].", [["VPDs", "DISEASE", 233, 237], ["vaccine preventable diseases", "PROBLEM", 203, 231]]], ["Yet, the fight against VPDs is a major public health priority.", [["VPDs", "DISEASE", 23, 27]]], ["The tremendous positive clinical, social and economic impacts of vaccines on preventable infectious diseases are part of a multidimensional and integrated approach to healthy ageing.", [["infectious diseases", "DISEASE", 89, 108], ["vaccines", "TREATMENT", 65, 73], ["preventable infectious diseases", "PROBLEM", 77, 108], ["tremendous", "OBSERVATION_MODIFIER", 4, 14], ["positive", "OBSERVATION_MODIFIER", 15, 23]]], ["In their paper, Antonelli Incalzi et al. propose homogeneous and efficacious strategies to scale up vaccination rates from children to seniors in Italy [5], recipes that will be very useful in other European countries.", [["children", "ORGANISM", 123, 131], ["children", "SPECIES", 123, 131], ["homogeneous", "OBSERVATION_MODIFIER", 49, 60]]], ["Among the most important recommendations, the following stand out in particular:Set-up of a centralized registry of immunization, enabling continuous monitoring at regional and national levels, which will enable epidemiological evaluation of the impact of vaccinations as well as their socio-economic benefits.Implementation of specific teaching about vaccines and vaccination, not only in paediatrics or public health but also in internal and geriatric medicine in all medical and health care faculties.Development of a wide-reaching, attractive and repeated media campaign about vaccinations, explaining how they positively impact survival and life expectancy.IntroductionMoreover, it is now scientifically proven that vaccines have a significant efficacy on the prevention of cardio- and neuro-vascular events.", [["neuro-vascular", "ANATOMY", 791, 805], ["cardio- and neuro-vascular events", "DISEASE", 779, 812], ["immunization", "TREATMENT", 116, 128], ["epidemiological evaluation", "TEST", 212, 238], ["vaccinations", "TREATMENT", 256, 268], ["specific teaching", "TREATMENT", 328, 345], ["vaccines", "TREATMENT", 352, 360], ["vaccination", "TREATMENT", 365, 376], ["vaccinations", "TREATMENT", 581, 593], ["vaccines", "TREATMENT", 721, 729], ["neuro-vascular events", "PROBLEM", 791, 812], ["wide", "OBSERVATION_MODIFIER", 521, 525], ["cardio", "ANATOMY", 779, 785]]], ["These benefits are only known to a few professionals [8], who are also aware of the expected benefits of vaccines in the fight against another major health threat, namely antimicrobial resistance.The well-known and too often forgotten anti infectious efficacy of current vaccinesAs stressed by Antonelli Incalzi et al., vaccination (for adults as well as for children) is recognized as a right and a social value for all.", [["children", "ORGANISM", 359, 367], ["children", "SPECIES", 359, 367], ["vaccines", "TREATMENT", 105, 113], ["current vaccines", "TREATMENT", 263, 279], ["antimicrobial resistance", "OBSERVATION", 171, 195], ["right", "ANATOMY_MODIFIER", 388, 393]]], ["In 2017, thirty-six different vaccines were developed, and over the last thirty years, a number of vaccines have appeared, using firstly live-attenuated strains, then killed whole organisms and more recently, protein or polysaccharide subunits technology [9].", [["polysaccharide subunits", "PROTEIN", 220, 243], ["vaccines", "TREATMENT", 99, 107], ["attenuated strains", "PROBLEM", 142, 160], ["polysaccharide subunits technology", "TREATMENT", 220, 254]]], ["These developments have enabled comparison of morbidity and mortality data on VPDs between the pre-vaccine era and the modern era, across various regions of the world (including Australia, Canada, the UK and the USA).", [["mortality data", "TEST", 60, 74], ["VPDs", "TREATMENT", 78, 82]]], ["These comparisons show an estimated 68 to 100% reduction in preventable infectious diseases such as congenital rubella, diphtheria, hemophilus influenza A, measles, mumps, pertussis, rubella, tetanus and indeed smallpox [9].", [["infectious diseases", "DISEASE", 72, 91], ["congenital rubella", "DISEASE", 100, 118], ["diphtheria", "DISEASE", 120, 130], ["hemophilus influenza A", "DISEASE", 132, 154], ["measles, mumps, pertussis, rubella, tetanus and indeed smallpox", "DISEASE", 156, 219], ["hemophilus influenza A", "ORGANISM", 132, 154], ["hemophilus influenza", "SPECIES", 132, 152], ["mumps, pertussis", "SPECIES", 165, 181], ["preventable infectious diseases", "PROBLEM", 60, 91], ["congenital rubella", "PROBLEM", 100, 118], ["diphtheria", "PROBLEM", 120, 130], ["hemophilus influenza A", "PROBLEM", 132, 154], ["measles", "PROBLEM", 156, 163], ["mumps", "PROBLEM", 165, 170], ["pertussis", "PROBLEM", 172, 181], ["rubella", "PROBLEM", 183, 190], ["tetanus", "PROBLEM", 192, 199], ["preventable", "OBSERVATION_MODIFIER", 60, 71], ["infectious", "OBSERVATION", 72, 82], ["congenital", "OBSERVATION_MODIFIER", 100, 110], ["rubella", "OBSERVATION", 111, 118], ["hemophilus influenza", "OBSERVATION", 132, 152]]], ["These findings explain the observation that communicable diseases worldwide decreased from 33% of total deaths in 1990 to 25% in 2010 [10], thus preventing more than 2.5 million deaths annually from communicable diseases [11].", [["communicable diseases", "DISEASE", 44, 65], ["deaths", "DISEASE", 104, 110], ["deaths", "DISEASE", 178, 184], ["communicable diseases", "DISEASE", 199, 220], ["communicable diseases", "PROBLEM", 44, 65], ["communicable diseases", "PROBLEM", 199, 220]]], ["A related question is whether vaccines have other beneficial impacts on health, in addition to preventing infectious diseases.Positive vaccine outcomes on the global health burdenThe positive impact of seasonal influenza (flu) vaccination on cardiovascular health was first suspected in the 1990s by Siscovick et al., who observed in a population-based case\u2013control study of 342 cases of primary cardiac arrest (registered from 1988 to 1994 in the Washington area) and 549 demographically similar controls that flu vaccination appeared to be associated with a reduced risk of primary cardiac arrest [odds ratio (OR) = 0.51 (95% confidence interval (CI) 0.33\u20130.79)] [12].", [["cardiovascular", "ANATOMY", 242, 256], ["cardiac", "ANATOMY", 396, 403], ["cardiac", "ANATOMY", 584, 591], ["infectious diseases", "DISEASE", 106, 125], ["influenza", "DISEASE", 211, 220], ["primary cardiac arrest", "DISEASE", 388, 410], ["flu", "DISEASE", 511, 514], ["primary cardiac arrest", "DISEASE", 576, 598], ["cardiovascular", "ANATOMICAL_SYSTEM", 242, 256], ["cardiac", "ORGAN", 396, 403], ["cardiac", "ORGAN", 584, 591], ["vaccines", "TREATMENT", 30, 38], ["infectious diseases", "PROBLEM", 106, 125], ["seasonal influenza (flu) vaccination", "PROBLEM", 202, 238], ["primary cardiac arrest", "PROBLEM", 388, 410], ["flu vaccination", "PROBLEM", 511, 526], ["primary cardiac arrest", "PROBLEM", 576, 598], ["CI", "TEST", 649, 651], ["infectious", "OBSERVATION", 106, 116], ["vaccine", "OBSERVATION", 135, 142], ["positive", "OBSERVATION_MODIFIER", 183, 191], ["seasonal", "OBSERVATION_MODIFIER", 202, 210], ["influenza", "OBSERVATION", 211, 220], ["cardiac", "ANATOMY", 396, 403], ["arrest", "OBSERVATION", 404, 410], ["arrest", "OBSERVATION", 592, 598]]], ["This hypothesis was subsequently confirmed by a randomized, controlled trial including 301 patients hospitalized for myocardial infarction or planned angiography/stenting, showing that mortality at one year was significantly lower in patients who were vaccinated compared to non-vaccinated patients [relative risk of cardiovascular death at 1 year with vaccination = 0.34 (95% CI 0.17\u20130.71)] [13, 14].", [["myocardial", "ANATOMY", 117, 127], ["cardiovascular", "ANATOMY", 317, 331], ["myocardial infarction", "DISEASE", 117, 138], ["cardiovascular death", "DISEASE", 317, 337], ["patients", "ORGANISM", 91, 99], ["myocardial", "MULTI-TISSUE_STRUCTURE", 117, 127], ["patients", "ORGANISM", 234, 242], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 234, 242], ["patients", "SPECIES", 290, 298], ["myocardial infarction", "PROBLEM", 117, 138], ["angiography", "TEST", 150, 161], ["stenting", "TREATMENT", 162, 170], ["cardiovascular death", "PROBLEM", 317, 337], ["vaccination", "TEST", 353, 364], ["CI", "TEST", 377, 379], ["myocardial", "ANATOMY", 117, 127], ["infarction", "OBSERVATION", 128, 138], ["stenting", "OBSERVATION", 162, 170], ["cardiovascular", "ANATOMY", 317, 331]]], ["Another randomized, double blind, placebo-controlled study of two population groups (vaccinated vs non-vaccinated) that had 12-month follow-up of 658 optimally treated coronary artery disease patients (72% men, mean age 59.9 \u00b1 10.3 years) also demonstrated differences in cardiovascular death and coronary revascularization in vaccinated patients [hazard ratio (HR) for ischemic coronary events at 1 year 0.54; 95% CI 0.29\u20130.99)[15].", [["coronary artery", "ANATOMY", 168, 183], ["cardiovascular", "ANATOMY", 272, 286], ["coronary", "ANATOMY", 297, 305], ["coronary", "ANATOMY", 379, 387], ["coronary artery disease", "DISEASE", 168, 191], ["cardiovascular death", "DISEASE", 272, 292], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 168, 183], ["patients", "ORGANISM", 192, 200], ["men", "ORGANISM", 206, 209], ["cardiovascular", "ANATOMICAL_SYSTEM", 272, 286], ["coronary", "MULTI-TISSUE_STRUCTURE", 297, 305], ["patients", "ORGANISM", 338, 346], ["coronary", "MULTI-TISSUE_STRUCTURE", 379, 387], ["patients", "SPECIES", 192, 200], ["men", "SPECIES", 206, 209], ["patients", "SPECIES", 338, 346], ["placebo", "TREATMENT", 34, 41], ["optimally treated coronary artery disease", "PROBLEM", 150, 191], ["cardiovascular death", "PROBLEM", 272, 292], ["coronary revascularization", "TREATMENT", 297, 323], ["hazard ratio", "TEST", 348, 360], ["ischemic coronary events", "PROBLEM", 370, 394], ["CI", "TEST", 415, 417], ["coronary artery", "ANATOMY", 168, 183], ["coronary", "ANATOMY", 297, 305], ["revascularization", "OBSERVATION", 306, 323], ["coronary", "ANATOMY", 379, 387]]], ["These results prompted the American Heart Association and American College of Cardiology to recommend influenza vaccine (inactivated vaccine administered intra-muscularly) for secondary prevention in persons with coronary and other atherosclerotic diseases [16].Positive vaccine outcomes on the global health burdenMore recent evidence has been provided by two successive data analyses from the Taiwan Longitudinal Health Insurance Database (1996\u20132008).", [["coronary", "ANATOMY", 213, 221], ["atherosclerotic", "ANATOMY", 232, 247], ["atherosclerotic diseases", "DISEASE", 232, 256], ["persons", "ORGANISM", 200, 207], ["coronary", "MULTI-TISSUE_STRUCTURE", 213, 221], ["persons", "SPECIES", 200, 207], ["influenza vaccine", "TREATMENT", 102, 119], ["inactivated vaccine", "TREATMENT", 121, 140], ["coronary and other atherosclerotic diseases", "PROBLEM", 213, 256], ["coronary", "ANATOMY", 213, 221], ["atherosclerotic", "OBSERVATION", 232, 247]]], ["Both concern the prevention of cardiovascular events by flu vaccine.", [["cardiovascular", "ANATOMY", 31, 45], ["cardiovascular", "ANATOMICAL_SYSTEM", 31, 45], ["cardiovascular events", "PROBLEM", 31, 52], ["flu vaccine", "TREATMENT", 56, 67]]], ["The first study involved 7722 patients aged over 55 years with chronic obstructive pulmonary disease (and without known cardiovascular disease) and showed a significant decrease in the cumulative event rates for acute coronary syndrome in vaccinated versus non-vaccinated individual (p < 0.001).", [["pulmonary", "ANATOMY", 83, 92], ["cardiovascular", "ANATOMY", 120, 134], ["coronary", "ANATOMY", 218, 226], ["chronic obstructive pulmonary disease", "DISEASE", 63, 100], ["cardiovascular disease", "DISEASE", 120, 142], ["acute coronary syndrome", "DISEASE", 212, 235], ["patients", "ORGANISM", 30, 38], ["pulmonary", "ORGAN", 83, 92], ["patients", "SPECIES", 30, 38], ["chronic obstructive pulmonary disease", "PROBLEM", 63, 100], ["known cardiovascular disease", "PROBLEM", 114, 142], ["a significant decrease", "PROBLEM", 155, 177], ["acute coronary syndrome", "PROBLEM", 212, 235], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["obstructive", "OBSERVATION_MODIFIER", 71, 82], ["pulmonary", "ANATOMY", 83, 92], ["disease", "OBSERVATION", 93, 100], ["without", "UNCERTAINTY", 106, 113], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["decrease", "OBSERVATION_MODIFIER", 169, 177], ["coronary", "ANATOMY", 218, 226], ["syndrome", "OBSERVATION", 227, 235]]], ["Moreover, persons who got four flu vaccines during the course of the study period were better protected against hospitalization for acute coronary syndrome than those who received only one vaccine (p < 0.001) [17].", [["coronary", "ANATOMY", 138, 146], ["acute coronary syndrome", "DISEASE", 132, 155], ["persons", "ORGANISM", 10, 17], ["persons", "SPECIES", 10, 17], ["four flu vaccines", "TREATMENT", 26, 43], ["acute coronary syndrome", "PROBLEM", 132, 155], ["coronary", "ANATOMY", 138, 146], ["syndrome", "OBSERVATION", 147, 155]]], ["The second analysis from the same database included 4,406 patients aged over 55 years, with chronic kidney disease (without known cardiovascular disease) [18].", [["kidney", "ANATOMY", 100, 106], ["cardiovascular", "ANATOMY", 130, 144], ["chronic kidney disease", "DISEASE", 92, 114], ["cardiovascular disease", "DISEASE", 130, 152], ["patients", "ORGANISM", 58, 66], ["kidney", "ORGAN", 100, 106], ["cardiovascular", "ANATOMICAL_SYSTEM", 130, 144], ["patients", "SPECIES", 58, 66], ["The second analysis", "TEST", 0, 19], ["chronic kidney disease", "PROBLEM", 92, 114], ["known cardiovascular disease)", "PROBLEM", 124, 153], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["kidney", "ANATOMY", 100, 106], ["disease", "OBSERVATION", 107, 114], ["without", "UNCERTAINTY", 116, 123], ["cardiovascular disease", "OBSERVATION", 130, 152]]], ["Again, patients who received repeated flu vaccines (N = 4) had significantly lower cumulative event rates for acute coronary syndrome compared to those who received only one flu vaccine during the study period (p < 0.001) [18].", [["coronary", "ANATOMY", 116, 124], ["acute coronary syndrome", "DISEASE", 110, 133], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["repeated flu vaccines", "TREATMENT", 29, 50], ["significantly lower cumulative event rates", "PROBLEM", 63, 105], ["acute coronary syndrome", "PROBLEM", 110, 133], ["one flu vaccine", "TREATMENT", 170, 185], ["coronary", "ANATOMY", 116, 124], ["syndrome", "OBSERVATION", 125, 133]]], ["Furthermore, CKD patients receiving influenza vaccination had a lower risk of hospitalization for heart failure [adjusted HR, 0.31 (95% CI 0.26\u20130.39), p < 0.001] [18].", [["heart", "ANATOMY", 98, 103], ["CKD", "DISEASE", 13, 16], ["heart failure", "DISEASE", 98, 111], ["patients", "ORGANISM", 17, 25], ["heart", "ORGAN", 98, 103], ["patients", "SPECIES", 17, 25], ["CKD", "PROBLEM", 13, 16], ["influenza vaccination", "TREATMENT", 36, 57], ["heart failure", "PROBLEM", 98, 111], ["HR", "TEST", 122, 124], ["CI", "TEST", 136, 138], ["heart", "ANATOMY", 98, 103], ["failure", "OBSERVATION", 104, 111]]], ["Finally, the protective effect of flu vaccination on cardiovascular events was also demonstrated in a Danish nationwide cohort study including all patients over 18 years of age and diagnosed with heart failure (from January 2003 to June 2015) (n = 134,048).", [["cardiovascular", "ANATOMY", 53, 67], ["heart", "ANATOMY", 196, 201], ["heart failure", "DISEASE", 196, 209], ["cardiovascular", "ANATOMICAL_SYSTEM", 53, 67], ["patients", "ORGANISM", 147, 155], ["heart", "ORGAN", 196, 201], ["patients", "SPECIES", 147, 155], ["flu vaccination", "TREATMENT", 34, 49], ["cohort study", "TEST", 120, 132], ["heart failure", "PROBLEM", 196, 209], ["heart", "ANATOMY", 196, 201], ["failure", "OBSERVATION", 202, 209]]], ["After the diagnosis of heart failure, one flu vaccination alone was sufficient to significantly reduce cardiovascular mortality [HR = 0.82 (0.81\u20130.84)], while four vaccinations were even more protective [HR = 0.72 (0.69\u20130.74)] (p < 0.001) [19].Positive vaccine outcomes on the global health burdenAnother frequent disease among older adults is herpes zoster, and it has been shown that there is an increased risk of stroke after clinically proven onset of herpes zoster in adults between the age of 50 and 60 years[20].", [["heart", "ANATOMY", 23, 28], ["cardiovascular", "ANATOMY", 103, 117], ["heart failure", "DISEASE", 23, 36], ["herpes zoster", "DISEASE", 344, 357], ["stroke", "DISEASE", 416, 422], ["herpes zoster", "DISEASE", 456, 469], ["heart", "ORGAN", 23, 28], ["herpes zoster", "ORGANISM", 344, 357], ["herpes zoster", "ORGANISM", 456, 469], ["herpes zoster", "SPECIES", 344, 357], ["herpes zoster", "SPECIES", 456, 469], ["heart failure", "PROBLEM", 23, 36], ["one flu vaccination", "TREATMENT", 38, 57], ["cardiovascular mortality", "TEST", 103, 127], ["HR", "TEST", 129, 131], ["HR", "TEST", 204, 206], ["Another frequent disease", "PROBLEM", 297, 321], ["herpes zoster", "PROBLEM", 344, 357], ["stroke", "PROBLEM", 416, 422], ["herpes zoster", "PROBLEM", 456, 469], ["heart", "ANATOMY", 23, 28], ["failure", "OBSERVATION", 29, 36], ["vaccine", "OBSERVATION", 253, 260], ["frequent", "OBSERVATION_MODIFIER", 305, 313], ["disease", "OBSERVATION", 314, 321], ["herpes zoster", "OBSERVATION", 344, 357], ["increased", "OBSERVATION_MODIFIER", 398, 407], ["stroke", "OBSERVATION", 416, 422], ["herpes zoster", "OBSERVATION", 456, 469]]], ["Here again, the positive preventive efficacy of herpes zoster vaccination was recently demonstrated by a cross-sectional nationwide telephone survey of 265,568 non-institutionalized US adults aged 50 to 79 years old [21].", [["herpes zoster", "DISEASE", 48, 61], ["herpes zoster", "ORGANISM", 48, 61], ["herpes zoster", "SPECIES", 48, 61], ["herpes zoster vaccination", "PROBLEM", 48, 73], ["herpes zoster", "OBSERVATION", 48, 61]]], ["After stratification of participants into six 5-year age groups, Cox proportional hazards analysis indicated that those without zoster vaccination were at significantly higher risk of stroke compared to those receiving vaccination with the live attenuated vaccine (HR = 1.73, 95% CI 1.71\u20131.76) [21].Positive vaccine outcomes on the global health burdenThis cumulating body of evidence now clearly testifies to the incontestable beneficial effect of flu vaccination on the onset of cardiovascular events (coronary artery disease, heart failure and cardiovascular death).", [["cardiovascular", "ANATOMY", 481, 495], ["coronary artery", "ANATOMY", 504, 519], ["heart", "ANATOMY", 529, 534], ["cardiovascular", "ANATOMY", 547, 561], ["zoster", "DISEASE", 128, 134], ["stroke", "DISEASE", 184, 190], ["coronary artery disease", "DISEASE", 504, 527], ["heart failure", "DISEASE", 529, 542], ["cardiovascular death", "DISEASE", 547, 567], ["zoster", "ORGANISM", 128, 134], ["cardiovascular", "ANATOMICAL_SYSTEM", 481, 495], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 504, 519], ["heart", "ORGAN", 529, 534], ["cardiovascular", "ANATOMICAL_SYSTEM", 547, 561], ["participants", "SPECIES", 24, 36], ["Cox proportional hazards analysis", "TEST", 65, 98], ["zoster vaccination", "PROBLEM", 128, 146], ["stroke", "PROBLEM", 184, 190], ["vaccination", "TREATMENT", 219, 230], ["the live attenuated vaccine", "TREATMENT", 236, 263], ["HR", "TEST", 265, 267], ["CI", "TEST", 280, 282], ["flu vaccination", "TREATMENT", 449, 464], ["cardiovascular events", "PROBLEM", 481, 502], ["coronary artery disease", "PROBLEM", 504, 527], ["heart failure", "PROBLEM", 529, 542], ["cardiovascular death", "PROBLEM", 547, 567], ["stroke", "OBSERVATION", 184, 190], ["vaccine", "OBSERVATION", 308, 315], ["coronary artery", "ANATOMY", 504, 519], ["disease", "OBSERVATION", 520, 527], ["heart", "ANATOMY", 529, 534], ["failure", "OBSERVATION", 535, 542]]], ["Moreover, live attenuated herpes zoster vaccine reduces the incidence of post-herpes zoster stroke.", [["herpes zoster", "DISEASE", 26, 39], ["post-herpes zoster stroke", "DISEASE", 73, 98], ["herpes zoster", "ORGANISM", 26, 39], ["post-herpes zoster", "ORGANISM", 73, 91], ["herpes zoster vaccine", "SPECIES", 26, 47], ["live attenuated herpes zoster vaccine", "PROBLEM", 10, 47], ["post-herpes zoster stroke", "PROBLEM", 73, 98], ["zoster", "OBSERVATION_MODIFIER", 85, 91], ["stroke", "OBSERVATION", 92, 98]]], ["It is evident that up to now, the positive outcomes of immunization on all cardiovascular events in the older population are most definitely not receiving enough attention [22].Positive vaccine outcomes on antimicrobial resistanceIn the European Union, approximately 25,000 people die each year from resistant infections, which are estimated to engender an annual financial burden in the order of 1.5 billion Euro [23].", [["cardiovascular", "ANATOMY", 75, 89], ["infections", "DISEASE", 310, 320], ["cardiovascular", "ANATOMICAL_SYSTEM", 75, 89], ["people", "ORGANISM", 274, 280], ["people", "SPECIES", 274, 280], ["immunization", "TREATMENT", 55, 67], ["all cardiovascular events", "PROBLEM", 71, 96], ["antimicrobial", "TREATMENT", 206, 219], ["resistant infections", "PROBLEM", 300, 320], ["resistant", "OBSERVATION_MODIFIER", 300, 309], ["infections", "OBSERVATION", 310, 320]]], ["Among the many well-known measures that can control antimicrobial resistance, which include sanitation and hygiene, development of rapid diagnostic tests, education to avoid inappropriate antibiotic use, promotion of antibiotic stewardship and elimination of routine antibiotic use in livestock production, an additional avenue towards eradicating resistance is the development of new antimicrobial agents and vaccines [24].", [["antimicrobial resistance", "TREATMENT", 52, 76], ["rapid diagnostic tests", "TEST", 131, 153], ["inappropriate antibiotic use", "TREATMENT", 174, 202], ["antibiotic stewardship", "TREATMENT", 217, 239], ["routine antibiotic use", "TREATMENT", 259, 281], ["new antimicrobial agents", "TREATMENT", 381, 405], ["vaccines", "TREATMENT", 410, 418], ["antimicrobial resistance", "OBSERVATION", 52, 76]]], ["However, the time to first detection of human pathogens resistant to antimicrobial drugs is critically shorter and shorter, while new antibiotics are becoming scarce [25].", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["human pathogens", "PROBLEM", 40, 55], ["antimicrobial drugs", "TREATMENT", 69, 88], ["new antibiotics", "TREATMENT", 130, 145]]], ["In the USA, between 2000 and 2014, the level of antibiotic resistance associated with pneumococcal pneumonia, Staphylococcus aureus, Escherichia coli and Enterobacter spp. reached 34%, 45%, 55% and 88%, respectively [26], even without taking into account the proportion of strains that are resistant to more than one antibiotic class.Positive vaccine outcomes on antimicrobial resistanceOn the contrary, vaccines do not acquire significant resistance.", [["pneumococcal pneumonia", "DISEASE", 86, 108], ["Staphylococcus aureus", "DISEASE", 110, 131], ["pneumococcal pneumonia", "ORGANISM", 86, 108], ["Staphylococcus aureus", "ORGANISM", 110, 131], ["Escherichia coli", "ORGANISM", 133, 149], ["Enterobacter spp", "ORGANISM", 154, 170], ["Staphylococcus aureus", "SPECIES", 110, 131], ["Escherichia coli", "SPECIES", 133, 149], ["pneumococcal", "SPECIES", 86, 98], ["Staphylococcus aureus", "SPECIES", 110, 131], ["Escherichia coli", "SPECIES", 133, 149], ["antibiotic resistance", "TREATMENT", 48, 69], ["pneumococcal pneumonia", "PROBLEM", 86, 108], ["Staphylococcus aureus", "PROBLEM", 110, 131], ["Escherichia coli", "PROBLEM", 133, 149], ["Enterobacter spp", "PROBLEM", 154, 170], ["strains", "PROBLEM", 273, 280], ["one antibiotic class", "TREATMENT", 313, 333], ["Positive vaccine", "TREATMENT", 334, 350], ["antimicrobial resistanceOn", "TREATMENT", 363, 389], ["vaccines", "TREATMENT", 404, 412], ["antibiotic resistance", "OBSERVATION", 48, 69], ["pneumococcal", "OBSERVATION_MODIFIER", 86, 98], ["pneumonia", "OBSERVATION", 99, 108], ["Staphylococcus aureus", "OBSERVATION", 110, 131], ["Escherichia coli", "OBSERVATION", 133, 149], ["Enterobacter spp", "OBSERVATION", 154, 170]]], ["This makes them an attractive solution in the fight against antimicrobial resistance, by protecting people against major infectious diseases such as influenza or pneumococcal pneumonia, thereby reducing the spread of disease and the use of antibiotics.", [["infectious diseases", "DISEASE", 121, 140], ["influenza", "DISEASE", 149, 158], ["pneumococcal pneumonia", "DISEASE", 162, 184], ["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106], ["pneumococcal", "SPECIES", 162, 174], ["an attractive solution", "TREATMENT", 16, 38], ["antimicrobial resistance", "TREATMENT", 60, 84], ["major infectious diseases", "PROBLEM", 115, 140], ["influenza", "PROBLEM", 149, 158], ["pneumococcal pneumonia", "PROBLEM", 162, 184], ["disease", "PROBLEM", 217, 224], ["antibiotics", "TREATMENT", 240, 251], ["infectious", "OBSERVATION", 121, 131], ["pneumococcal", "OBSERVATION_MODIFIER", 162, 174], ["pneumonia", "OBSERVATION", 175, 184], ["spread", "OBSERVATION_MODIFIER", 207, 213]]], ["Moreover, herd immunity protects not only vaccinated people, but also those who cannot be immunized, such as the immunocompromized.", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59]]], ["Anti-pneumococcal vaccines that protect against multiple strains also decrease the density of oral carriage of the microbes and thereby diminish genetic exchanges of resistance, even though a few serotypes that are not contained in the vaccine (A19) have emerged.", [["oral", "ANATOMY", 94, 98], ["oral", "ORGANISM_SUBDIVISION", 94, 98], ["Anti-pneumococcal vaccines", "TREATMENT", 0, 26], ["multiple strains", "PROBLEM", 48, 64], ["a few serotypes", "PROBLEM", 190, 205], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["density", "OBSERVATION_MODIFIER", 83, 90], ["few", "OBSERVATION_MODIFIER", 192, 195], ["serotypes", "OBSERVATION", 196, 205]]], ["Two years after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010, the resistance of macrolides, cephalosporins, tetracyclines and penicillin decreased, respectively, by 63%, 81%, 81% and 83% [24], which is very impressive.", [["PCV13", "CHEMICAL", 82, 87], ["macrolides", "CHEMICAL", 116, 126], ["cephalosporins", "CHEMICAL", 128, 142], ["tetracyclines", "CHEMICAL", 144, 157], ["penicillin", "CHEMICAL", 162, 172], ["macrolides", "CHEMICAL", 116, 126], ["cephalosporins", "CHEMICAL", 128, 142], ["tetracyclines", "CHEMICAL", 144, 157], ["penicillin", "CHEMICAL", 162, 172], ["macrolides", "SIMPLE_CHEMICAL", 116, 126], ["cephalosporins", "SIMPLE_CHEMICAL", 128, 142], ["tetracyclines", "SIMPLE_CHEMICAL", 144, 157], ["penicillin", "SIMPLE_CHEMICAL", 162, 172], ["pneumococcal", "SPECIES", 50, 62], ["PCV13", "SPECIES", 82, 87], ["the 13-valent pneumococcal conjugate vaccine", "TREATMENT", 36, 80], ["PCV13", "TREATMENT", 82, 87], ["macrolides", "TREATMENT", 116, 126], ["cephalosporins", "TREATMENT", 128, 142], ["tetracyclines", "TREATMENT", 144, 157], ["penicillin", "TREATMENT", 162, 172], ["very", "OBSERVATION_MODIFIER", 238, 242], ["impressive", "OBSERVATION_MODIFIER", 243, 253]]], ["Therefore, while currently available vaccines are considered as excellent tools to fight against antimicrobial resistance, it is nonetheless necessary to facilitate access to vaccines, increase coverage rates and accelerate the development and licensing procedures of new vaccines [24].", [["vaccines", "TREATMENT", 37, 45], ["antimicrobial resistance", "TREATMENT", 97, 121], ["vaccines", "TREATMENT", 175, 183], ["increase coverage rates", "TREATMENT", 185, 208], ["licensing procedures", "TREATMENT", 244, 264], ["new vaccines", "TREATMENT", 268, 280]]], ["The WHO has already identified possible targets for new vaccines, and clinical trials will investigate extended epidemiological outcomes, including the impact on clinical prescription of antibiotics and reduction in antimicrobial resistance [22].Positive vaccine outcomes on antimicrobial resistanceThe useful public health paper from Antonelli Incalziet al. in this issue [5] underlines with strong arguments and acknowledgeable scientific honesty, the need for increased vaccine awareness among the general public, health care professionals and health care deciders.", [["new vaccines", "TREATMENT", 52, 64], ["antibiotics", "TREATMENT", 187, 198], ["reduction in antimicrobial resistance", "TREATMENT", 203, 240], ["Positive vaccine", "TREATMENT", 246, 262], ["antimicrobial resistance", "TREATMENT", 275, 299], ["Antonelli Incalziet al", "TREATMENT", 335, 357], ["antimicrobial resistance", "OBSERVATION", 216, 240], ["antimicrobial resistance", "OBSERVATION_MODIFIER", 275, 299]]], ["To succeed in the current era marked by successive new infectious pandemics, vaccine policies must be better harmonized, widely disseminated and constantly updated.", [["successive new infectious pandemics", "PROBLEM", 40, 75], ["vaccine policies", "TREATMENT", 77, 93], ["new", "OBSERVATION_MODIFIER", 51, 54], ["infectious", "OBSERVATION", 55, 65]]], ["The less well-known effects of vaccines on the prevention of cardiovascular events and reduction of antimicrobial resistance are good examples of the constant and growing interest of lifelong immunization.", [["cardiovascular", "ANATOMY", 61, 75], ["cardiovascular", "ANATOMICAL_SYSTEM", 61, 75], ["vaccines", "TREATMENT", 31, 39], ["cardiovascular events", "PROBLEM", 61, 82], ["antimicrobial resistance", "TREATMENT", 100, 124], ["lifelong immunization", "TREATMENT", 183, 204], ["less", "OBSERVATION_MODIFIER", 4, 8], ["well-known effects", "OBSERVATION_MODIFIER", 9, 27], ["antimicrobial resistance", "OBSERVATION", 100, 124]]]], "PMC4008647": [["Preparation of Human Leiomyoma Cells ::: Materials and methodsLeiomyoma samples were obtained from surgeries from 38 women (age range, 27\u201353 years) undergoing hysterectomy or myomectomy.", [["Leiomyoma Cells", "ANATOMY", 21, 36], ["Leiomyoma samples", "ANATOMY", 62, 79], ["Human", "ORGANISM", 15, 20], ["Leiomyoma Cells", "CELL", 21, 36], ["Leiomyoma samples", "CANCER", 62, 79], ["women", "ORGANISM", 117, 122], ["Human", "SPECIES", 15, 20], ["women", "SPECIES", 117, 122], ["methodsLeiomyoma samples", "PROBLEM", 55, 79], ["surgeries", "TREATMENT", 99, 108], ["hysterectomy", "TREATMENT", 159, 171], ["myomectomy", "TREATMENT", 175, 185], ["Leiomyoma Cells", "OBSERVATION", 21, 36], ["Leiomyoma", "OBSERVATION", 62, 71], ["hysterectomy", "OBSERVATION", 159, 171], ["myomectomy", "OBSERVATION", 175, 185]]], ["We used leiomyomas derived from patients without receiving hormonal treatment.", [["leiomyomas", "ANATOMY", 8, 18], ["leiomyomas", "DISEASE", 8, 18], ["leiomyomas", "CANCER", 8, 18], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["leiomyomas", "PROBLEM", 8, 18], ["hormonal treatment", "TREATMENT", 59, 77], ["leiomyomas", "OBSERVATION", 8, 18]]], ["Deidentified patient information was collected, including age, weight, height, race, day of last menstrual cycle, parity, and use of oral contraceptives.", [["oral", "ANATOMY", 133, 137], ["oral contraceptives", "CHEMICAL", 133, 152], ["patient", "ORGANISM", 13, 20], ["oral", "ORGANISM_SUBDIVISION", 133, 137], ["patient", "SPECIES", 13, 20], ["weight", "TEST", 63, 69], ["oral contraceptives", "TREATMENT", 133, 152]]], ["Written informed consent was obtained from each patient, and the use of human tissue was approved by the Institutional Review Board for Human Research at Northwestern University, Chicago, Illinois.", [["tissue", "ANATOMY", 78, 84], ["patient", "ORGANISM", 48, 55], ["human", "ORGANISM", 72, 77], ["tissue", "TISSUE", 78, 84], ["Human", "ORGANISM", 136, 141], ["patient", "SPECIES", 48, 55], ["human", "SPECIES", 72, 77], ["Human", "SPECIES", 136, 141], ["human", "SPECIES", 72, 77]]], ["None of the women had a previous history of uterine cancer, and all samples were confirmed by histopathologic examination to be free of malignancy.Cell Culture and Treatment ::: Materials and methodsWe isolated leiomyoma cells using a technique that was previously described 35, 36.", [["uterine cancer", "ANATOMY", 44, 58], ["samples", "ANATOMY", 68, 75], ["Cell", "ANATOMY", 147, 151], ["leiomyoma cells", "ANATOMY", 211, 226], ["uterine cancer", "DISEASE", 44, 58], ["malignancy", "DISEASE", 136, 146], ["leiomyoma", "DISEASE", 211, 220], ["women", "ORGANISM", 12, 17], ["uterine cancer", "CANCER", 44, 58], ["samples", "CANCER", 68, 75], ["malignancy", "CANCER", 136, 146], ["Cell", "CELL", 147, 151], ["leiomyoma cells", "CELL", 211, 226], ["leiomyoma cells", "CELL_TYPE", 211, 226], ["women", "SPECIES", 12, 17], ["uterine cancer", "PROBLEM", 44, 58], ["all samples", "TEST", 64, 75], ["histopathologic examination", "TEST", 94, 121], ["malignancy", "PROBLEM", 136, 146], ["Cell Culture", "TEST", 147, 159], ["isolated leiomyoma cells", "PROBLEM", 202, 226], ["a technique", "TEST", 233, 244], ["uterine", "ANATOMY", 44, 51], ["cancer", "OBSERVATION", 52, 58], ["malignancy", "OBSERVATION", 136, 146], ["leiomyoma cells", "OBSERVATION", 211, 226]]], ["We used \u03b1-smooth muscle actin protein expression and MED12 gene mutations as a marker for leiomyoma cells.", [["\u03b1-smooth muscle", "ANATOMY", 8, 23], ["leiomyoma cells", "ANATOMY", 90, 105], ["leiomyoma", "DISEASE", 90, 99], ["\u03b1-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 8, 29], ["MED12", "GENE_OR_GENE_PRODUCT", 53, 58], ["leiomyoma cells", "CELL", 90, 105], ["\u03b1-smooth muscle actin protein", "PROTEIN", 8, 37], ["MED12 gene", "DNA", 53, 63], ["leiomyoma cells", "CELL_TYPE", 90, 105], ["\u03b1-smooth muscle actin protein expression", "TREATMENT", 8, 48], ["MED12 gene mutations", "PROBLEM", 53, 73], ["leiomyoma cells", "PROBLEM", 90, 105], ["muscle", "ANATOMY", 17, 23], ["actin protein expression", "OBSERVATION", 24, 48]]], ["Leiomyoma cells were cultured in 96-well flat-bottomed plates in Dulbecco's modified eagle medium (DMEM)/F12 1:1 (Life Technologies) containing 10% fetal bovine serum and grown in a humidified atmosphere with 5% CO2 at 37\u00b0C. Freshly cultured leiomyoma cells were treated with 30 mmol/L of NaCl (Sigma) for the baseline \u03b2-catenin condition or 30 mmol/L of LiCl (Sigma) to inhibit GSK-3\u03b2 activity, thereby activating \u03b2-catenin (37).", [["Leiomyoma cells", "ANATOMY", 0, 15], ["fetal bovine serum", "ANATOMY", 148, 166], ["leiomyoma cells", "ANATOMY", 242, 257], ["CO2", "CHEMICAL", 212, 215], ["NaCl", "CHEMICAL", 289, 293], ["\u03b2-catenin", "CHEMICAL", 319, 328], ["LiCl", "CHEMICAL", 355, 359], ["CO2", "CHEMICAL", 212, 215], ["NaCl", "CHEMICAL", 289, 293], ["LiCl", "CHEMICAL", 355, 359], ["Leiomyoma cells", "CELL", 0, 15], ["bovine", "ORGANISM", 154, 160], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["CO2", "SIMPLE_CHEMICAL", 212, 215], ["leiomyoma cells", "CELL", 242, 257], ["NaCl", "SIMPLE_CHEMICAL", 289, 293], ["\u03b2-catenin", "SIMPLE_CHEMICAL", 319, 328], ["LiCl", "SIMPLE_CHEMICAL", 355, 359], ["Sigma", "SIMPLE_CHEMICAL", 361, 366], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 379, 385], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 415, 424], ["Leiomyoma cells", "CELL_TYPE", 0, 15], ["leiomyoma cells", "CELL_TYPE", 242, 257], ["GSK-3\u03b2", "PROTEIN", 379, 385], ["bovine", "SPECIES", 154, 160], ["bovine", "SPECIES", 154, 160], ["Leiomyoma cells", "PROBLEM", 0, 15], ["10% fetal bovine serum", "TREATMENT", 144, 166], ["a humidified atmosphere", "TREATMENT", 180, 203], ["5% CO2", "TREATMENT", 209, 215], ["Freshly cultured leiomyoma cells", "PROBLEM", 225, 257], ["NaCl", "TREATMENT", 289, 293], ["the baseline \u03b2-catenin condition", "PROBLEM", 306, 338], ["leiomyoma cells", "OBSERVATION", 242, 257]]], ["For cell proliferation assays, leiomyoma cells were incubated for 3 days with various concentrations of niclosamide (0.4, 2, or 10 \u03bcmol/L; Sigma) or XAV939 (0.1, 1, 10, or 20 \u03bcmol/L; R&D Systems).", [["cell", "ANATOMY", 4, 8], ["leiomyoma cells", "ANATOMY", 31, 46], ["niclosamide", "CHEMICAL", 104, 115], ["XAV939", "CHEMICAL", 149, 155], ["niclosamide", "CHEMICAL", 104, 115], ["XAV939", "CHEMICAL", 149, 155], ["cell", "CELL", 4, 8], ["leiomyoma cells", "CELL", 31, 46], ["niclosamide", "SIMPLE_CHEMICAL", 104, 115], ["XAV939", "SIMPLE_CHEMICAL", 149, 155], ["leiomyoma cells", "CELL_TYPE", 31, 46], ["cell proliferation assays", "TEST", 4, 29], ["leiomyoma cells", "PROBLEM", 31, 46], ["niclosamide", "TREATMENT", 104, 115], ["cell proliferation", "OBSERVATION", 4, 22]]], ["Reagents were diluted with dimethyl sulfoxide (DMSO; Sigma).", [["dimethyl sulfoxide", "CHEMICAL", 27, 45], ["DMSO", "CHEMICAL", 47, 51], ["dimethyl sulfoxide", "CHEMICAL", 27, 45], ["DMSO", "CHEMICAL", 47, 51], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 27, 45], ["DMSO", "SIMPLE_CHEMICAL", 47, 51], ["Sigma", "SIMPLE_CHEMICAL", 53, 58], ["dimethyl sulfoxide (DMSO", "TREATMENT", 27, 51]]], ["Control cells were treated with DMSO.ICAT Adenoviral Transduction ::: Materials and methodsLeiomyoma cells were cultured in 96-well flat-bottom plates and infected with adenovirus encoding green fluorescent protein (Ad-GFP) and Ad-ICAT for 72 hours.", [["cells", "ANATOMY", 8, 13], ["Leiomyoma cells", "ANATOMY", 91, 106], ["DMSO", "CHEMICAL", 32, 36], ["DMSO", "CHEMICAL", 32, 36], ["cells", "CELL", 8, 13], ["DMSO", "SIMPLE_CHEMICAL", 32, 36], ["Leiomyoma cells", "CELL", 91, 106], ["adenovirus", "ORGANISM", 169, 179], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 189, 214], ["Ad-GFP", "GENE_OR_GENE_PRODUCT", 216, 222], ["Ad-ICAT", "GENE_OR_GENE_PRODUCT", 228, 235], ["Leiomyoma cells", "CELL_TYPE", 91, 106], ["green fluorescent protein", "PROTEIN", 189, 214], ["GFP", "PROTEIN", 219, 222], ["ICAT", "PROTEIN", 231, 235], ["Adenoviral", "SPECIES", 42, 52], ["adenovirus", "SPECIES", 169, 179], ["DMSO", "TREATMENT", 32, 36], ["methodsLeiomyoma cells", "PROBLEM", 84, 106], ["bottom plates", "TEST", 137, 150], ["adenovirus", "PROBLEM", 169, 179], ["fluorescent protein", "TEST", 195, 214], ["Leiomyoma", "OBSERVATION", 91, 100]]], ["The myc-ICAT complementary DNA was provided by Tetsu Akiyama (University of Tokyo) and re-engineered by Vector Biolabs to encode a bicistronic messenger RNA that translates myc-ICAT and GFP proteins [Ad-ICAT (Myc)-Internal Ribosome Entry Site-GFP], and Ad-GFP viruses were used as a control for ICAT treatment and supplied by Tong Chuan He (University of Chicago).", [["DNA", "CELLULAR_COMPONENT", 27, 30], ["Vector Biolabs", "GENE_OR_GENE_PRODUCT", 104, 118], ["myc-ICAT", "GENE_OR_GENE_PRODUCT", 173, 181], ["GFP", "GENE_OR_GENE_PRODUCT", 186, 189], ["Ad-ICAT", "GENE_OR_GENE_PRODUCT", 200, 207], ["Myc", "GENE_OR_GENE_PRODUCT", 209, 212], ["GFP", "GENE_OR_GENE_PRODUCT", 243, 246], ["Ad-GFP", "GENE_OR_GENE_PRODUCT", 253, 259], ["myc-ICAT complementary DNA", "DNA", 4, 30], ["Vector Biolabs", "PROTEIN", 104, 118], ["bicistronic messenger RNA", "RNA", 131, 156], ["myc-ICAT and GFP proteins", "PROTEIN", 173, 198], ["Ad-ICAT", "PROTEIN", 200, 207], ["Myc", "PROTEIN", 209, 212], ["GFP", "PROTEIN", 243, 246], ["a bicistronic messenger RNA", "TREATMENT", 129, 156], ["GFP proteins", "TEST", 186, 198], ["Myc", "TEST", 209, 212], ["Ad-GFP viruses", "TREATMENT", 253, 267], ["ICAT treatment", "TREATMENT", 295, 309]]], ["Infection efficiency of >90% was confirmed by visualizing GFP expression in living cells.", [["cells", "ANATOMY", 83, 88], ["GFP", "GENE_OR_GENE_PRODUCT", 58, 61], ["cells", "CELL", 83, 88], ["GFP", "PROTEIN", 58, 61], ["living cells", "CELL_TYPE", 76, 88], ["Infection efficiency", "PROBLEM", 0, 20], ["GFP expression", "OBSERVATION", 58, 72], ["living cells", "OBSERVATION", 76, 88]]], ["Leiomyoma cells without adenoviral infection were used as controls.Cell Proliferation Assay ::: Materials and methodsAfter viral transduction, cells were incubated for 3 days.", [["Leiomyoma cells", "ANATOMY", 0, 15], ["Cell", "ANATOMY", 67, 71], ["cells", "ANATOMY", 143, 148], ["adenoviral infection", "DISEASE", 24, 44], ["Leiomyoma cells", "CELL", 0, 15], ["adenoviral", "ORGANISM", 24, 34], ["Cell", "CELL", 67, 71], ["cells", "CELL", 143, 148], ["Leiomyoma cells", "CELL_TYPE", 0, 15], ["Leiomyoma cells", "PROBLEM", 0, 15], ["adenoviral infection", "PROBLEM", 24, 44], ["viral transduction", "TREATMENT", 123, 141], ["without", "UNCERTAINTY", 16, 23], ["adenoviral", "OBSERVATION_MODIFIER", 24, 34], ["infection", "OBSERVATION", 35, 44]]], ["Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay.", [["Cell", "ANATOMY", 0, 4], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 35, 123], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 35, 123], ["MTS", "CHEMICAL", 137, 140], ["Cell", "CELL", 0, 4], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "SIMPLE_CHEMICAL", 35, 123], ["inner salt", "SIMPLE_CHEMICAL", 125, 135], ["Cell proliferation", "PROBLEM", 0, 18], ["dimethylthiazol", "TREATMENT", 42, 57], ["carboxymethoxyphenyl)", "TREATMENT", 69, 90], ["tetrazolium, inner salt (MTS)", "TREATMENT", 112, 141]]], ["Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega) was used according to the manufacturer's instructions.", [["Cell", "ANATOMY", 0, 4], ["Cell", "ANATOMY", 35, 39], ["Cell", "CELL", 0, 4], ["Cell Titer", "TREATMENT", 0, 10], ["Aqueous One Solution Cell Proliferation Assay (Promega)", "TREATMENT", 14, 69]]], ["Proliferation was measured as the optical density (OD) at 490 nm on a Synergy-HT plate reader (Bio-Tek Instruments).Lactate Dehydrogenase Cell Death Assay ::: Materials and methodsLeiomyoma cell death was assayed as previously described (38).", [["Leiomyoma cell", "ANATOMY", 180, 194], ["Lactate", "CHEMICAL", 116, 123], ["Leiomyoma cell death", "DISEASE", 180, 200], ["Lactate", "CHEMICAL", 116, 123], ["Lactate", "SIMPLE_CHEMICAL", 116, 123], ["Leiomyoma cell", "CELL", 180, 194], ["a Synergy-HT plate", "TREATMENT", 68, 86], ["Bio-Tek Instruments", "TREATMENT", 95, 114], ["Lactate Dehydrogenase Cell Death Assay", "TEST", 116, 154], ["methodsLeiomyoma cell death", "PROBLEM", 173, 200], ["optical", "OBSERVATION_MODIFIER", 34, 41], ["density", "OBSERVATION", 42, 49], ["Dehydrogenase Cell Death", "OBSERVATION", 124, 148], ["Leiomyoma cell death", "OBSERVATION", 180, 200]]], ["Lactate dehydrogenase (LDH) activity was measured using a Cytotoxicity Detection Kit (Roche).", [["Lactate", "CHEMICAL", 0, 7], ["Lactate", "CHEMICAL", 0, 7], ["Lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 21], ["LDH", "GENE_OR_GENE_PRODUCT", 23, 26], ["Lactate dehydrogenase", "PROTEIN", 0, 21], ["LDH", "PROTEIN", 23, 26], ["Lactate dehydrogenase", "TEST", 0, 21], ["LDH) activity", "TEST", 23, 36], ["a Cytotoxicity", "TEST", 56, 70]]], ["The OD490 was read using a Synergy-HT plate reader and software (Bio-Tek Instruments).Quantitative Real-time Reverse Transcription\u2013polymerase Chain Reaction ::: Materials and methodsTotal RNA was extracted using the RNeasy Mini Kit (Qiagen) according to manufacturer's instructions.", [["OD490", "DNA", 4, 9], ["a Synergy-HT plate", "TREATMENT", 25, 43], ["software (Bio-Tek Instruments", "TREATMENT", 55, 84], ["Total RNA", "TREATMENT", 182, 191], ["the RNeasy Mini Kit (Qiagen)", "TREATMENT", 212, 240]]], ["Complementary DNA was synthesized from 1 \u03bcg of RNA using qScript cDNA SuperMix (Quanta Biosciences).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["qScript cDNA SuperMix", "DNA", 57, 78], ["Complementary DNA", "PROBLEM", 0, 17], ["RNA", "TREATMENT", 47, 50], ["qScript cDNA SuperMix (Quanta Biosciences", "TREATMENT", 57, 98]]], ["Quantitative real-time reverse transcription\u2013polymerase chain reaction (RT-PCR) of the WNT target genes AXIN2 (NM_004655) and Naked 1 (NKD1) (NM_033119) was performed using the ABI 7900HT (Life Technologies) and Power SYBR Green PCR Master Mix (Life Technologies) for 40 cycles, with each cycle consisting of a 15-second denaturation at 95.0\u00b0C, followed by 1 minute of annealing at 60.0\u00b0C. The sizes of amplicons were 102 bp and 99 bp for AXIN2 and NKD1, respectively.", [["WNT", "GENE_OR_GENE_PRODUCT", 87, 90], ["Naked 1", "GENE_OR_GENE_PRODUCT", 126, 133], ["NKD1", "GENE_OR_GENE_PRODUCT", 135, 139], ["AXIN2", "GENE_OR_GENE_PRODUCT", 439, 444], ["NKD1", "GENE_OR_GENE_PRODUCT", 449, 453], ["WNT target genes", "DNA", 87, 103], ["AXIN2", "DNA", 104, 109], ["NM_004655", "DNA", 111, 120], ["Naked 1", "DNA", 126, 133], ["NKD1", "DNA", 135, 139], ["NM_033119", "DNA", 142, 151], ["AXIN2", "DNA", 439, 444], ["NKD1", "DNA", 449, 453], ["reverse transcription\u2013polymerase chain reaction", "PROBLEM", 23, 70], ["RT-PCR", "TEST", 72, 78], ["AXIN2", "TEST", 104, 109], ["NM_", "TEST", 111, 114], ["the ABI", "TEST", 173, 180], ["Power SYBR Green PCR Master Mix (Life Technologies", "TREATMENT", 212, 262], ["a 15-second denaturation", "TREATMENT", 309, 333], ["amplicons", "TEST", 403, 412], ["bp", "TEST", 422, 424], ["bp", "TEST", 432, 434], ["AXIN2", "TEST", 439, 444], ["NKD1", "TEST", 449, 453], ["sizes", "OBSERVATION_MODIFIER", 394, 399]]], ["The specificity of each PCR product was analyzed using the built-in melting curve analysis tool for each DNA product identified.", [["DNA", "CELLULAR_COMPONENT", 105, 108], ["each PCR product", "TEST", 19, 35], ["melting curve analysis", "TEST", 68, 90], ["each DNA product", "TREATMENT", 100, 116]]], ["For any sample, the expression level, normalized to the housekeeping gene encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (NM_002046), was determined with the comparative threshold cycle (Ct) method.Transfections and \u03b2-Catenin/TCF Reporter Assay ::: Materials and methodsLeiomyoma cells were transfected with a TCF optimal luciferase promoter plasmid (TOPflash; containing four consensus TCF-binding sites upstream of a minimal c-fos promoter) or FOPflash (containing four mutant TCF-binding sites; kindly provided by H. Clevers, Utrecht, the Netherlands), using Lipofectamine 2000 (Invitrogen).", [["Leiomyoma cells", "ANATOMY", 281, 296], ["glyceraldehyde-3-phosphate", "CHEMICAL", 83, 109], ["glyceraldehyde-3-phosphate", "CHEMICAL", 83, 109], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 83, 123], ["GAPDH", "GENE_OR_GENE_PRODUCT", 125, 130], ["NM_002046", "SIMPLE_CHEMICAL", 133, 142], ["\u03b2-Catenin", "GENE_OR_GENE_PRODUCT", 227, 236], ["TCF", "GENE_OR_GENE_PRODUCT", 237, 240], ["Leiomyoma cells", "CELL", 281, 296], ["TCF", "GENE_OR_GENE_PRODUCT", 321, 324], ["luciferase", "GENE_OR_GENE_PRODUCT", 333, 343], ["TCF", "GENE_OR_GENE_PRODUCT", 398, 401], ["c-fos", "GENE_OR_GENE_PRODUCT", 438, 443], ["TCF", "GENE_OR_GENE_PRODUCT", 490, 493], ["housekeeping gene", "DNA", 56, 73], ["glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 83, 123], ["GAPDH", "PROTEIN", 125, 130], ["NM_002046", "PROTEIN", 133, 142], ["\u03b2-Catenin", "PROTEIN", 227, 236], ["TCF", "PROTEIN", 237, 240], ["Leiomyoma cells", "CELL_TYPE", 281, 296], ["TCF optimal luciferase promoter plasmid", "DNA", 321, 360], ["TOPflash", "DNA", 362, 370], ["consensus TCF-binding sites", "DNA", 388, 415], ["minimal c-fos promoter", "DNA", 430, 452], ["FOPflash", "DNA", 457, 465], ["mutant TCF-binding sites", "DNA", 483, 507], ["the expression level", "TEST", 16, 36], ["phosphate dehydrogenase (GAPDH)", "PROBLEM", 100, 131], ["Ct) method", "TEST", 198, 208], ["methodsLeiomyoma cells", "PROBLEM", 274, 296], ["a TCF optimal luciferase promoter plasmid (TOPflash", "TREATMENT", 319, 370], ["binding sites", "PROBLEM", 402, 415], ["a minimal c-fos promoter", "TREATMENT", 428, 452], ["FOPflash", "PROBLEM", 457, 465], ["Lipofectamine", "TREATMENT", 573, 586], ["Leiomyoma", "OBSERVATION", 281, 290]]], ["A thymidine kinase\u2013Renilla plasmid (50 ng) was cotransfected to normalize luciferase values to transfection efficiency.", [["thymidine", "CHEMICAL", 2, 11], ["thymidine", "CHEMICAL", 2, 11], ["thymidine kinase\u2013", "GENE_OR_GENE_PRODUCT", 2, 19], ["luciferase", "GENE_OR_GENE_PRODUCT", 74, 84], ["thymidine kinase\u2013Renilla plasmid", "DNA", 2, 34], ["luciferase", "PROTEIN", 74, 84], ["A thymidine kinase\u2013Renilla plasmid", "TREATMENT", 0, 34], ["luciferase values", "TEST", 74, 91], ["transfection efficiency", "PROBLEM", 95, 118], ["transfection efficiency", "OBSERVATION", 95, 118]]], ["Cells were treated with niclosamide or XAV939, with or without LiCl, 24 hours after transfection.", [["Cells", "ANATOMY", 0, 5], ["niclosamide", "CHEMICAL", 24, 35], ["XAV939", "CHEMICAL", 39, 45], ["LiCl", "CHEMICAL", 63, 67], ["niclosamide", "CHEMICAL", 24, 35], ["XAV939", "CHEMICAL", 39, 45], ["LiCl", "CHEMICAL", 63, 67], ["Cells", "CELL", 0, 5], ["niclosamide", "SIMPLE_CHEMICAL", 24, 35], ["XAV939", "SIMPLE_CHEMICAL", 39, 45], ["LiCl", "SIMPLE_CHEMICAL", 63, 67], ["niclosamide", "TREATMENT", 24, 35], ["LiCl", "TREATMENT", 63, 67]]], ["Cells were solubilized 2 days after transfection using the Dual-Luciferase Assay Kit (Promega), and luciferase activity was quantified with a Synergy-HT plate reader (Bio-Tek Instruments).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Kit", "GENE_OR_GENE_PRODUCT", 81, 84], ["luciferase", "GENE_OR_GENE_PRODUCT", 100, 110], ["luciferase", "PROTEIN", 100, 110], ["transfection", "TREATMENT", 36, 48], ["the Dual-Luciferase Assay Kit (Promega)", "TREATMENT", 55, 94], ["a Synergy-HT plate reader (Bio-Tek Instruments", "TREATMENT", 140, 186]]], ["Firefly luciferase readings were first normalized to the reading for the corresponding Renilla luciferase reading to normalize for transfection efficiency.", [["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["luciferase", "GENE_OR_GENE_PRODUCT", 95, 105], ["luciferase", "PROTEIN", 8, 18], ["Renilla luciferase reading", "DNA", 87, 113], ["Firefly luciferase readings", "TEST", 0, 27], ["the corresponding Renilla luciferase", "TEST", 69, 105], ["transfection efficiency", "PROBLEM", 131, 154]]], ["The adjusted TOPflash reading was then normalized to the corresponding adjusted FOPflash reading to account for background reading of the TOPflash construct.Immunofluorescence Staining ::: Materials and methodsIndirect immunofluorescence staining was performed as described previously 35, 36, 39.", [["TOPflash reading", "DNA", 13, 29], ["FOPflash reading", "DNA", 80, 96], ["TOPflash construct", "DNA", 138, 156], ["The adjusted TOPflash", "TEST", 0, 21], ["Indirect immunofluorescence staining", "TEST", 210, 246]]], ["Background fluorescence was determined by applying the secondary conjugated antibody alone and by replacement of the primary antibody with nonimmune serum.", [["serum", "ANATOMY", 149, 154], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["secondary conjugated antibody", "PROTEIN", 55, 84], ["primary antibody", "PROTEIN", 117, 133], ["Background fluorescence", "PROBLEM", 0, 23], ["the secondary conjugated antibody", "TREATMENT", 51, 84], ["the primary antibody", "TEST", 113, 133], ["nonimmune serum", "PROBLEM", 139, 154]]], ["Slides were successively stained with \u03b2-catenin antibody (clone 14; 1:100; BD Biosciences), followed by incubation with secondary antibodies labeled with Alexa Fluor 488 Dye (Molecular Probes Life Technologies).", [["Alexa Fluor 488", "CHEMICAL", 154, 169], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 38, 47], ["Alexa Fluor 488 Dye", "SIMPLE_CHEMICAL", 154, 173], ["\u03b2-catenin antibody", "PROTEIN", 38, 56], ["BD Biosciences", "PROTEIN", 75, 89], ["secondary antibodies", "PROTEIN", 120, 140], ["Slides", "TEST", 0, 6], ["\u03b2-catenin antibody", "TEST", 38, 56], ["BD Biosciences", "TEST", 75, 89], ["secondary antibodies", "PROBLEM", 120, 140], ["Alexa Fluor", "TREATMENT", 154, 165]]], ["Images were collected using a confocal laser scanning system (LSM 510; Karl Zeiss).Cadherin-free \u03b2-catenin\u2013binding Assays ::: Materials and methodsTo evaluate activation of canonical WNT signaling, intracellular levels of cadherin-free \u03b2-catenin were determined by pull-down assays using glutathione S-transferase (GST)/ICAT, as previously described (40).", [["intracellular", "ANATOMY", 198, 211], ["glutathione", "CHEMICAL", 288, 299], ["glutathione", "CHEMICAL", 288, 299], ["S", "CHEMICAL", 300, 301], ["Cadherin", "GENE_OR_GENE_PRODUCT", 83, 91], ["WNT", "GENE_OR_GENE_PRODUCT", 183, 186], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 211], ["cadherin", "GENE_OR_GENE_PRODUCT", 222, 230], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 236, 245], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 288, 313], ["GST", "GENE_OR_GENE_PRODUCT", 315, 318], ["ICAT", "GENE_OR_GENE_PRODUCT", 320, 324], ["Cadherin", "PROTEIN", 83, 91], ["WNT", "PROTEIN", 183, 186], ["cadherin", "PROTEIN", 222, 230], ["\u03b2-catenin", "PROTEIN", 236, 245], ["glutathione S-transferase", "PROTEIN", 288, 313], ["GST", "PROTEIN", 315, 318], ["ICAT", "PROTEIN", 320, 324], ["Images", "TEST", 0, 6], ["canonical WNT signaling", "PROBLEM", 173, 196], ["cadherin-free \u03b2-catenin", "TREATMENT", 222, 245], ["glutathione S-transferase (GST)/ICAT", "TREATMENT", 288, 324]]], ["At the end of the treatment period, cells were harvested, solubilized in a nonionic detergent buffer (1% Nonidet P40, 50 mM Tris [pH 7.5], 150 mM NaCl, and 2 mM ethylenediaminetetraacetic acid including protease inhibitors) and centrifuged at 14,000 \u00d7 g.", [["cells", "ANATOMY", 36, 41], ["NaCl", "CHEMICAL", 146, 150], ["ethylenediaminetetraacetic acid", "CHEMICAL", 161, 192], ["NaCl", "CHEMICAL", 146, 150], ["ethylenediaminetetraacetic acid", "CHEMICAL", 161, 192], ["cells", "CELL", 36, 41], ["Nonidet P40", "SIMPLE_CHEMICAL", 105, 116], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 161, 192], ["cells", "PROBLEM", 36, 41], ["a nonionic detergent buffer", "TREATMENT", 73, 100], ["pH", "TEST", 130, 132], ["NaCl", "TEST", 146, 150], ["2 mM ethylenediaminetetraacetic acid", "TREATMENT", 156, 192], ["protease inhibitors", "TREATMENT", 203, 222]]], ["Cellular \u03b2-catenin was affinity-precipitated using GST-ICAT immobilized to glutathione-coupled Sepharose (Sigma), washed with buffer A (10 mM Tris [pH 8.0], 140 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 0.1% Nonidet P40, and 10 \u03bcg/mL leupeptin and aprotinin), and subjected to sodium dodecyl sulfate\u2013polyacrylamide gel electrophoresis and immunoblot analysis using \u03b2-catenin, ICAT (polyclonal; Santa Cruz Biotechnology) and \u03b2-actin antibody (clone; AC-15, Sigma).Statistical Analysis ::: Materials and methodsEach experiment was repeated using cells from at least three subjects, followed by statistical analysis.", [["Cellular", "ANATOMY", 0, 8], ["cells", "ANATOMY", 549, 554], ["\u03b2-catenin", "CHEMICAL", 9, 18], ["glutathione", "CHEMICAL", 75, 86], ["NaCl", "CHEMICAL", 164, 168], ["ethylenediaminetetraacetic acid", "CHEMICAL", 175, 206], ["sodium dodecyl sulfate\u2013polyacrylamide", "CHEMICAL", 282, 319], ["glutathione", "CHEMICAL", 75, 86], ["NaCl", "CHEMICAL", 164, 168], ["ethylenediaminetetraacetic acid", "CHEMICAL", 175, 206], ["Nonidet P40", "CHEMICAL", 213, 224], ["leupeptin", "CHEMICAL", 239, 248], ["aprotinin", "CHEMICAL", 253, 262], ["sodium dodecyl sulfate\u2013polyacrylamide", "CHEMICAL", 282, 319], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 9, 18], ["GST-ICAT", "GENE_OR_GENE_PRODUCT", 51, 59], ["glutathione", "SIMPLE_CHEMICAL", 75, 86], ["Sepharose", "SIMPLE_CHEMICAL", 95, 104], ["Sigma", "SIMPLE_CHEMICAL", 106, 111], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 175, 206], ["Nonidet P40", "SIMPLE_CHEMICAL", 213, 224], ["leupeptin", "SIMPLE_CHEMICAL", 239, 248], ["aprotinin", "SIMPLE_CHEMICAL", 253, 262], ["sodium dodecyl sulfate\u2013polyacrylamide", "SIMPLE_CHEMICAL", 282, 319], ["\u03b2-catenin", "SIMPLE_CHEMICAL", 370, 379], ["ICAT", "GENE_OR_GENE_PRODUCT", 381, 385], ["\u03b2-actin antibody", "GENE_OR_GENE_PRODUCT", 429, 445], ["clone", "CELL", 447, 452], ["cells", "CELL", 549, 554], ["\u03b2-catenin", "PROTEIN", 9, 18], ["GST", "PROTEIN", 51, 54], ["ICAT", "PROTEIN", 55, 59], ["\u03b2-catenin", "PROTEIN", 370, 379], ["ICAT", "PROTEIN", 381, 385], ["polyclonal; Santa Cruz Biotechnology", "PROTEIN", 387, 423], ["\u03b2-actin antibody", "PROTEIN", 429, 445], ["AC", "PROTEIN", 454, 456], ["affinity", "TEST", 23, 31], ["GST", "TEST", 51, 54], ["glutathione", "TEST", 75, 86], ["pH", "TEST", 148, 150], ["140 mM NaCl", "TREATMENT", 157, 168], ["1 mM ethylenediaminetetraacetic acid", "TREATMENT", 170, 206], ["0.1% Nonidet P40", "TREATMENT", 208, 224], ["leupeptin", "TREATMENT", 239, 248], ["aprotinin", "TREATMENT", 253, 262], ["sodium dodecyl sulfate\u2013polyacrylamide", "TREATMENT", 282, 319], ["gel electrophoresis", "TEST", 320, 339], ["immunoblot analysis", "TEST", 344, 363], ["\u03b2-catenin", "TEST", 370, 379], ["ICAT", "TEST", 381, 385], ["\u03b2-actin antibody", "TEST", 429, 445], ["AC", "TEST", 454, 456], ["statistical analysis", "TEST", 597, 617]]], ["Probability (P) values were calculated using the Student t test.", [["the Student t test", "TEST", 45, 63]]], ["Values of P<.05 were considered statistically significant.Adenoviral Overexpression of ICAT Inhibits Human Leiomyoma Cell Proliferation ::: ResultsBecause leiomyoma proliferation is thought to be a critical step in leiomyoma tumorigenesis, we addressed the contribution of WNT/\u03b2-catenin signaling to these phenotypes using cultures of human leiomyoma cells and adenoviruses (Ad-ICAT), which can inhibit WNT/\u03b2-catenin signaling.", [["Leiomyoma Cell", "ANATOMY", 107, 121], ["leiomyoma", "ANATOMY", 155, 164], ["leiomyoma", "ANATOMY", 215, 224], ["leiomyoma cells", "ANATOMY", 341, 356], ["leiomyoma", "DISEASE", 155, 164], ["leiomyoma", "DISEASE", 215, 224], ["leiomyoma", "DISEASE", 341, 350], ["Adenoviral", "ORGANISM", 58, 68], ["ICAT", "GENE_OR_GENE_PRODUCT", 87, 91], ["Human", "ORGANISM", 101, 106], ["Leiomyoma Cell", "CELL", 107, 121], ["leiomyoma", "CANCER", 155, 164], ["leiomyoma", "CANCER", 215, 224], ["WNT", "GENE_OR_GENE_PRODUCT", 273, 276], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 277, 286], ["human", "ORGANISM", 335, 340], ["leiomyoma cells", "CELL", 341, 356], ["adenoviruses", "ORGANISM", 361, 373], ["Ad-ICAT", "GENE_OR_GENE_PRODUCT", 375, 382], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 403, 416], ["ICAT", "PROTEIN", 87, 91], ["WNT", "PROTEIN", 273, 276], ["\u03b2-catenin", "PROTEIN", 277, 286], ["human leiomyoma cells", "CELL_TYPE", 335, 356], ["WNT", "PROTEIN", 403, 406], ["\u03b2-catenin", "PROTEIN", 407, 416], ["Human", "SPECIES", 101, 106], ["human", "SPECIES", 335, 340], ["Adenoviral", "SPECIES", 58, 68], ["human", "SPECIES", 335, 340], ["Values", "TEST", 0, 6], ["P", "TEST", 10, 11], ["leiomyoma proliferation", "PROBLEM", 155, 178], ["a critical step in leiomyoma tumorigenesis", "PROBLEM", 196, 238], ["WNT/\u03b2-catenin", "TREATMENT", 273, 286], ["these phenotypes", "PROBLEM", 300, 316], ["cultures", "TEST", 323, 331], ["human leiomyoma cells", "PROBLEM", 335, 356], ["adenoviruses", "PROBLEM", 361, 373], ["catenin signaling", "PROBLEM", 409, 426], ["Leiomyoma Cell Proliferation", "OBSERVATION", 107, 135], ["leiomyoma", "OBSERVATION", 155, 164], ["thought to be", "UNCERTAINTY", 182, 195], ["leiomyoma", "OBSERVATION", 215, 224], ["leiomyoma cells", "OBSERVATION", 341, 356]]], ["Human leiomyoma cells were transduced with Ad-GFP or Ad-ICAT for 72 hours.", [["leiomyoma cells", "ANATOMY", 6, 21], ["Human", "ORGANISM", 0, 5], ["leiomyoma cells", "CELL", 6, 21], ["Ad", "ORGANISM", 43, 45], ["GFP", "GENE_OR_GENE_PRODUCT", 46, 49], ["Ad", "ORGANISM", 53, 55], ["-ICAT", "GENE_OR_GENE_PRODUCT", 55, 60], ["Human leiomyoma cells", "CELL_TYPE", 0, 21], ["ICAT", "PROTEIN", 56, 60], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human leiomyoma cells", "PROBLEM", 0, 21], ["leiomyoma", "OBSERVATION", 6, 15]]], ["After viral transduction, cells were incubated for 3 days.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["viral transduction", "TREATMENT", 6, 24]]], ["Cell proliferation was measured by MTS assay (n = 3).", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell proliferation", "PROBLEM", 0, 18], ["MTS assay", "TEST", 35, 44]]], ["Leiomyoma cells transduced with Ad-ICAT exhibited significantly lower proliferation compared with Ad-GFP transduced cells (Supplemental Fig. 1A, available online).", [["Leiomyoma cells", "ANATOMY", 0, 15], ["cells", "ANATOMY", 116, 121], ["Leiomyoma cells", "CELL", 0, 15], ["Ad-ICAT", "GENE_OR_GENE_PRODUCT", 32, 39], ["Ad", "ORGANISM", 98, 100], ["GFP", "GENE_OR_GENE_PRODUCT", 101, 104], ["cells", "CELL", 116, 121], ["Leiomyoma cells", "CELL_TYPE", 0, 15], ["ICAT", "PROTEIN", 35, 39], ["Ad-GFP transduced cells", "CELL_LINE", 98, 121], ["Ad", "SPECIES", 98, 100], ["Leiomyoma cells", "PROBLEM", 0, 15], ["significantly lower proliferation", "PROBLEM", 50, 83], ["Supplemental Fig", "TREATMENT", 123, 139], ["significantly", "OBSERVATION_MODIFIER", 50, 63], ["lower", "OBSERVATION_MODIFIER", 64, 69], ["proliferation", "OBSERVATION", 70, 83]]], ["The observed reduction in proliferation with ICAT overexpression was not due to diffuse cellular toxicity, becaise Ad-GFP or Ad-ICAT transduced leiomyoma cells showed no difference in LDH levels compared with the control group (No Tx; Supplemental Fig. 1B).Overexpression of ICAT Inhibits Expression of WNT/\u03b2-catenin Target Genes in Human Leiomyoma Cells ::: ResultsLeiomyoma cells (n = 4) were treated with LiCl for 24 hours to induce \u03b2-catenin and transcription of WNT pathway target genes AXIN2 and NKD1 (Supplemental Fig. 1C and D).", [["cellular", "ANATOMY", 88, 96], ["leiomyoma cells", "ANATOMY", 144, 159], ["Leiomyoma Cells", "ANATOMY", 339, 354], ["ResultsLeiomyoma cells", "ANATOMY", 359, 381], ["toxicity", "DISEASE", 97, 105], ["LiCl", "CHEMICAL", 408, 412], ["LiCl", "CHEMICAL", 408, 412], ["ICAT", "GENE_OR_GENE_PRODUCT", 45, 49], ["cellular", "CELL", 88, 96], ["Ad-GFP", "GENE_OR_GENE_PRODUCT", 115, 121], ["Ad-ICAT", "GENE_OR_GENE_PRODUCT", 125, 132], ["leiomyoma cells", "CELL", 144, 159], ["LDH", "GENE_OR_GENE_PRODUCT", 184, 187], ["ICAT", "GENE_OR_GENE_PRODUCT", 275, 279], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 303, 316], ["Human", "ORGANISM", 333, 338], ["Leiomyoma Cells", "CELL", 339, 354], ["ResultsLeiomyoma cells", "CELL", 359, 381], ["LiCl", "SIMPLE_CHEMICAL", 408, 412], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 436, 445], ["WNT", "GENE_OR_GENE_PRODUCT", 467, 470], ["AXIN2", "GENE_OR_GENE_PRODUCT", 492, 497], ["NKD1", "GENE_OR_GENE_PRODUCT", 502, 506], ["D", "SIMPLE_CHEMICAL", 533, 534], ["ICAT", "PROTEIN", 45, 49], ["Ad-ICAT transduced leiomyoma cells", "CELL_LINE", 125, 159], ["LDH", "PROTEIN", 184, 187], ["ICAT", "PROTEIN", 275, 279], ["WNT/\u03b2-catenin Target Genes", "DNA", 303, 329], ["ResultsLeiomyoma cells", "CELL_TYPE", 359, 381], ["\u03b2-catenin", "PROTEIN", 436, 445], ["WNT pathway target genes", "DNA", 467, 491], ["AXIN2", "DNA", 492, 497], ["NKD1", "DNA", 502, 506], ["Human", "SPECIES", 333, 338], ["proliferation", "PROBLEM", 26, 39], ["ICAT overexpression", "PROBLEM", 45, 64], ["diffuse cellular toxicity", "PROBLEM", 80, 105], ["leiomyoma cells", "PROBLEM", 144, 159], ["difference in LDH levels", "PROBLEM", 170, 194], ["Tx", "TREATMENT", 231, 233], ["WNT/\u03b2-catenin", "TREATMENT", 303, 316], ["ResultsLeiomyoma cells", "PROBLEM", 359, 381], ["LiCl", "TREATMENT", 408, 412], ["\u03b2-catenin", "TREATMENT", 436, 445], ["WNT pathway", "TREATMENT", 467, 478], ["Supplemental Fig", "TREATMENT", 508, 524], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["proliferation", "OBSERVATION", 26, 39], ["not due to", "UNCERTAINTY", 69, 79], ["diffuse", "OBSERVATION_MODIFIER", 80, 87], ["cellular toxicity", "OBSERVATION", 88, 105], ["leiomyoma", "OBSERVATION", 144, 153], ["no", "UNCERTAINTY", 167, 169], ["difference", "OBSERVATION_MODIFIER", 170, 180], ["Leiomyoma Cells", "OBSERVATION", 339, 354]]], ["Subsequent adenoviral expression of ICAT significantly inhibited LiCl-stimulated AXIN2 and NKD1 gene expression, measured by real-time PCR.", [["LiCl", "CHEMICAL", 65, 69], ["LiCl", "CHEMICAL", 65, 69], ["adenoviral", "ORGANISM", 11, 21], ["ICAT", "GENE_OR_GENE_PRODUCT", 36, 40], ["LiCl", "SIMPLE_CHEMICAL", 65, 69], ["AXIN2", "GENE_OR_GENE_PRODUCT", 81, 86], ["NKD1", "GENE_OR_GENE_PRODUCT", 91, 95], ["ICAT", "PROTEIN", 36, 40], ["AXIN2", "PROTEIN", 81, 86], ["NKD1", "PROTEIN", 91, 95], ["ICAT", "PROBLEM", 36, 40], ["LiCl", "TEST", 65, 69], ["stimulated AXIN2", "PROBLEM", 70, 86], ["gene expression", "PROBLEM", 96, 111]]], ["Ad-ICAT transduced cells without LiCl treatment had messenger RNA expression levels of AXIN2 and NKD1 similar to those in Ad-GFP transduced cells.Niclosamide Treatment Inhibits Human Leiomyoma Cell Proliferation ::: ResultsNiclosamide has been shown to inhibit WNT pathway activation in colorectal cancer cells 41, 42.", [["cells", "ANATOMY", 19, 24], ["cells", "ANATOMY", 140, 145], ["Leiomyoma Cell", "ANATOMY", 183, 197], ["colorectal cancer cells", "ANATOMY", 287, 310], ["LiCl", "CHEMICAL", 33, 37], ["Niclosamide", "CHEMICAL", 146, 157], ["Niclosamide", "CHEMICAL", 223, 234], ["colorectal cancer", "DISEASE", 287, 304], ["LiCl", "CHEMICAL", 33, 37], ["Niclosamide", "CHEMICAL", 146, 157], ["Niclosamide", "CHEMICAL", 223, 234], ["Ad-ICAT", "GENE_OR_GENE_PRODUCT", 0, 7], ["cells", "CELL", 19, 24], ["LiCl", "SIMPLE_CHEMICAL", 33, 37], ["AXIN2", "GENE_OR_GENE_PRODUCT", 87, 92], ["NKD1", "GENE_OR_GENE_PRODUCT", 97, 101], ["Ad", "ORGANISM", 122, 124], ["GFP", "GENE_OR_GENE_PRODUCT", 125, 128], ["cells", "CELL", 140, 145], ["Niclosamide", "SIMPLE_CHEMICAL", 146, 157], ["Human", "ORGANISM", 177, 182], ["Leiomyoma Cell", "CELL", 183, 197], ["Niclosamide", "SIMPLE_CHEMICAL", 223, 234], ["WNT", "GENE_OR_GENE_PRODUCT", 261, 264], ["colorectal cancer cells", "CELL", 287, 310], ["Ad-ICAT transduced cells", "CELL_LINE", 0, 24], ["AXIN2", "PROTEIN", 87, 92], ["NKD1", "PROTEIN", 97, 101], ["Ad-GFP transduced cells", "CELL_LINE", 122, 145], ["WNT", "PROTEIN", 261, 264], ["colorectal cancer cells", "CELL_TYPE", 287, 310], ["Human", "SPECIES", 177, 182], ["LiCl treatment", "TREATMENT", 33, 47], ["messenger RNA expression levels of AXIN2", "PROBLEM", 52, 92], ["NKD1", "PROBLEM", 97, 101], ["Niclosamide Treatment", "TREATMENT", 146, 167], ["Niclosamide", "TREATMENT", 223, 234], ["colorectal cancer cells", "PROBLEM", 287, 310], ["without", "UNCERTAINTY", 25, 32], ["transduced cells", "OBSERVATION", 129, 145], ["Leiomyoma Cell Proliferation", "OBSERVATION", 183, 211], ["colorectal cancer", "OBSERVATION", 287, 304]]], ["Human leiomyoma cells (n = 4) were treated with DMSO or increasing concentrations of niclosamide for 3 days before analysis by MTS assay.", [["leiomyoma cells", "ANATOMY", 6, 21], ["leiomyoma", "DISEASE", 6, 15], ["DMSO", "CHEMICAL", 48, 52], ["niclosamide", "CHEMICAL", 85, 96], ["DMSO", "CHEMICAL", 48, 52], ["niclosamide", "CHEMICAL", 85, 96], ["Human", "ORGANISM", 0, 5], ["leiomyoma cells", "CELL", 6, 21], ["DMSO", "SIMPLE_CHEMICAL", 48, 52], ["niclosamide", "SIMPLE_CHEMICAL", 85, 96], ["Human leiomyoma cells", "CELL_TYPE", 0, 21], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human leiomyoma cells", "PROBLEM", 0, 21], ["DMSO", "TREATMENT", 48, 52], ["niclosamide", "TREATMENT", 85, 96], ["MTS assay", "TEST", 127, 136], ["leiomyoma", "OBSERVATION", 6, 15]]], ["Niclosamide inhibited proliferation of leiomyoma cells in a dose-dependent manner (Fig. 1A and B).", [["leiomyoma cells", "ANATOMY", 39, 54], ["Niclosamide", "CHEMICAL", 0, 11], ["leiomyoma", "DISEASE", 39, 48], ["Niclosamide", "CHEMICAL", 0, 11], ["Niclosamide", "SIMPLE_CHEMICAL", 0, 11], ["leiomyoma cells", "CELL", 39, 54], ["B", "GENE_OR_GENE_PRODUCT", 95, 96], ["leiomyoma cells", "CELL_TYPE", 39, 54], ["Niclosamide", "TREATMENT", 0, 11], ["leiomyoma cells", "PROBLEM", 39, 54], ["proliferation", "OBSERVATION_MODIFIER", 22, 35], ["leiomyoma cells", "OBSERVATION", 39, 54]]], ["The observed reduction in proliferation after niclosamide treatment was not related to decreased cell survival: LDH activity levels were similar for leiomyoma cells in all treatment groups (Fig. 1C).Niclosamide Inhibits WNT\u03b2-catenin Pathway Activation in Human Leiomyoma Cells ::: ResultsActivation of the WNT/\u03b2-catenin pathway results in stimulation of the TCF/LEF transcription factor, which binds to TCF elements in the promoters of target genes 12, 13.", [["cell", "ANATOMY", 97, 101], ["leiomyoma cells", "ANATOMY", 149, 164], ["Leiomyoma Cells", "ANATOMY", 261, 276], ["niclosamide", "CHEMICAL", 46, 57], ["leiomyoma", "DISEASE", 149, 158], ["Niclosamide", "CHEMICAL", 199, 210], ["niclosamide", "CHEMICAL", 46, 57], ["Niclosamide", "CHEMICAL", 199, 210], ["niclosamide", "SIMPLE_CHEMICAL", 46, 57], ["cell", "CELL", 97, 101], ["LDH", "GENE_OR_GENE_PRODUCT", 112, 115], ["leiomyoma cells", "CELL", 149, 164], ["Niclosamide", "SIMPLE_CHEMICAL", 199, 210], ["WNT\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 220, 232], ["Human", "ORGANISM", 255, 260], ["Leiomyoma Cells", "CELL", 261, 276], ["WNT", "GENE_OR_GENE_PRODUCT", 306, 309], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 310, 319], ["TCF", "GENE_OR_GENE_PRODUCT", 358, 361], ["LEF", "GENE_OR_GENE_PRODUCT", 362, 365], ["TCF", "GENE_OR_GENE_PRODUCT", 403, 406], ["LDH", "PROTEIN", 112, 115], ["leiomyoma cells", "CELL_TYPE", 149, 164], ["WNT\u03b2-catenin", "PROTEIN", 220, 232], ["WNT", "PROTEIN", 306, 309], ["\u03b2-catenin", "PROTEIN", 310, 319], ["TCF", "PROTEIN", 358, 361], ["LEF transcription factor", "PROTEIN", 362, 386], ["TCF elements", "DNA", 403, 415], ["promoters", "DNA", 423, 432], ["target genes 12, 13", "DNA", 436, 455], ["Human", "SPECIES", 255, 260], ["The observed reduction in proliferation", "PROBLEM", 0, 39], ["niclosamide treatment", "TREATMENT", 46, 67], ["decreased cell survival", "PROBLEM", 87, 110], ["LDH activity levels", "TEST", 112, 131], ["leiomyoma cells", "PROBLEM", 149, 164], ["all treatment groups", "TREATMENT", 168, 188], ["Niclosamide Inhibits", "TREATMENT", 199, 219], ["the WNT/\u03b2-catenin pathway", "TEST", 302, 327], ["the TCF/LEF transcription factor", "TREATMENT", 354, 386], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["proliferation", "OBSERVATION_MODIFIER", 26, 39], ["decreased cell survival", "OBSERVATION", 87, 110], ["leiomyoma cells", "OBSERVATION", 149, 164]]], ["To analyze the effects of niclosamide on WNT/\u03b2-catenin signaling in human leiomyoma cells, we transfected cells (n = 6) with luciferase reporter constructs consisting of four copies of the TCF element (TOPflash), then treated the cells with increasing concentrations of niclosamide in the presence of LiCl.", [["leiomyoma cells", "ANATOMY", 74, 89], ["cells", "ANATOMY", 106, 111], ["cells", "ANATOMY", 230, 235], ["niclosamide", "CHEMICAL", 26, 37], ["niclosamide", "CHEMICAL", 270, 281], ["LiCl", "CHEMICAL", 301, 305], ["niclosamide", "CHEMICAL", 26, 37], ["niclosamide", "CHEMICAL", 270, 281], ["LiCl", "CHEMICAL", 301, 305], ["niclosamide", "SIMPLE_CHEMICAL", 26, 37], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 41, 54], ["human", "ORGANISM", 68, 73], ["leiomyoma cells", "CELL", 74, 89], ["cells", "CELL", 106, 111], ["luciferase", "GENE_OR_GENE_PRODUCT", 125, 135], ["TCF", "GENE_OR_GENE_PRODUCT", 189, 192], ["cells", "CELL", 230, 235], ["niclosamide", "SIMPLE_CHEMICAL", 270, 281], ["LiCl", "SIMPLE_CHEMICAL", 301, 305], ["WNT", "PROTEIN", 41, 44], ["\u03b2-catenin", "PROTEIN", 45, 54], ["human leiomyoma cells", "CELL_TYPE", 68, 89], ["transfected cells", "CELL_LINE", 94, 111], ["luciferase reporter constructs", "DNA", 125, 155], ["TCF element", "DNA", 189, 200], ["TOPflash", "DNA", 202, 210], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["niclosamide", "TREATMENT", 26, 37], ["WNT/\u03b2-catenin signaling", "TREATMENT", 41, 64], ["human leiomyoma cells", "PROBLEM", 68, 89], ["luciferase reporter constructs", "TREATMENT", 125, 155], ["niclosamide", "TREATMENT", 270, 281], ["leiomyoma cells", "OBSERVATION", 74, 89], ["LiCl", "OBSERVATION", 301, 305]]], ["As expected, LiCl treatment (activates \u03b2-catenin) up-regulated TOPflash reporter activity.", [["LiCl", "CHEMICAL", 13, 17], ["LiCl", "CHEMICAL", 13, 17], ["LiCl", "SIMPLE_CHEMICAL", 13, 17], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 39, 48], ["TOPflash", "GENE_OR_GENE_PRODUCT", 63, 71], ["\u03b2-catenin", "PROTEIN", 39, 48], ["TOPflash", "PROTEIN", 63, 71], ["LiCl treatment", "TREATMENT", 13, 27], ["activates \u03b2-catenin)", "TREATMENT", 29, 49]]], ["This effect was blunted by treatment with increasing concentrations of niclosamide (Fig. 2A).", [["niclosamide", "CHEMICAL", 71, 82], ["niclosamide", "CHEMICAL", 71, 82], ["niclosamide", "SIMPLE_CHEMICAL", 71, 82], ["increasing concentrations of niclosamide", "TREATMENT", 42, 82]]], ["Niclosamide treatment also down-regulated LiCl-induced AXIN2 and NKD1 expression in human leiomyoma cells (n = 4) (Fig. 2B).Niclosamide Inhibits WNT\u03b2-catenin Pathway Activation in Human Leiomyoma Cells ::: ResultsActivation of the WNT signaling pathway results in the accumulation of \u03b2-catenin in the nucleus, followed by heterodimer formation with TCF and activation of TCF-dependent transcription 12, 13.", [["leiomyoma cells", "ANATOMY", 90, 105], ["Leiomyoma Cells", "ANATOMY", 186, 201], ["nucleus", "ANATOMY", 301, 308], ["Niclosamide", "CHEMICAL", 0, 11], ["LiCl", "CHEMICAL", 42, 46], ["leiomyoma", "DISEASE", 90, 99], ["Niclosamide", "CHEMICAL", 124, 135], ["Niclosamide", "CHEMICAL", 0, 11], ["LiCl", "CHEMICAL", 42, 46], ["Niclosamide", "CHEMICAL", 124, 135], ["Niclosamide", "SIMPLE_CHEMICAL", 0, 11], ["LiCl", "SIMPLE_CHEMICAL", 42, 46], ["AXIN2", "GENE_OR_GENE_PRODUCT", 55, 60], ["NKD1", "GENE_OR_GENE_PRODUCT", 65, 69], ["human", "ORGANISM", 84, 89], ["leiomyoma cells", "CELL", 90, 105], ["Niclosamide", "SIMPLE_CHEMICAL", 124, 135], ["WNT\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 145, 157], ["Human", "ORGANISM", 180, 185], ["Leiomyoma Cells", "CELL", 186, 201], ["WNT", "GENE_OR_GENE_PRODUCT", 231, 234], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 284, 293], ["nucleus", "CELLULAR_COMPONENT", 301, 308], ["TCF", "GENE_OR_GENE_PRODUCT", 349, 352], ["TCF", "GENE_OR_GENE_PRODUCT", 371, 374], ["AXIN2", "PROTEIN", 55, 60], ["NKD1", "PROTEIN", 65, 69], ["human leiomyoma cells", "CELL_TYPE", 84, 105], ["WNT\u03b2-catenin", "PROTEIN", 145, 157], ["WNT", "PROTEIN", 231, 234], ["\u03b2-catenin", "PROTEIN", 284, 293], ["TCF", "PROTEIN", 349, 352], ["TCF", "PROTEIN", 371, 374], ["human", "SPECIES", 84, 89], ["Human", "SPECIES", 180, 185], ["human", "SPECIES", 84, 89], ["Niclosamide treatment", "TREATMENT", 0, 21], ["AXIN2", "PROBLEM", 55, 60], ["NKD1 expression in human leiomyoma cells", "PROBLEM", 65, 105], ["Niclosamide Inhibits", "TREATMENT", 124, 144], ["the WNT signaling pathway", "TEST", 227, 252], ["the accumulation of \u03b2-catenin in the nucleus", "PROBLEM", 264, 308], ["TCF", "TREATMENT", 349, 352], ["TCF-dependent transcription", "TREATMENT", 371, 398], ["leiomyoma cells", "OBSERVATION", 90, 105], ["accumulation", "OBSERVATION_MODIFIER", 268, 280], ["\u03b2-catenin", "OBSERVATION", 284, 293], ["nucleus", "ANATOMY", 301, 308]]], ["We examined the effects of niclosamide on subcellular localization of \u03b2-catenin in human leiomyoma cells (n = 5) (Fig. 2C).", [["subcellular", "ANATOMY", 42, 53], ["leiomyoma cells", "ANATOMY", 89, 104], ["niclosamide", "CHEMICAL", 27, 38], ["\u03b2-catenin", "CHEMICAL", 70, 79], ["leiomyoma", "DISEASE", 89, 98], ["niclosamide", "CHEMICAL", 27, 38], ["niclosamide", "SIMPLE_CHEMICAL", 27, 38], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 70, 79], ["human", "ORGANISM", 83, 88], ["leiomyoma cells", "CELL", 89, 104], ["\u03b2-catenin", "PROTEIN", 70, 79], ["human leiomyoma cells", "CELL_TYPE", 83, 104], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["niclosamide", "TREATMENT", 27, 38], ["subcellular localization", "TEST", 42, 66], ["\u03b2-catenin in human leiomyoma cells", "TREATMENT", 70, 104], ["leiomyoma cells", "OBSERVATION", 89, 104]]], ["Treatment with LiCl induced nuclear accumulation of \u03b2-catenin, whereas treatment with niclosamide blocked both baseline and LiCl-induced \u03b2-catenin nuclear translocation.", [["nuclear", "ANATOMY", 28, 35], ["nuclear", "ANATOMY", 147, 154], ["LiCl", "CHEMICAL", 15, 19], ["niclosamide", "CHEMICAL", 86, 97], ["LiCl", "CHEMICAL", 124, 128], ["LiCl", "CHEMICAL", 15, 19], ["niclosamide", "CHEMICAL", 86, 97], ["LiCl", "CHEMICAL", 124, 128], ["LiCl", "SIMPLE_CHEMICAL", 15, 19], ["nuclear", "CELLULAR_COMPONENT", 28, 35], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 52, 61], ["niclosamide", "SIMPLE_CHEMICAL", 86, 97], ["LiCl", "SIMPLE_CHEMICAL", 124, 128], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 137, 146], ["\u03b2-catenin", "PROTEIN", 52, 61], ["\u03b2-catenin", "PROTEIN", 137, 146], ["LiCl", "TREATMENT", 15, 19], ["\u03b2-catenin", "TREATMENT", 52, 61], ["niclosamide blocked", "TREATMENT", 86, 105], ["LiCl", "TREATMENT", 124, 128], ["accumulation of \u03b2-catenin", "OBSERVATION", 36, 61], ["nuclear translocation", "OBSERVATION", 147, 168]]], ["We evaluated the amount of \u03b2-catenin in human leiomyoma cells (n = 3) with GST-ICAT pull-down assays.", [["leiomyoma cells", "ANATOMY", 46, 61], ["\u03b2-catenin", "CHEMICAL", 27, 36], ["leiomyoma", "DISEASE", 46, 55], ["\u03b2-catenin", "CHEMICAL", 27, 36], ["\u03b2-catenin", "SIMPLE_CHEMICAL", 27, 36], ["human", "ORGANISM", 40, 45], ["leiomyoma cells", "CELL", 46, 61], ["GST-ICAT", "GENE_OR_GENE_PRODUCT", 75, 83], ["\u03b2-catenin", "PROTEIN", 27, 36], ["human leiomyoma cells", "CELL_TYPE", 40, 61], ["GST", "PROTEIN", 75, 78], ["ICAT", "PROTEIN", 79, 83], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["\u03b2-catenin in human leiomyoma cells", "TREATMENT", 27, 61], ["GST", "TEST", 75, 78], ["ICAT pull", "TEST", 79, 88], ["leiomyoma cells", "OBSERVATION", 46, 61]]], ["As expected, \u03b2-catenin levels were significantly lower in niclosamide-treated leiomyoma cells compared with vehicle-treated cells (Fig. 2D).Tankyrase Inhibitor (XAV939) Disrupts Leiomyoma Cell Proliferation ::: ResultsTankyrases 1 and 2 are proteins with poly (adenosine diphosphate\u2013ribose) polymerase activity.", [["leiomyoma cells", "ANATOMY", 78, 93], ["cells", "ANATOMY", 124, 129], ["Cell", "ANATOMY", 188, 192], ["niclosamide", "CHEMICAL", 58, 69], ["leiomyoma", "DISEASE", 78, 87], ["adenosine", "CHEMICAL", 261, 270], ["niclosamide", "CHEMICAL", 58, 69], ["XAV939", "CHEMICAL", 161, 167], ["poly (adenosine diphosphate\u2013ribose)", "CHEMICAL", 255, 290], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 13, 22], ["niclosamide", "SIMPLE_CHEMICAL", 58, 69], ["leiomyoma cells", "CELL", 78, 93], ["cells", "CELL", 124, 129], ["Tankyrase Inhibitor", "GENE_OR_GENE_PRODUCT", 140, 159], ["Tankyrases 1", "GENE_OR_GENE_PRODUCT", 218, 230], ["2", "GENE_OR_GENE_PRODUCT", 235, 236], ["poly (adenosine diphosphate\u2013ribose) polymerase", "GENE_OR_GENE_PRODUCT", 255, 301], ["\u03b2-catenin", "PROTEIN", 13, 22], ["niclosamide-treated leiomyoma cells", "CELL_LINE", 58, 93], ["vehicle-treated cells", "CELL_LINE", 108, 129], ["poly (adenosine diphosphate\u2013ribose) polymerase", "PROTEIN", 255, 301], ["\u03b2-catenin levels", "TEST", 13, 29], ["niclosamide", "TREATMENT", 58, 69], ["leiomyoma cells", "PROBLEM", 78, 93], ["vehicle-treated cells", "TREATMENT", 108, 129], ["Tankyrase Inhibitor", "TREATMENT", 140, 159], ["Leiomyoma Cell Proliferation", "PROBLEM", 178, 206], ["Tankyrases", "TEST", 218, 228], ["poly (adenosine diphosphate\u2013ribose)", "TREATMENT", 255, 290], ["significantly", "OBSERVATION_MODIFIER", 35, 48], ["lower", "OBSERVATION_MODIFIER", 49, 54], ["leiomyoma cells", "OBSERVATION", 78, 93], ["Leiomyoma Cell Proliferation", "OBSERVATION", 178, 206]]], ["Tankyrases have been shown be involved in the WNT signaling pathway.", [["Tankyrases", "GENE_OR_GENE_PRODUCT", 0, 10], ["WNT", "GENE_OR_GENE_PRODUCT", 46, 49], ["Tankyrases", "PROTEIN", 0, 10], ["WNT", "PROTEIN", 46, 49]]], ["Tankyrases bind directly to AXIN, a member of the \u201cdestruction complex\u201d involved in \u03b2-catenin degradation.", [["Tankyrases", "GENE_OR_GENE_PRODUCT", 0, 10], ["AXIN", "GENE_OR_GENE_PRODUCT", 28, 32], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 84, 93], ["Tankyrases", "PROTEIN", 0, 10], ["AXIN", "PROTEIN", 28, 32], ["\u201cdestruction complex", "PROTEIN", 50, 70], ["\u03b2-catenin", "PROTEIN", 84, 93]]], ["Inhibition of tankyrase stabilizes AXIN, increases the activity of the destruction complex, and promotes degradation of \u03b2-catenin.", [["tankyrase", "GENE_OR_GENE_PRODUCT", 14, 23], ["AXIN", "GENE_OR_GENE_PRODUCT", 35, 39], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 120, 129], ["tankyrase", "PROTEIN", 14, 23], ["AXIN", "PROTEIN", 35, 39], ["destruction complex", "PROTEIN", 71, 90], ["\u03b2-catenin", "PROTEIN", 120, 129], ["tankyrase stabilizes AXIN", "PROBLEM", 14, 39], ["the destruction complex", "PROBLEM", 67, 90], ["\u03b2-catenin", "TREATMENT", 120, 129], ["tankyrase", "OBSERVATION", 14, 23], ["activity", "OBSERVATION_MODIFIER", 55, 63]]], ["XAV939 is a tankyrase inhibitor, thereby inhibiting WNT/\u03b2-catenin signaling.", [["XAV939", "CHEMICAL", 0, 6], ["XAV939", "CHEMICAL", 0, 6], ["XAV939", "SIMPLE_CHEMICAL", 0, 6], ["tankyrase", "GENE_OR_GENE_PRODUCT", 12, 21], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 52, 65], ["WNT", "PROTEIN", 52, 55], ["\u03b2-catenin", "PROTEIN", 56, 65], ["a tankyrase inhibitor", "TREATMENT", 10, 31], ["catenin signaling", "PROBLEM", 58, 75]]], ["Human leiomyoma cells (n = 6) were treated with DMSO or increasing concentrations of XAV939 for 3 days before analysis by MTS assay.", [["leiomyoma cells", "ANATOMY", 6, 21], ["leiomyoma", "DISEASE", 6, 15], ["DMSO", "CHEMICAL", 48, 52], ["XAV939", "CHEMICAL", 85, 91], ["DMSO", "CHEMICAL", 48, 52], ["XAV939", "CHEMICAL", 85, 91], ["Human", "ORGANISM", 0, 5], ["leiomyoma cells", "CELL", 6, 21], ["DMSO", "SIMPLE_CHEMICAL", 48, 52], ["XAV939", "SIMPLE_CHEMICAL", 85, 91], ["Human leiomyoma cells", "CELL_TYPE", 0, 21], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human leiomyoma cells", "PROBLEM", 0, 21], ["DMSO", "TREATMENT", 48, 52], ["increasing concentrations of XAV939", "TREATMENT", 56, 91], ["MTS assay", "TEST", 122, 131], ["leiomyoma", "OBSERVATION", 6, 15]]], ["XAV939 inhibited the proliferation of leiomyoma cells in a dose-dependent manner (Fig. 3A and B).", [["leiomyoma cells", "ANATOMY", 38, 53], ["XAV939", "CHEMICAL", 0, 6], ["leiomyoma", "DISEASE", 38, 47], ["XAV939", "CHEMICAL", 0, 6], ["XAV939", "SIMPLE_CHEMICAL", 0, 6], ["leiomyoma cells", "CELL", 38, 53], ["leiomyoma cells", "CELL_TYPE", 38, 53], ["leiomyoma cells", "PROBLEM", 38, 53], ["proliferation", "OBSERVATION_MODIFIER", 21, 34], ["leiomyoma cells", "OBSERVATION", 38, 53]]], ["The reduced proliferation observed with XAV939 was not due to an effect on diffuse cell toxicity, because LDH activity levels were the same across treatment groups (Fig. 3C).XAV939 Inhibits WNT/\u03b2-catenin Pathway Activation in Human Leiomyoma Cells ::: ResultsTo analyze the effect of XAV939 on WNT/\u03b2-catenin signaling in human leiomyoma cells (n = 6), we transfected cells with the TCF reporter constructs (TOPflash or FOPflash) and treated the cells with increasing concentrations of XAV939 in the presence of LiCl.", [["cell", "ANATOMY", 83, 87], ["Leiomyoma Cells", "ANATOMY", 232, 247], ["leiomyoma cells", "ANATOMY", 327, 342], ["cells", "ANATOMY", 367, 372], ["cells", "ANATOMY", 445, 450], ["XAV939", "CHEMICAL", 40, 46], ["toxicity", "DISEASE", 88, 96], ["XAV939", "CHEMICAL", 284, 290], ["leiomyoma", "DISEASE", 327, 336], ["XAV939", "CHEMICAL", 485, 491], ["LiCl", "CHEMICAL", 511, 515], ["XAV939", "CHEMICAL", 40, 46], ["XAV939", "CHEMICAL", 174, 180], ["XAV939", "CHEMICAL", 284, 290], ["XAV939", "CHEMICAL", 485, 491], ["LiCl", "CHEMICAL", 511, 515], ["XAV939", "SIMPLE_CHEMICAL", 40, 46], ["cell", "CELL", 83, 87], ["LDH", "GENE_OR_GENE_PRODUCT", 106, 109], ["XAV939", "SIMPLE_CHEMICAL", 174, 180], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 190, 203], ["Human", "ORGANISM", 226, 231], ["Leiomyoma Cells", "CELL", 232, 247], ["XAV939", "SIMPLE_CHEMICAL", 284, 290], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 294, 307], ["human", "ORGANISM", 321, 326], ["leiomyoma cells", "CELL", 327, 342], ["cells", "CELL", 367, 372], ["TCF", "GENE_OR_GENE_PRODUCT", 382, 385], ["cells", "CELL", 445, 450], ["XAV939", "SIMPLE_CHEMICAL", 485, 491], ["LiCl", "SIMPLE_CHEMICAL", 511, 515], ["LDH", "PROTEIN", 106, 109], ["XAV939", "PROTEIN", 174, 180], ["WNT", "PROTEIN", 190, 193], ["\u03b2-catenin", "PROTEIN", 194, 203], ["WNT", "PROTEIN", 294, 297], ["\u03b2-catenin", "PROTEIN", 298, 307], ["human leiomyoma cells", "CELL_TYPE", 321, 342], ["TCF reporter constructs", "DNA", 382, 405], ["TOPflash", "DNA", 407, 415], ["FOPflash", "DNA", 419, 427], ["Human", "SPECIES", 226, 231], ["human", "SPECIES", 321, 326], ["human", "SPECIES", 321, 326], ["The reduced proliferation", "PROBLEM", 0, 25], ["diffuse cell toxicity", "PROBLEM", 75, 96], ["LDH activity levels", "TEST", 106, 125], ["WNT", "TEST", 294, 297], ["human leiomyoma cells", "PROBLEM", 321, 342], ["the TCF reporter constructs", "PROBLEM", 378, 405], ["increasing concentrations", "PROBLEM", 456, 481], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["proliferation", "OBSERVATION", 12, 25], ["diffuse", "OBSERVATION_MODIFIER", 75, 82], ["cell toxicity", "OBSERVATION", 83, 96], ["Leiomyoma Cells", "OBSERVATION", 232, 247], ["leiomyoma cells", "OBSERVATION", 327, 342], ["increasing", "OBSERVATION_MODIFIER", 456, 466], ["concentrations", "OBSERVATION_MODIFIER", 467, 481], ["LiCl", "OBSERVATION", 511, 515]]], ["XAV939 inhibited LiCl-induced TCF reporter activation in a dose-dependent manner (Fig. 4A).", [["XAV939", "CHEMICAL", 0, 6], ["LiCl", "CHEMICAL", 17, 21], ["XAV939", "CHEMICAL", 0, 6], ["LiCl", "CHEMICAL", 17, 21], ["XAV939", "SIMPLE_CHEMICAL", 0, 6], ["LiCl", "SIMPLE_CHEMICAL", 17, 21], ["TCF", "GENE_OR_GENE_PRODUCT", 30, 33], ["TCF", "PROTEIN", 30, 33], ["LiCl", "TREATMENT", 17, 21]]], ["XAV939 also down-regulated LiCl-induced AXIN2 and NKD1 expression in human leiomyoma cells, measured by real-time quantitative PCR (Fig. 4B).", [["leiomyoma cells", "ANATOMY", 75, 90], ["XAV939", "CHEMICAL", 0, 6], ["LiCl", "CHEMICAL", 27, 31], ["XAV939", "CHEMICAL", 0, 6], ["LiCl", "CHEMICAL", 27, 31], ["XAV939", "SIMPLE_CHEMICAL", 0, 6], ["LiCl", "SIMPLE_CHEMICAL", 27, 31], ["AXIN2", "GENE_OR_GENE_PRODUCT", 40, 45], ["NKD1", "GENE_OR_GENE_PRODUCT", 50, 54], ["human", "ORGANISM", 69, 74], ["leiomyoma cells", "CELL", 75, 90], ["AXIN2", "PROTEIN", 40, 45], ["NKD1", "PROTEIN", 50, 54], ["human leiomyoma cells", "CELL_TYPE", 69, 90], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["LiCl", "TEST", 27, 31], ["AXIN2", "PROBLEM", 40, 45], ["NKD1 expression in human leiomyoma cells", "PROBLEM", 50, 90], ["quantitative PCR", "TEST", 114, 130], ["leiomyoma cells", "OBSERVATION", 75, 90]]], ["XAV939 significantly inhibited LiCl-stimulated nuclear translocation of \u03b2-catenin in human leiomyoma cells (Fig. 4C).", [["nuclear", "ANATOMY", 47, 54], ["leiomyoma cells", "ANATOMY", 91, 106], ["XAV939", "CHEMICAL", 0, 6], ["LiCl", "CHEMICAL", 31, 35], ["XAV939", "CHEMICAL", 0, 6], ["LiCl", "CHEMICAL", 31, 35], ["XAV939", "SIMPLE_CHEMICAL", 0, 6], ["LiCl", "SIMPLE_CHEMICAL", 31, 35], ["nuclear", "CELLULAR_COMPONENT", 47, 54], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 72, 81], ["human", "ORGANISM", 85, 90], ["leiomyoma cells", "CELL", 91, 106], ["Fig. 4C", "CELL", 108, 115], ["\u03b2-catenin", "PROTEIN", 72, 81], ["human leiomyoma cells", "CELL_TYPE", 85, 106], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["LiCl", "TEST", 31, 35], ["\u03b2-catenin in human leiomyoma cells", "TREATMENT", 72, 106], ["leiomyoma cells", "OBSERVATION", 91, 106]]], ["The GST-ICAT pull-down assays revealed a remarkable decrease in active \u03b2-catenin upon treatment of human leiomyoma cells with XAV939 (Fig. 4D).DiscussionBecause many \u03b2-catenin target genes are involved in cell proliferation, we hypothesized that enhanced WNT/\u03b2-catenin signaling in leiomyoma cells contributes to leiomyoma tumor growth in humans.", [["leiomyoma cells", "ANATOMY", 105, 120], ["cell", "ANATOMY", 205, 209], ["leiomyoma cells", "ANATOMY", 282, 297], ["leiomyoma tumor", "ANATOMY", 313, 328], ["\u03b2-catenin", "CHEMICAL", 71, 80], ["leiomyoma", "DISEASE", 282, 291], ["leiomyoma tumor", "DISEASE", 313, 328], ["\u03b2-catenin", "CHEMICAL", 71, 80], ["GST-ICAT", "GENE_OR_GENE_PRODUCT", 4, 12], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 71, 80], ["human", "ORGANISM", 99, 104], ["leiomyoma cells", "CELL", 105, 120], ["XAV939", "CELL", 126, 132], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 166, 175], ["cell", "CELL", 205, 209], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 255, 268], ["leiomyoma cells", "CELL", 282, 297], ["leiomyoma tumor", "CANCER", 313, 328], ["humans", "ORGANISM", 339, 345], ["GST", "PROTEIN", 4, 7], ["ICAT", "PROTEIN", 8, 12], ["\u03b2-catenin", "PROTEIN", 71, 80], ["human leiomyoma cells", "CELL_TYPE", 99, 120], ["\u03b2-catenin target genes", "DNA", 166, 188], ["WNT", "PROTEIN", 255, 258], ["\u03b2-catenin", "PROTEIN", 259, 268], ["leiomyoma cells", "CELL_TYPE", 282, 297], ["human", "SPECIES", 99, 104], ["humans", "SPECIES", 339, 345], ["human", "SPECIES", 99, 104], ["humans", "SPECIES", 339, 345], ["The GST", "TEST", 0, 7], ["ICAT pull", "TEST", 8, 17], ["assays", "TEST", 23, 29], ["a remarkable decrease", "PROBLEM", 39, 60], ["human leiomyoma cells", "PROBLEM", 99, 120], ["leiomyoma cells", "PROBLEM", 282, 297], ["leiomyoma tumor growth in humans", "PROBLEM", 313, 345], ["remarkable", "OBSERVATION_MODIFIER", 41, 51], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["active \u03b2-catenin", "OBSERVATION", 64, 80], ["leiomyoma cells", "OBSERVATION", 105, 120], ["cell proliferation", "OBSERVATION", 205, 223], ["leiomyoma cells", "OBSERVATION", 282, 297], ["leiomyoma", "OBSERVATION_MODIFIER", 313, 322], ["tumor", "OBSERVATION", 323, 328]]], ["Notably, human leiomyoma cell primary cultures contain a substantial level of GST-ICAT\u2013precipitable \u03b2-catenin at baseline (Figs.", [["leiomyoma cell primary cultures", "ANATOMY", 15, 46], ["human", "ORGANISM", 9, 14], ["leiomyoma cell primary cultures", "CELL", 15, 46], ["GST", "GENE_OR_GENE_PRODUCT", 78, 81], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 100, 109], ["human leiomyoma cell primary cultures", "CELL_LINE", 9, 46], ["GST", "PROTEIN", 78, 81], ["ICAT\u2013precipitable \u03b2-catenin", "PROTEIN", 82, 109], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["human leiomyoma cell primary cultures", "TEST", 9, 46], ["GST", "TEST", 78, 81], ["leiomyoma cell", "OBSERVATION", 15, 29]]], ["Activation of \u03b2-catenin signaling has been spontaneously observed in a number of primary cell cultures 38, 43.", [["primary cell cultures", "ANATOMY", 81, 102], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 14, 23], ["cell cultures", "CELL", 89, 102], ["\u03b2-catenin", "PROTEIN", 14, 23], ["primary cell cultures", "CELL_LINE", 81, 102], ["Activation of \u03b2-catenin signaling", "PROBLEM", 0, 33], ["primary cell cultures", "TEST", 81, 102]]], ["We tested whether the inhibition of WNT/\u03b2-catenin signaling alters human leiomyoma cell proliferation.", [["leiomyoma cell", "ANATOMY", 73, 87], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 36, 49], ["human", "ORGANISM", 67, 72], ["leiomyoma cell", "CELL", 73, 87], ["WNT", "PROTEIN", 36, 39], ["\u03b2-catenin", "PROTEIN", 40, 49], ["human leiomyoma cell", "CELL_TYPE", 67, 87], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["human leiomyoma cell proliferation", "PROBLEM", 67, 101], ["leiomyoma cell proliferation", "OBSERVATION", 73, 101]]], ["Results showed that ICAT, niclosamide, and XAV939 specifically inhibited canonical WNT/\u03b2-catenin signaling and decreased WNT-dependent transcription in primary cultures of human leiomyoma cells, which resulted in reduced cell growth and proliferation in vitro.DiscussionOur findings add to the existing body of knowledge on the critical role that the WNT/\u03b2-catenin signaling pathway plays in not only development and adult tissue homeostasis but also tumor development and fibrogenesis 11, 27, 44, 45.", [["primary cultures", "ANATOMY", 152, 168], ["leiomyoma cells", "ANATOMY", 178, 193], ["cell", "ANATOMY", 221, 225], ["adult tissue", "ANATOMY", 417, 429], ["tumor", "ANATOMY", 451, 456], ["niclosamide", "CHEMICAL", 26, 37], ["XAV939", "CHEMICAL", 43, 49], ["leiomyoma", "DISEASE", 178, 187], ["tumor", "DISEASE", 451, 456], ["fibrogenesis", "DISEASE", 473, 485], ["niclosamide", "CHEMICAL", 26, 37], ["XAV939", "CHEMICAL", 43, 49], ["ICAT", "GENE_OR_GENE_PRODUCT", 20, 24], ["niclosamide", "SIMPLE_CHEMICAL", 26, 37], ["XAV939", "SIMPLE_CHEMICAL", 43, 49], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 83, 96], ["WNT", "GENE_OR_GENE_PRODUCT", 121, 124], ["human", "ORGANISM", 172, 177], ["leiomyoma cells", "CELL", 178, 193], ["cell", "CELL", 221, 225], ["WNT", "GENE_OR_GENE_PRODUCT", 351, 354], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 355, 364], ["adult tissue", "TISSUE", 417, 429], ["tumor", "CANCER", 451, 456], ["WNT", "PROTEIN", 83, 86], ["\u03b2-catenin", "PROTEIN", 87, 96], ["WNT", "PROTEIN", 121, 124], ["human leiomyoma cells", "CELL_TYPE", 172, 193], ["WNT", "PROTEIN", 351, 354], ["\u03b2-catenin", "PROTEIN", 355, 364], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["ICAT", "TEST", 20, 24], ["niclosamide", "TREATMENT", 26, 37], ["canonical WNT", "PROBLEM", 73, 86], ["\u03b2-catenin signaling", "PROBLEM", 87, 106], ["decreased WNT", "PROBLEM", 111, 124], ["dependent transcription", "PROBLEM", 125, 148], ["primary cultures", "TEST", 152, 168], ["human leiomyoma cells", "PROBLEM", 172, 193], ["reduced cell growth", "PROBLEM", 213, 232], ["proliferation in vitro", "PROBLEM", 237, 259], ["adult tissue homeostasis", "PROBLEM", 417, 441], ["fibrogenesis", "TEST", 473, 485], ["leiomyoma cells", "OBSERVATION", 178, 193], ["reduced cell", "OBSERVATION", 213, 225], ["growth", "OBSERVATION_MODIFIER", 226, 232], ["proliferation", "OBSERVATION_MODIFIER", 237, 250], ["tumor", "OBSERVATION", 451, 456]]], ["Selective deletion of \u03b2-catenin in uterine mesenchyme during embryonic development significantly reduces uterine size and replaces it with adipocytes, thus completely disrupting normal myometrial smooth-muscle differentiation and regeneration 35, 36, 46, 47.", [["uterine mesenchyme", "ANATOMY", 35, 53], ["embryonic", "ANATOMY", 61, 70], ["uterine", "ANATOMY", 105, 112], ["adipocytes", "ANATOMY", 139, 149], ["myometrial smooth-muscle", "ANATOMY", 185, 209], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 22, 31], ["uterine mesenchyme", "TISSUE", 35, 53], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 61, 70], ["uterine", "ORGAN", 105, 112], ["adipocytes", "CELL", 139, 149], ["myometrial smooth-muscle", "TISSUE", 185, 209], ["\u03b2-catenin", "PROTEIN", 22, 31], ["adipocytes", "CELL_TYPE", 139, 149], ["Selective deletion of \u03b2-catenin in uterine mesenchyme", "TREATMENT", 0, 53], ["embryonic development", "PROBLEM", 61, 82], ["uterine size", "PROBLEM", 105, 117], ["adipocytes", "PROBLEM", 139, 149], ["\u03b2-catenin", "OBSERVATION", 22, 31], ["uterine", "ANATOMY", 35, 42], ["mesenchyme", "ANATOMY_MODIFIER", 43, 53], ["embryonic", "OBSERVATION_MODIFIER", 61, 70], ["uterine", "ANATOMY", 105, 112], ["size", "OBSERVATION_MODIFIER", 113, 117], ["adipocytes", "ANATOMY", 139, 149], ["normal", "OBSERVATION", 178, 184], ["myometrial", "OBSERVATION", 185, 195], ["smooth", "OBSERVATION_MODIFIER", 196, 202], ["muscle", "ANATOMY", 203, 209], ["differentiation", "OBSERVATION_MODIFIER", 210, 225], ["regeneration", "OBSERVATION_MODIFIER", 230, 242]]], ["Conversely, selective overexpression of constitutively activated \u03b2-catenin in uterine mesenchyme during embryonic development and in adults gives rise to leiomyoma-like tumors in the uterus of all female mice (11).", [["uterine mesenchyme", "ANATOMY", 78, 96], ["embryonic", "ANATOMY", 104, 113], ["leiomyoma-like tumors", "ANATOMY", 154, 175], ["uterus", "ANATOMY", 183, 189], ["leiomyoma", "DISEASE", 154, 163], ["tumors", "DISEASE", 169, 175], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 65, 74], ["uterine mesenchyme", "TISSUE", 78, 96], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 104, 113], ["leiomyoma-like tumors", "CANCER", 154, 175], ["uterus", "ORGAN", 183, 189], ["mice", "ORGANISM", 204, 208], ["constitutively activated \u03b2-catenin", "PROTEIN", 40, 74], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 204, 208], ["constitutively activated \u03b2-catenin in uterine mesenchyme", "PROBLEM", 40, 96], ["embryonic development", "PROBLEM", 104, 125], ["leiomyoma", "PROBLEM", 154, 163], ["tumors in the uterus", "PROBLEM", 169, 189], ["uterine", "ANATOMY", 78, 85], ["mesenchyme", "ANATOMY_MODIFIER", 86, 96], ["leiomyoma", "OBSERVATION", 154, 163], ["tumors", "OBSERVATION", 169, 175], ["uterus", "ANATOMY", 183, 189]]], ["This suggests that \u03b2-catenin plays a key role in stem cell renewal and differentiation to the smooth-muscle phenotype observed in myometrial and leiomyoma tissues, and that the WNT/\u03b2-catenin pathway may be promising target for new therapeutics (48).DiscussionUterine leiomyomas are monoclonal tumors, with growth of the neoplasm occurring via clonal expansion from a single cell; this raises the possibility that interventions targeted at the mechanisms that underlie cell expansion may be particularly effective in the treatment of uterine leiomyomas (49).", [["stem cell", "ANATOMY", 49, 58], ["smooth-muscle", "ANATOMY", 94, 107], ["myometrial", "ANATOMY", 130, 140], ["leiomyoma tissues", "ANATOMY", 145, 162], ["leiomyomas", "ANATOMY", 267, 277], ["tumors", "ANATOMY", 293, 299], ["neoplasm", "ANATOMY", 320, 328], ["cell", "ANATOMY", 374, 378], ["cell", "ANATOMY", 468, 472], ["uterine leiomyomas", "ANATOMY", 533, 551], ["\u03b2-catenin", "CHEMICAL", 19, 28], ["leiomyomas", "DISEASE", 267, 277], ["monoclonal tumors", "DISEASE", 282, 299], ["neoplasm", "DISEASE", 320, 328], ["uterine leiomyomas", "DISEASE", 533, 551], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 19, 28], ["stem cell", "CELL", 49, 58], ["smooth-muscle", "TISSUE", 94, 107], ["myometrial", "TISSUE", 130, 140], ["leiomyoma tissues", "TISSUE", 145, 162], ["WNT", "GENE_OR_GENE_PRODUCT", 177, 180], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 181, 190], ["DiscussionUterine leiomyomas", "CANCER", 249, 277], ["tumors", "CANCER", 293, 299], ["neoplasm", "CANCER", 320, 328], ["cell", "CELL", 374, 378], ["cell", "CELL", 468, 472], ["uterine leiomyomas", "CANCER", 533, 551], ["\u03b2-catenin", "PROTEIN", 19, 28], ["WNT", "PROTEIN", 177, 180], ["\u03b2-catenin", "PROTEIN", 181, 190], ["stem cell renewal", "TREATMENT", 49, 66], ["the smooth-muscle phenotype", "PROBLEM", 90, 117], ["myometrial and leiomyoma tissues", "PROBLEM", 130, 162], ["DiscussionUterine leiomyomas", "PROBLEM", 249, 277], ["monoclonal tumors", "PROBLEM", 282, 299], ["the neoplasm", "PROBLEM", 316, 328], ["clonal expansion", "PROBLEM", 343, 359], ["a single cell", "PROBLEM", 365, 378], ["interventions", "TREATMENT", 413, 426], ["cell expansion", "PROBLEM", 468, 482], ["uterine leiomyomas", "PROBLEM", 533, 551], ["stem cell", "OBSERVATION", 49, 58], ["muscle", "ANATOMY", 101, 107], ["myometrial", "ANATOMY", 130, 140], ["leiomyoma", "OBSERVATION", 145, 154], ["leiomyomas", "OBSERVATION", 267, 277], ["monoclonal tumors", "OBSERVATION", 282, 299], ["growth", "OBSERVATION_MODIFIER", 306, 312], ["neoplasm", "OBSERVATION", 320, 328], ["clonal", "OBSERVATION_MODIFIER", 343, 349], ["expansion", "OBSERVATION_MODIFIER", 350, 359], ["single cell", "OBSERVATION_MODIFIER", 367, 378], ["raises the possibility", "UNCERTAINTY", 385, 407], ["cell expansion", "OBSERVATION", 468, 482], ["uterine", "ANATOMY", 533, 540], ["leiomyomas", "OBSERVATION", 541, 551]]], ["Components of the WNT pathway are prime drug development targets, particularly the accessible plasma membrane receptors such as Frizzled.", [["plasma membrane", "ANATOMY", 94, 109], ["WNT", "GENE_OR_GENE_PRODUCT", 18, 21], ["plasma membrane", "CELLULAR_COMPONENT", 94, 109], ["Frizzled", "GENE_OR_GENE_PRODUCT", 128, 136], ["WNT", "PROTEIN", 18, 21], ["plasma membrane receptors", "PROTEIN", 94, 119], ["Frizzled", "PROTEIN", 128, 136], ["the accessible plasma membrane receptors", "TREATMENT", 79, 119]]], ["Vuga et al. (50) found that WNT5a can increase fibroblast proliferation through a \u201cnoncanonical\u201d or \u03b2-catenin/TCF-independent signaling mechanism, indicating that both canonical and noncanonical WNTs may contribute to tumorigenesis.", [["fibroblast", "ANATOMY", 47, 57], ["WNT5a", "CHEMICAL", 28, 33], ["WNT5a", "GENE_OR_GENE_PRODUCT", 28, 33], ["fibroblast", "CELL", 47, 57], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 100, 109], ["TCF", "GENE_OR_GENE_PRODUCT", 110, 113], ["WNTs", "GENE_OR_GENE_PRODUCT", 195, 199], ["WNT5a", "PROTEIN", 28, 33], ["\u03b2-catenin", "PROTEIN", 100, 109], ["TCF", "PROTEIN", 110, 113], ["WNTs", "PROTEIN", 195, 199], ["fibroblast proliferation", "PROBLEM", 47, 71], ["\u03b2-catenin/TCF", "TREATMENT", 100, 113], ["tumorigenesis", "PROBLEM", 218, 231], ["fibroblast proliferation", "OBSERVATION", 47, 71]]], ["Given that WNT/\u03b2-catenin target genes are cell-type and cell-context dependent, identifying the WNT/\u03b2-catenin\u2013regulated target genes in human leiomyoma requires similar unbiased approaches.DiscussionMost leiomyomas contain specific genetic mutations, such as those found in MED12, suggesting that transformation of normal myocytes into abnormal myocytes is required at some point during the genesis of a leiomyoma (51).", [["cell", "ANATOMY", 42, 46], ["cell", "ANATOMY", 56, 60], ["leiomyoma", "ANATOMY", 142, 151], ["leiomyomas", "ANATOMY", 204, 214], ["myocytes", "ANATOMY", 322, 330], ["myocytes", "ANATOMY", 345, 353], ["leiomyoma", "ANATOMY", 404, 413], ["leiomyoma", "DISEASE", 142, 151], ["leiomyomas", "DISEASE", 204, 214], ["leiomyoma", "DISEASE", 404, 413], ["WNT", "GENE_OR_GENE_PRODUCT", 11, 14], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 15, 24], ["cell", "CELL", 42, 46], ["cell", "CELL", 56, 60], ["WNT", "GENE_OR_GENE_PRODUCT", 96, 99], ["\u03b2-", "GENE_OR_GENE_PRODUCT", 100, 102], ["human", "ORGANISM", 136, 141], ["leiomyoma", "CANCER", 142, 151], ["leiomyomas", "CANCER", 204, 214], ["MED12", "GENE_OR_GENE_PRODUCT", 274, 279], ["myocytes", "CELL", 322, 330], ["myocytes", "CELL", 345, 353], ["leiomyoma", "CANCER", 404, 413], ["WNT/\u03b2-catenin target genes", "DNA", 11, 37], ["WNT/\u03b2-catenin\u2013regulated target genes", "DNA", 96, 132], ["MED12", "DNA", 274, 279], ["normal myocytes", "CELL_TYPE", 315, 330], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["catenin\u2013regulated target genes in human leiomyoma", "PROBLEM", 102, 151], ["specific genetic mutations", "PROBLEM", 223, 249], ["abnormal myocytes", "PROBLEM", 336, 353], ["a leiomyoma", "PROBLEM", 402, 413], ["leiomyoma", "OBSERVATION", 142, 151], ["normal myocytes", "OBSERVATION", 315, 330], ["myocytes", "ANATOMY", 345, 353], ["leiomyoma", "OBSERVATION", 404, 413]]], ["MED12 binds directly to \u03b2-catenin and regulates canonical WNT signaling (52).", [["MED12", "GENE_OR_GENE_PRODUCT", 0, 5], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 24, 33], ["WNT", "GENE_OR_GENE_PRODUCT", 58, 61], ["MED12", "PROTEIN", 0, 5], ["\u03b2-catenin", "PROTEIN", 24, 33], ["WNT", "PROTEIN", 58, 61], ["MED12 binds", "TREATMENT", 0, 11]]], ["Interestingly, expression of WNT4, an activator of \u03b2-catenin, is markedly elevated in leiomyoma with MED12 mutations vs. those without mutations (44).", [["leiomyoma", "ANATOMY", 86, 95], ["leiomyoma", "DISEASE", 86, 95], ["WNT4", "GENE_OR_GENE_PRODUCT", 29, 33], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 51, 60], ["leiomyoma", "CANCER", 86, 95], ["MED12", "GENE_OR_GENE_PRODUCT", 101, 106], ["WNT4", "PROTEIN", 29, 33], ["\u03b2-catenin", "PROTEIN", 51, 60], ["MED12", "PROTEIN", 101, 106], ["markedly elevated in leiomyoma", "PROBLEM", 65, 95], ["MED12 mutations", "PROBLEM", 101, 116], ["mutations", "PROBLEM", 135, 144], ["markedly", "OBSERVATION_MODIFIER", 65, 73], ["elevated", "OBSERVATION_MODIFIER", 74, 82], ["leiomyoma", "OBSERVATION", 86, 95], ["MED12 mutations", "OBSERVATION", 101, 116]]], ["These observations point to a mechanism involving MED12 mutations and WNT/\u03b2-catenin activation that supports cell proliferation in uterine leiomyoma tissue 52, 53.DiscussionInterestingly, the size and number of \u03b2-catenin\u2013driven leiomyoma-like tumors increases with parity in mice, suggesting that exposure to steroid hormones may interact with activated \u03b2-catenin to accelerate tumorigenesis.", [["cell", "ANATOMY", 109, 113], ["uterine leiomyoma tissue", "ANATOMY", 131, 155], ["\u03b2-catenin\u2013driven leiomyoma-like tumors", "ANATOMY", 211, 249], ["uterine leiomyoma", "DISEASE", 131, 148], ["leiomyoma", "DISEASE", 228, 237], ["tumors", "DISEASE", 243, 249], ["steroid", "CHEMICAL", 309, 316], ["\u03b2-catenin", "CHEMICAL", 354, 363], ["steroid", "CHEMICAL", 309, 316], ["MED12", "GENE_OR_GENE_PRODUCT", 50, 55], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 70, 83], ["cell", "CELL", 109, 113], ["uterine leiomyoma tissue", "TISSUE", 131, 155], ["\u03b2-catenin\u2013driven leiomyoma-like tumors", "CANCER", 211, 249], ["mice", "ORGANISM", 275, 279], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 354, 363], ["MED12", "PROTEIN", 50, 55], ["WNT", "PROTEIN", 70, 73], ["\u03b2-catenin", "PROTEIN", 74, 83], ["\u03b2-catenin", "PROTEIN", 354, 363], ["mice", "SPECIES", 275, 279], ["mice", "SPECIES", 275, 279], ["MED12 mutations", "PROBLEM", 50, 65], ["WNT/\u03b2-catenin activation", "TREATMENT", 70, 94], ["cell proliferation in uterine leiomyoma tissue", "PROBLEM", 109, 155], ["\u03b2-catenin\u2013driven leiomyoma", "PROBLEM", 211, 237], ["tumors", "PROBLEM", 243, 249], ["steroid hormones", "TREATMENT", 309, 325], ["activated \u03b2-catenin", "TREATMENT", 344, 363], ["cell proliferation", "OBSERVATION", 109, 127], ["uterine", "ANATOMY", 131, 138], ["leiomyoma", "OBSERVATION", 139, 148], ["size", "OBSERVATION_MODIFIER", 192, 196], ["leiomyoma", "OBSERVATION", 228, 237], ["tumors", "OBSERVATION", 243, 249], ["tumorigenesis", "OBSERVATION", 378, 391]]], ["Moreover, activated \u03b2-catenin induces expression of transforming growth factor-\u03b23, which induces proliferation and extracellular matrix formation in human leiomyoma tissue 11, 54.", [["extracellular matrix", "ANATOMY", 115, 135], ["leiomyoma tissue", "ANATOMY", 155, 171], ["\u03b2-catenin", "CHEMICAL", 20, 29], ["leiomyoma", "DISEASE", 155, 164], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 20, 29], ["transforming growth factor-\u03b23", "GENE_OR_GENE_PRODUCT", 52, 81], ["extracellular matrix", "CELLULAR_COMPONENT", 115, 135], ["human", "ORGANISM", 149, 154], ["leiomyoma tissue", "TISSUE", 155, 171], ["\u03b2-catenin", "PROTEIN", 20, 29], ["transforming growth factor-\u03b23", "PROTEIN", 52, 81], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 149, 154], ["transforming growth factor", "PROBLEM", 52, 78], ["extracellular matrix formation in human leiomyoma tissue", "PROBLEM", 115, 171], ["proliferation", "OBSERVATION", 97, 110], ["extracellular matrix", "OBSERVATION", 115, 135], ["human leiomyoma", "OBSERVATION", 149, 164]]], ["It is known that \u03b2-catenin signaling antagonizes adipogenesis by inhibiting the adipogenic transcription factors CCAAT/enhancer binding protein-\u03b1 and peroxisome proliferator-activated receptor \u03b3 (55).", [["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 17, 26], ["CCAAT/enhancer binding protein-\u03b1", "GENE_OR_GENE_PRODUCT", 113, 145], ["peroxisome proliferator-activated receptor \u03b3", "GENE_OR_GENE_PRODUCT", 150, 194], ["\u03b2-catenin", "PROTEIN", 17, 26], ["adipogenic transcription factors", "PROTEIN", 80, 112], ["CCAAT/enhancer binding protein", "PROTEIN", 113, 143], ["\u03b1", "PROTEIN", 144, 145], ["peroxisome proliferator-activated receptor \u03b3", "PROTEIN", 150, 194], ["\u03b2-catenin signaling antagonizes adipogenesis", "PROBLEM", 17, 61], ["CCAAT/enhancer binding protein", "TEST", 113, 143], ["peroxisome proliferator", "TEST", 150, 173]]], ["Two percent of all leiomyomas contain adipocytes that have undergone metaplasia.", [["leiomyomas", "ANATOMY", 19, 29], ["adipocytes", "ANATOMY", 38, 48], ["metaplasia", "ANATOMY", 69, 79], ["leiomyomas", "DISEASE", 19, 29], ["leiomyomas", "CANCER", 19, 29], ["adipocytes", "CELL", 38, 48], ["metaplasia", "CANCER", 69, 79], ["adipocytes", "CELL_TYPE", 38, 48], ["all leiomyomas", "PROBLEM", 15, 29], ["adipocytes", "PROBLEM", 38, 48], ["metaplasia", "PROBLEM", 69, 79], ["percent", "OBSERVATION_MODIFIER", 4, 11], ["all", "OBSERVATION_MODIFIER", 15, 18], ["leiomyomas", "OBSERVATION", 19, 29], ["adipocytes", "ANATOMY", 38, 48], ["metaplasia", "OBSERVATION", 69, 79]]], ["This suggests that aberrant \u03b2-catenin signaling affects the tumor initiation and tumor maintenance in uterine leiomyoma.DiscussionThe mechanism of action of niclosamide is thought to be through the internalization of Fzd1 and down-regulation of WNT pathway intermediaries (41).", [["tumor", "ANATOMY", 60, 65], ["tumor", "ANATOMY", 81, 86], ["uterine leiomyoma", "ANATOMY", 102, 119], ["tumor", "DISEASE", 60, 65], ["tumor", "DISEASE", 81, 86], ["uterine leiomyoma", "DISEASE", 102, 119], ["niclosamide", "CHEMICAL", 157, 168], ["niclosamide", "CHEMICAL", 157, 168], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 28, 37], ["tumor", "CANCER", 60, 65], ["tumor", "CANCER", 81, 86], ["uterine leiomyoma", "CANCER", 102, 119], ["niclosamide", "SIMPLE_CHEMICAL", 157, 168], ["Fzd1", "GENE_OR_GENE_PRODUCT", 217, 221], ["WNT", "GENE_OR_GENE_PRODUCT", 245, 248], ["\u03b2-catenin", "PROTEIN", 28, 37], ["Fzd1", "PROTEIN", 217, 221], ["WNT", "PROTEIN", 245, 248], ["aberrant \u03b2-catenin signaling", "PROBLEM", 19, 47], ["the tumor initiation", "PROBLEM", 56, 76], ["tumor maintenance in uterine leiomyoma", "PROBLEM", 81, 119], ["niclosamide", "TREATMENT", 157, 168], ["Fzd1", "TEST", 217, 221], ["aberrant", "OBSERVATION_MODIFIER", 19, 27], ["\u03b2-catenin", "OBSERVATION", 28, 37], ["tumor", "OBSERVATION", 60, 65], ["tumor", "OBSERVATION", 81, 86], ["uterine", "ANATOMY", 102, 109], ["leiomyoma", "OBSERVATION", 110, 119]]], ["In its common usage as an antihelminthic, it is believed to uncouple oxidative phosphorylation 56, 57.", [["oxidative phosphorylation", "TEST", 69, 94]]], ["It has recently been found to be effective at low micromolar concentrations in preventing the synthesis of corona virus proteins in a tissue culture model of severe acute respiratory syndrome (58).", [["tissue culture", "ANATOMY", 134, 148], ["acute respiratory syndrome", "DISEASE", 165, 191], ["corona virus", "ORGANISM", 107, 119], ["tissue", "TISSUE", 134, 140], ["corona virus proteins", "PROTEIN", 107, 128], ["low micromolar concentrations", "PROBLEM", 46, 75], ["corona virus proteins", "PROBLEM", 107, 128], ["a tissue culture", "TEST", 132, 148], ["severe acute respiratory syndrome", "PROBLEM", 158, 191], ["effective", "OBSERVATION_MODIFIER", 33, 42], ["low micromolar", "OBSERVATION_MODIFIER", 46, 60], ["concentrations", "OBSERVATION_MODIFIER", 61, 75], ["corona virus", "OBSERVATION", 107, 119], ["tissue", "ANATOMY", 134, 140], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["respiratory syndrome", "OBSERVATION", 171, 191]]], ["It is known that the function of \u03b2-catenin is controlled by ubiquitination and ultimately degradation by the proteasome; a possible mechanism of niclosamide function might be its effect on either the ubiquitination or a proteolytic pathway to cause degradation of \u03b2-catenin (59).", [["\u03b2-catenin", "CHEMICAL", 33, 42], ["niclosamide", "CHEMICAL", 145, 156], ["niclosamide", "CHEMICAL", 145, 156], ["\u03b2-catenin", "CHEMICAL", 264, 273], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 33, 42], ["niclosamide", "SIMPLE_CHEMICAL", 145, 156], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 264, 273], ["\u03b2-catenin", "PROTEIN", 33, 42], ["proteasome", "PROTEIN", 109, 119], ["\u03b2-catenin", "PROTEIN", 264, 273], ["the proteasome", "TREATMENT", 105, 119], ["niclosamide function", "TREATMENT", 145, 165], ["the ubiquitination", "PROBLEM", 196, 214], ["a proteolytic pathway", "PROBLEM", 218, 239]]], ["Recent studies found that XAV939 inhibits the Poly (ADP-ribose) polymerase (PARP) domain of tankyrase 1 and 2 and destabilizes AXIN1 and 2 by Poly-ADP-ribosylation (PARsylation) (60).", [["XAV939", "CHEMICAL", 26, 32], ["Poly (ADP-ribose", "CHEMICAL", 46, 62], ["Poly-ADP", "CHEMICAL", 142, 150], ["XAV939", "CHEMICAL", 26, 32], ["Poly (ADP-ribose)", "CHEMICAL", 46, 63], ["ADP", "CHEMICAL", 147, 150], ["XAV939", "SIMPLE_CHEMICAL", 26, 32], ["Poly (ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 46, 74], ["PARP", "GENE_OR_GENE_PRODUCT", 76, 80], ["tankyrase 1", "GENE_OR_GENE_PRODUCT", 92, 103], ["2", "GENE_OR_GENE_PRODUCT", 108, 109], ["AXIN1", "GENE_OR_GENE_PRODUCT", 127, 132], ["Poly-ADP-ribosylation", "GENE_OR_GENE_PRODUCT", 142, 163], ["Poly (ADP-ribose) polymerase (PARP) domain", "PROTEIN", 46, 88], ["tankyrase 1 and 2", "PROTEIN", 92, 109], ["AXIN1", "PROTEIN", 127, 132], ["Poly-ADP-ribosylation", "PROTEIN", 142, 163], ["Recent studies", "TEST", 0, 14], ["the Poly (ADP-ribose) polymerase", "TEST", 42, 74], ["PARP", "TEST", 76, 80], ["tankyrase", "TEST", 92, 101], ["AXIN1", "TEST", 127, 132]]], ["In the present study we showed by TOPflash assay that niclosamide and XAV939 can inhibit WNT pathway activation in leiomyoma cells.", [["leiomyoma cells", "ANATOMY", 115, 130], ["niclosamide", "CHEMICAL", 54, 65], ["XAV939", "CHEMICAL", 70, 76], ["leiomyoma", "DISEASE", 115, 124], ["niclosamide", "CHEMICAL", 54, 65], ["XAV939", "CHEMICAL", 70, 76], ["niclosamide", "SIMPLE_CHEMICAL", 54, 65], ["XAV939", "SIMPLE_CHEMICAL", 70, 76], ["WNT", "GENE_OR_GENE_PRODUCT", 89, 92], ["leiomyoma cells", "CELL", 115, 130], ["WNT", "PROTEIN", 89, 92], ["leiomyoma cells", "CELL_TYPE", 115, 130], ["the present study", "TEST", 3, 20], ["niclosamide", "TREATMENT", 54, 65], ["WNT pathway activation in leiomyoma cells", "PROBLEM", 89, 130], ["leiomyoma cells", "OBSERVATION", 115, 130]]], ["We attempted to rule out nonspecific toxic effects of niclosamide or XAV939 on cells using the LDH assay.", [["cells", "ANATOMY", 79, 84], ["niclosamide", "CHEMICAL", 54, 65], ["XAV939", "CHEMICAL", 69, 75], ["niclosamide", "CHEMICAL", 54, 65], ["XAV939", "CHEMICAL", 69, 75], ["niclosamide", "SIMPLE_CHEMICAL", 54, 65], ["XAV939", "SIMPLE_CHEMICAL", 69, 75], ["cells", "CELL", 79, 84], ["LDH", "GENE_OR_GENE_PRODUCT", 95, 98], ["LDH", "PROTEIN", 95, 98], ["nonspecific toxic effects", "PROBLEM", 25, 50], ["niclosamide", "TREATMENT", 54, 65], ["cells", "TREATMENT", 79, 84], ["the LDH assay", "TEST", 91, 104], ["nonspecific", "OBSERVATION_MODIFIER", 25, 36], ["toxic", "OBSERVATION_MODIFIER", 37, 42]]], ["We noticed morphologic changes in these cells after treatments.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["morphologic changes in these cells", "PROBLEM", 11, 45], ["treatments", "TREATMENT", 52, 62], ["these cells", "OBSERVATION", 34, 45]]], ["Thus, further studies will be needed to assess nonspecific toxic effects of these compounds on both diseased and healthy tissues.DiscussionNiclosamide and XAV939 were administered orally in the referenced reports 42, 61.", [["tissues", "ANATOMY", 121, 128], ["Niclosamide", "CHEMICAL", 139, 150], ["XAV939", "CHEMICAL", 155, 161], ["Niclosamide", "CHEMICAL", 139, 150], ["XAV939", "CHEMICAL", 155, 161], ["tissues", "TISSUE", 121, 128], ["Niclosamide", "SIMPLE_CHEMICAL", 139, 150], ["XAV939", "SIMPLE_CHEMICAL", 155, 161], ["further studies", "TEST", 6, 21], ["nonspecific toxic effects", "PROBLEM", 47, 72], ["these compounds", "PROBLEM", 76, 91], ["both diseased and healthy tissues", "PROBLEM", 95, 128], ["Niclosamide", "TREATMENT", 139, 150], ["XAV939", "TREATMENT", 155, 161], ["both", "OBSERVATION_MODIFIER", 95, 99], ["diseased", "OBSERVATION", 100, 108], ["healthy tissues", "OBSERVATION", 113, 128]]], ["It can be speculated that the systemic treatment works because the WNT canonical signaling is highly active in the diseased tissue, therefore it is more susceptible to the effects of the drugs compared with healthy tissue, allowing for a lower dose to be administered.", [["tissue", "ANATOMY", 124, 130], ["tissue", "ANATOMY", 215, 221], ["WNT", "GENE_OR_GENE_PRODUCT", 67, 70], ["tissue", "TISSUE", 124, 130], ["tissue", "TISSUE", 215, 221], ["WNT", "PROTEIN", 67, 70], ["the systemic treatment", "TREATMENT", 26, 48], ["the diseased tissue", "PROBLEM", 111, 130], ["the drugs", "TREATMENT", 183, 192], ["a lower dose", "TREATMENT", 236, 248], ["highly", "OBSERVATION_MODIFIER", 94, 100], ["active", "OBSERVATION_MODIFIER", 101, 107], ["diseased tissue", "OBSERVATION", 115, 130]]], ["However, reducing undesirable side effects should always be a goal when developing novel therapies.", [["novel therapies", "TREATMENT", 83, 98]]], ["Consequently, to avoid any off-target effects, it might be attractive to develop a vaginal delivery system, which can deliver therapeutics locally and avoid systemic complications.DiscussionIn summary, we showed that the down-regulation of WNT/\u03b2-catenin signaling, via ICAT, niclosamide, or XAV939, has antitumor effects on primary cultures of human leiomyoma cells in vitro.", [["vaginal", "ANATOMY", 83, 90], ["antitumor", "ANATOMY", 303, 312], ["primary cultures", "ANATOMY", 324, 340], ["leiomyoma cells", "ANATOMY", 350, 365], ["niclosamide", "CHEMICAL", 275, 286], ["XAV939", "CHEMICAL", 291, 297], ["leiomyoma", "DISEASE", 350, 359], ["niclosamide", "CHEMICAL", 275, 286], ["XAV939", "CHEMICAL", 291, 297], ["WNT", "GENE_OR_GENE_PRODUCT", 240, 243], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 244, 253], ["ICAT", "GENE_OR_GENE_PRODUCT", 269, 273], ["niclosamide", "SIMPLE_CHEMICAL", 275, 286], ["XAV939", "SIMPLE_CHEMICAL", 291, 297], ["antitumor", "CANCER", 303, 312], ["human", "ORGANISM", 344, 349], ["leiomyoma cells", "CELL", 350, 365], ["WNT", "PROTEIN", 240, 243], ["\u03b2-catenin", "PROTEIN", 244, 253], ["ICAT", "PROTEIN", 269, 273], ["primary cultures", "CELL_LINE", 324, 340], ["human leiomyoma cells", "CELL_TYPE", 344, 365], ["human", "SPECIES", 344, 349], ["human", "SPECIES", 344, 349], ["a vaginal delivery system", "TREATMENT", 81, 106], ["systemic complications", "PROBLEM", 157, 179], ["catenin signaling", "TREATMENT", 246, 263], ["niclosamide", "TREATMENT", 275, 286], ["XAV939", "TREATMENT", 291, 297], ["antitumor effects", "PROBLEM", 303, 320], ["primary cultures", "TEST", 324, 340], ["human leiomyoma cells", "PROBLEM", 344, 365], ["leiomyoma cells", "OBSERVATION", 350, 365]]], ["Our study demonstrates that sustained activation of WNT/\u03b2-catenin signaling in leiomyoma cells can enhance activities associated with leiomyoma formation, such as proliferation.", [["leiomyoma cells", "ANATOMY", 79, 94], ["leiomyoma", "ANATOMY", 134, 143], ["leiomyoma", "DISEASE", 79, 88], ["leiomyoma", "DISEASE", 134, 143], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 52, 65], ["leiomyoma cells", "CELL", 79, 94], ["leiomyoma", "CANCER", 134, 143], ["WNT", "PROTEIN", 52, 55], ["\u03b2-catenin", "PROTEIN", 56, 65], ["leiomyoma cells", "CELL_TYPE", 79, 94], ["Our study", "TEST", 0, 9], ["sustained activation of WNT/\u03b2-catenin signaling", "PROBLEM", 28, 75], ["leiomyoma cells", "PROBLEM", 79, 94], ["leiomyoma formation", "PROBLEM", 134, 153], ["proliferation", "PROBLEM", 163, 176], ["leiomyoma cells", "OBSERVATION", 79, 94], ["leiomyoma", "OBSERVATION", 134, 143], ["proliferation", "OBSERVATION_MODIFIER", 163, 176]]], ["However, given that WNT/\u03b2-catenin signaling controls cell-fate decisions throughout development, often controlling the balance between progenitor cells and their descendants, we speculate that cells serving as progenitors to leiomyoma may be a key target of WNT/\u03b2-catenin signaling in leiomyoma tumorigenesis (62).", [["cell", "ANATOMY", 53, 57], ["progenitor cells", "ANATOMY", 135, 151], ["cells", "ANATOMY", 193, 198], ["progenitors", "ANATOMY", 210, 221], ["leiomyoma", "ANATOMY", 225, 234], ["leiomyoma", "ANATOMY", 285, 294], ["leiomyoma", "DISEASE", 225, 234], ["leiomyoma tumorigenesis", "DISEASE", 285, 308], ["WNT/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 20, 33], ["cell", "CELL", 53, 57], ["progenitor cells", "CELL", 135, 151], ["cells", "CELL", 193, 198], ["progenitors", "CELL", 210, 221], ["leiomyoma", "CANCER", 225, 234], ["WNT", "GENE_OR_GENE_PRODUCT", 258, 261], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 262, 271], ["leiomyoma", "CANCER", 285, 294], ["WNT", "PROTEIN", 20, 23], ["\u03b2-catenin", "PROTEIN", 24, 33], ["progenitor cells", "CELL_TYPE", 135, 151], ["WNT", "PROTEIN", 258, 261], ["\u03b2-catenin", "PROTEIN", 262, 271], ["leiomyoma tumorigenesis", "PROBLEM", 285, 308], ["leiomyoma", "OBSERVATION", 285, 294]]]], "4f58e879d9a7b5eb859057bbbd619a5f3847b5be": [["T he recent emergence of severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, family Coronaviridae, genus Betacoronavirus, first occurred in Wuhan, Hubei Province, China, in December 2019 (1) .", [["acute respiratory syndrome coronavirus", "DISEASE", 32, 70], ["SARS-CoV-2", "ORGANISM", 77, 87], ["severe acute respiratory syndrome coronavirus", "SPECIES", 25, 70], ["SARS-CoV-2", "SPECIES", 77, 87], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 25, 70], ["SARS", "PROBLEM", 77, 81], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome", "OBSERVATION", 38, 58]]], ["Since then, the virus has spread globally, and the World Health Organization (WHO) declared the disease COVID-19 a pandemic on 31 January 2020 (2) .", [["the virus", "PROBLEM", 12, 21], ["the disease COVID", "PROBLEM", 92, 109], ["virus", "OBSERVATION", 16, 21], ["spread", "OBSERVATION_MODIFIER", 26, 32], ["globally", "OBSERVATION_MODIFIER", 33, 41]]], ["Here, we report the coding-complete genomic sequences of five SARS-CoV-2 strains isolated from Bangladeshi patients with no travel history.", [["SARS-CoV-2", "ORGANISM", 62, 72], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["SARS-CoV-2", "SPECIES", 62, 72], ["five SARS", "TEST", 57, 66], ["CoV", "TEST", 67, 70]]]], "42de8988c1e9ddb5f21688ff219c9c26a9710a03": [["0.37, p< 0.0001), AST (r= -0.31, p<0.01), WBC (r= -0.49, p<0.0001), neutrophils count (r= -0.5, p<0.001).", [["neutrophils", "ANATOMY", 68, 79], ["AST", "SIMPLE_CHEMICAL", 18, 21], ["neutrophils", "CELL", 68, 79], ["AST", "PROTEIN", 18, 21], ["neutrophils", "CELL_TYPE", 68, 79], ["p", "TEST", 6, 7], ["AST", "TEST", 18, 21], ["p", "TEST", 33, 34], ["WBC", "TEST", 42, 45], ["p", "TEST", 57, 58], ["neutrophils count", "TEST", 68, 85], ["r", "TEST", 87, 88], ["p", "TEST", 96, 97]]], ["ROC 35 curves showed a sensitivity of 75% and specificity of 70% for the LDH cut-off value of 450 U/L and a 36 sensitivity of 72% and specificity of 71% for the CRP cut-off value of 11 mg/dl in identifying CoVID-19 with 37 moderate-severe ARDS. and viral evasion of cellular immune responses play a central role in disease progression and severity [7] . and kidney function and coagulation measures were significantly elevated in patients with both severe and severe disease [9] .70In the present study, we tested the hypothesis that some routine laboratory markers, used to detect tissue", [["cellular", "ANATOMY", 266, 274], ["kidney", "ANATOMY", 358, 364], ["tissue", "ANATOMY", 582, 588], ["ARDS", "DISEASE", 239, 243], ["LDH", "GENE_OR_GENE_PRODUCT", 73, 76], ["cellular", "CELL", 266, 274], ["kidney", "ORGAN", 358, 364], ["patients", "ORGANISM", 430, 438], ["tissue", "TISSUE", 582, 588], ["LDH", "PROTEIN", 73, 76], ["CRP", "PROTEIN", 161, 164], ["patients", "SPECIES", 430, 438], ["ROC 35 curves", "TEST", 0, 13], ["a sensitivity", "TEST", 21, 34], ["specificity", "TEST", 46, 57], ["the LDH cut", "TEST", 69, 80], ["U/L", "TEST", 98, 101], ["specificity", "TEST", 134, 145], ["the CRP cut", "TEST", 157, 168], ["CoVID", "TEST", 206, 211], ["moderate-severe ARDS", "PROBLEM", 223, 243], ["cellular immune responses", "TREATMENT", 266, 291], ["kidney function", "TEST", 358, 373], ["coagulation measures", "TEST", 378, 398], ["significantly elevated", "PROBLEM", 404, 426], ["both severe and severe disease", "PROBLEM", 444, 474], ["routine laboratory markers", "TEST", 539, 565], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["ARDS", "OBSERVATION", 239, 243], ["viral evasion", "OBSERVATION", 249, 262], ["cellular immune", "OBSERVATION", 266, 281], ["central", "OBSERVATION_MODIFIER", 299, 306], ["kidney", "ANATOMY", 358, 364], ["severe", "OBSERVATION_MODIFIER", 449, 455], ["severe", "OBSERVATION_MODIFIER", 460, 466], ["disease", "OBSERVATION", 467, 474]]]], "f935d0cc6aafe5d5f6cef966d8ac2b88d3658b15": [["All rights reserved.a b s t r a c tEntre le 11 et le 12 mars nous avons \u00e9t\u00e9 plong\u00e9s du \u00ab Carpe diem \u00bb au \u00ab Dies irae \u00bb, de l'insouciance \u00e0 l'ab\u00eeme !", [["a b s", "TEST", 20, 25], ["a c tEntre le", "TREATMENT", 30, 43]]], ["Nous ne renoncerons pas \u00e0 la libert\u00e9 [. . .] \u00bb 2 .a b s t r a c tD\u00e8s le lendemain pourtant dans une solennelle adresse aux fran\u00e7 ais le Pr\u00e9sident de la R\u00e9publique pr\u00f4nait un renoncement, temporaire.", [["a c", "TEST", 60, 63], ["tD\u00e8s", "TEST", 64, 68]]], ["Il nous exhortait \u00e0 \u00ab [. . .] continuer \u00e0 faire des sacrifices \u0b1d Nous esp\u00e9rons que le lecteur nous pardonnera d'avoir \u00ab d\u00e9tourn\u00e9 \u00bb le titre de l'ouvrage de Marc Bloch, \u00ab L'\u00e9trange d\u00e9faite \u00bb \u00e9crit en 1940, Soci\u00e9t\u00e9 des \u00c9ditions Franc-Tireur, Paris, 1946 .a b s t r a c tAdresse e-mail : f.vialla@gmail.com 1 https://www.elysee.fr/emmanuel-macron/2020/03/11/premiere-journeenationale-dhommage-aux-victimes-du-terrorisme-suivez-la-ceremonie-autrocadero 2 https://www.elysee.fr/emmanuel-macron/2020/03/11/premiere-journeenationale-dhommage-aux-victimes-du-terrorisme-suivez-la-ceremonie-autrocadero et plut\u00f4t [\u00e0] faire davantage, mais pour notre int\u00e9r\u00eat collectif \u00bb 3 .", [["Nous esp\u00e9rons que le lecteur nous pardonnera d'avoir \u00ab d\u00e9tourn\u00e9 \u00bb le titre de l'ouvrage de Marc Bloch, \u00ab L'\u00e9trange d\u00e9faite \u00bb \u00e9crit en 1940, Soci\u00e9t\u00e9 des \u00c9ditions Franc-Tireur, Paris, 1946 .a", "SPECIES", 65, 254], ["faire davantage", "PROBLEM", 608, 623]]], ["Le ton se faisait plus grave encore le 16 mars 4 dans une allocution aux accents guerriers.", [["Le ton", "TEST", 0, 6], ["grave", "OBSERVATION_MODIFIER", 23, 28]]], ["Si cette rh\u00e9torique martiale n'est pas unanimement partag\u00e9e, pour le pr\u00e9sident allemand, Frank-Walter Steinmeier, la pand\u00e9mie \u00ab n'est pas une guerre \u00bb mais un \u00ab test d'humanit\u00e9 \u00bb, elle n'en est pas moins indiscutablement assum\u00e9e par le Chef de l'\u00c9tat.", [["cette rh\u00e9torique martiale n'est pas unanimement partag\u00e9e, pour le pr\u00e9sident allemand, Frank-Walter Steinmeier, la pand\u00e9mie \u00ab n'est pas une guerre \u00bb mais un \u00ab test d'humanit\u00e9 \u00bb, elle n'en est pas moins indiscutablement assum\u00e9e par le Chef de l'\u00c9tat", "SPECIES", 3, 250]]], ["Pour les plus sceptiques rappelons que le mot \u00ab guerre \u00bb apparait \u00e0 sept occasions dans le propos pr\u00e9sidentiel, on croirait presque entendre Cl\u00e9menceau : \u00ab Ma politique \u00e9trang\u00e8re et ma politique int\u00e9rieure, c'est tout un.", [["Pour les plus sceptiques rappelons que le mot \u00ab guerre \u00bb apparait \u00e0 sept occasions dans le propos pr\u00e9sidentiel", "SPECIES", 0, 110]]], ["Politique int\u00e9rieure, je fais la guerre ; politique \u00e9trang\u00e8re, je fais la guerre.", [["Politique int\u00e9rieure", "PROBLEM", 0, 20]]], ["Je fais toujours la guerre \u00bb.a b s t r a c t\u00ab Alea jacta est \u00bb, la guerre est donc d\u00e9clar\u00e9e : \u00ab Nous sommes en guerre, en guerre sanitaire, certes : nous ne luttons ni contre une arm\u00e9e, ni contre une autre Nation.", [["a c", "TEST", 39, 42], ["Alea", "TEST", 46, 50], ["la", "ANATOMY", 64, 66]]], ["Mais l'ennemi[e] 5 est l\u00e0, invisible, insaisissable, qui progresse.", [["Mais l'ennemi", "TEST", 0, 13]]], ["Et cela requiert notre mobilisation g\u00e9n\u00e9rale.", [["mobilisation g\u00e9n\u00e9rale", "OBSERVATION", 23, 44]]], ["Nous sommes en guerre \u00bb.a b s t r a c tD\u00e9clarer la guerre, fut-elle sanitaire, n'est pas anodin,\u00ab La d\u00e9claration de guerre donne [. . .] la possibilit\u00e9 formidable [. . .] de bouleverser en quelques mots le sort des individus, comme le destin des Nations, et de substituer un ordre juridique \u00e0 un autre \u00bb 6 .", [["anodin", "CHEMICAL", 89, 95]]], ["Car c'est bien de cela qu'il s'agit, les enjeux et les logiques du \u00ab nous sommes en guerre \u00bb pr\u00e9sidentiel, consistent \u00e0 nous annoncer un bouleversement, momentan\u00e9, de notre r\u00e9gime juridique, \u00e0 nous faire entrer brutalement dans un syst\u00e8me de droit o\u00f9 l'interdit est la r\u00e8gle et dans lequel les libert\u00e9s sont suspendues.a b s t r a c t\u00ab Le corona-blocus a succ\u00e9d\u00e9 \u00e0 la corona-morbus \u00bb 7 .", [["a c", "TEST", 329, 332]]], ["C'est le paradoxe d'une m\u00e9decine moderne qui [. . .] adapte et \u00e9largit des m\u00e9thodes anciennes sans plus de preuve d'efficacit\u00e9.", [["adapte et \u00e9largit des", "TREATMENT", 53, 74]]], ["Face \u00e0 la croissance des chiffres de d\u00e9c\u00e8s et \u00e0 la crainte d'une propagation exponentielle, beaucoup de pays ont fait ce choix dict\u00e9 par la peur \u00bb 8 !", [["Face \u00e0 la croissance des", "TREATMENT", 0, 24]]], ["Comment ne pas \u00e9voquer les propos \u00ab \u00e9volutifs \u00bb de la ministre de la sant\u00e9 qui, le 24 janvier, consid\u00e9rait que \u00ab les risques de propagation du virus dans la population sont tr\u00e8s faibles \u00bb 9 avant de d\u00e9clarer au lendemain du premier tour des \u00e9lections municipales \u00ab Depuis le d\u00e9but je ne pensais qu'\u00e0 une seule chose : au coronavirus.", [["coronavirus", "ORGANISM", 321, 332], ["Depuis le d\u00e9but je ne pensais qu'\u00e0 une seule chose : au coronavirus", "SPECIES", 265, 332], ["au coronavirus", "PROBLEM", 318, 332]]], ["On aurait d\u00fb tout arr\u00eater, c'\u00e9tait une mascarade \u00bb 10 .", [["aurait", "TREATMENT", 3, 9]]], ["Nous avions confiance dans le \u00ab meilleurs syst\u00e8me de sant\u00e9 du monde \u00bb et \u00ab La France, comme d'autres pays, a baiss\u00e9 sa garde traditionnelle \u00bb 12 .", [["Nous avions confiance dans le \u00ab meilleurs syst\u00e8me de sant\u00e9 du monde \u00bb et \u00ab La France, comme d'autres pays, a baiss\u00e9 sa garde traditionnelle \u00bb", "SPECIES", 0, 141]]], ["Aujourd'hui comme hier la mal\u00e9diction d' consciences face au risque qui perdure 13 .", [["Aujourd'hui comme hier la mal\u00e9diction d' consciences face au risque qui perdure 13", "SPECIES", 0, 82]]], ["Anticiper, \u00ab Prius anditotum quam venenum \u00bb 14 n'est cependant pas chose ais\u00e9e face \u00e0 des menaces encore inconnues.", [["Anticiper", "TEST", 0, 9]]], ["Au commencement les pouvoirs publics se voulaient pourtant rassurants.a b s t r a c tSouvenons-nous. . .", [["Au", "CHEMICAL", 0, 2], ["Au", "CHEMICAL", 0, 2]]], ["Au reste, pourquoi aurions-nous eu peur puisque le ministre de la sant\u00e9 d\u00e9clarait le 18 f\u00e9vrier sur France Inter que la France \u00ab est pr\u00eate \u00bb.", [["Au", "CHEMICAL", 0, 2]]], ["Bref, comme le proclamait en 1870 le Mar\u00e9chal Le Boeuf 17 : \u00ab Nous sommes pr\u00eats et archi-pr\u00eats.", [["Bref, comme le proclamait en 1870 le Mar\u00e9chal Le Boeuf 17", "SPECIES", 0, 57]]], ["La guerre d\u00fbt-elle durer deux ans, il ne manquerait pas un bouton de gu\u00eatre \u00e0 nos soldats \u00bb.a b s t r a c tOn sait ce qu'il advint !", [["La guerre", "TEST", 0, 9]]], ["Une fois adopt\u00e9e la rh\u00e9torique martiale, une fois la guerre d\u00e9clar\u00e9e, une fois l'union sacr\u00e9e r\u00e9clam\u00e9e, une fois la mobilisation g\u00e9n\u00e9rale proclam\u00e9e 18 , il restait \u00e0 mener les combats et \u00e0 s'assurer de la victoire car \u00ab D\u00e9clarer la guerre n'est pas tout, il faut savoir la faire \u00bb 19 .a b s t r a c t\u00c9vacuons la question du \u00ab nerf de la guerre \u00bb puisque nous \u00e9tions assur\u00e9s que l'argent ne viendrait pas \u00e0 manquer, le Chef de l'\u00c9tat nous ayant tranquillis\u00e9 d'un \"encourageant\" \u00ab quoi qu'il en co\u00fbte \u00bb.a b s t r a c t\u00c9vacuons la question logistique puisque l'on sait qu'en France \u00ab L'intendance suivra \u00bb 20 .a b s t r a c tA On sait que dans un conflit arm\u00e9 la l\u00e9galit\u00e9 n'est pas toujours au coeur des pr\u00e9occupations des bellig\u00e9rants, en d\u00e9pit de l'existence d'un \u00ab jus ad bellum \u00bb 22 et d'un \u00ab jus in bello \u00bb 23 .", [["Une fois", "TEST", 0, 8], ["une fois", "TEST", 70, 78], ["l'union", "TEST", 79, 86], ["sacr\u00e9e", "TEST", 87, 93], ["r\u00e9clam\u00e9e", "TEST", 94, 102], ["proclam\u00e9e", "TEST", 138, 147], ["a c t\u00c9vacuons la", "TREATMENT", 511, 527], ["suivra", "TEST", 594, 600], ["a c tA", "TEST", 617, 623], ["sait", "TEST", 627, 631]]], ["Napol\u00e9on 1 er n'affirmait-il pas : \u00ab Les r\u00e8glements sont faits pour les soldats et non pour les guerriers ; la bataille se rit du code, elle en exige un nouveau, innov\u00e9 par elle et pour elle et qui dispara\u00eet d\u00e8s qu'elle est termin\u00e9e \u00bb.a b s t r a c tMais, s'agissant d'une \u00ab guerre sanitaire \u00bb pourrait-on accepter de dire avec Cic\u00e9ron : \u00ab Silent enim leges inter arma \u00bb \u00bb 24 .", [["Napol\u00e9on 1 er n'affirmait-il", "CHEMICAL", 0, 28], ["Napol\u00e9on 1 er n'affirmait-il pas", "SPECIES", 0, 32], ["Napol\u00e9on", "TREATMENT", 0, 8], ["Les r\u00e8glements", "TEST", 37, 51], ["tMais", "TEST", 249, 254]]], ["Assur\u00e9ment non, les principes de Syracuse 25 nous rappellent que les restrictions aux droits et libert\u00e9s, dans un objectif de sant\u00e9 publique, ob\u00e9issent aux imp\u00e9ratifs de l\u00e9galit\u00e9, de conformit\u00e9, de proportionnalit\u00e9, de subsidiarit\u00e9 et de l\u00e9gitimit\u00e9 scientifique.a b s t r a c tAu d\u00e9but du conflit l'arsenal juridique \u00e9tait d\u00e9j\u00e0 fourni, la sainte Barbe recelait de munitions : th\u00e9orie des circonstances exceptionnelles 26 , \u00e9tat d'urgence de la loi de 1955 27 , l\u00e9gislation relative aux \u00ab menaces et crises sanitaires graves \u00bb 28 permettant au ministre de la sant\u00e9 de prendre \u00ab toute mesure \u00bb.a b s t r a c tPourtant nous nous sommes livr\u00e9s \u00e0 une escalade dans la course aux armements juridiques et, dans la pr\u00e9cipitation, une nouvelle loi a \u00e9t\u00e9 adopt\u00e9e cr\u00e9ant un \u00ab \u00e9tat d'urgence sanitaire \u00bb 29 transf\u00e9rant le Grand Quartier G\u00e9n\u00e9ral \u00e0 Matignon et attribuant les \u00e9paulettes de g\u00e9n\u00e9ralissime au premier ministre, tout en pr\u00e9servant, r\u00e9flexe de superposition oblige, les pouvoir \u00e9tendus du ministre de la sant\u00e9 !", [["du", "PROBLEM", 286, 288], ["et crises", "PROBLEM", 496, 505], ["graves", "PROBLEM", 517, 523], ["sommes", "TEST", 626, 632], ["livr\u00e9s", "TEST", 633, 639], ["sanitaire", "TEST", 780, 789]]], ["La lecture du nouvel article 3131-15 du Code de la sant\u00e9 publique donne le vertige : \u00ab restreindre, interdire, ordonner, limiter, r\u00e9quisitionner, contr\u00f4ler . . . \u00bb.a b s t r a c tPourquoi cet amonc\u00e8lement ?", [["La lecture du nouvel article 3131-15 du Code de la sant\u00e9 publique donne le vertige : \u00ab restreindre", "SPECIES", 0, 98], ["tPourquoi cet amonc\u00e8lement", "TREATMENT", 178, 204]]], ["Le r\u00e9flexe c'est que chaque crise trouve sa solution dans la loi et dans l'adoption d'un texte ad hoc 30 codifi\u00e9, si possible, dans le \u00ab bon code \u00bb.", [["Le r\u00e9flexe c'est que chaque crise trouve sa solution dans la loi et dans l'adoption d'un texte ad hoc 30 codifi\u00e9", "SPECIES", 0, 112]]], ["La m\u00e9connaissance des dispositifs ant\u00e9rieurs participe du mouvement et la mauvaise r\u00e9putation de la loi de 1955 fait le reste.a b s t r a c tLe pourquoi, c'est aussi s'interroger sur l'impr\u00e9paration manifeste pour affronter la sournoise ennemie.", [["La m\u00e9connaissance des", "TREATMENT", 0, 21], ["le reste", "TEST", 117, 125]]], ["Oubli\u00e9 \u00ab Si vis pacem 22 \u00ab Droit \u00e0 la guerre \u00bb, \u00ab droit de faire la guerre \u00bb ; le \u00ab jus ad bellum \u00bb envisage les motifs de la guerre.", [["le \u00ab jus ad bellum", "TREATMENT", 79, 97], ["le", "ANATOMY", 79, 81]]], ["En d\u00e9pit des annonces initiales, \u00ab la France est pr\u00eate \u00bb, il a bien fallu confesser des \u00ab tensions \u00bb 32 et des \u00ab difficult\u00e9s logistiques \u00bb 33 .a b s t r a c tL'intendance n'aurait-elle pas suivie ?", [["logistiques", "TEST", 125, 136], ["n'aurait", "TEST", 171, 179]]], ["L'Empereur Napol\u00e9on 1 er n'affirmait-il pas qu'\u00ab Il faut sauver les peuples malgr\u00e9 eux \u00bb !", [["Napol\u00e9on 1 er n'affirmait-il pas qu'\u00ab", "SPECIES", 11, 48], ["L'Empereur Napol\u00e9on", "TREATMENT", 0, 19]]], ["La justification de la \u00ab d\u00e9claration de guerre \u00bb et la l\u00e9gitimation des mesures d'exception ne se trouveraient-elles pas dans l'ancienne sentence \u00ab Salus populi suprema lex est \u00bb 34 ?a b s t r a c tAssur\u00e9ment le terme \u00ab salus \u00bb est polys\u00e9mique 35 et il serait par trop na\u00eff de consid\u00e9rer que nos \u00ab [. . .]", [["La justification de la \u00ab d\u00e9claration de guerre \u00bb et la l\u00e9gitimation des mesures d'exception ne se trouveraient-elles pas dans l'ancienne sentence \u00ab", "SPECIES", 0, 147], ["et la l\u00e9gitimation des", "TREATMENT", 49, 71], ["tAssur\u00e9ment", "TEST", 197, 208], ["le terme", "TEST", 209, 217], ["salus", "TEST", 220, 225], ["est polys\u00e9mique", "TEST", 228, 243]]], ["La sant\u00e9, en effet, participe de la \u00ab salus populi \u00bb, puisque sans elle le \u00ab bien-\u00eatre de la population \u00bb est inatteignable, singuli\u00e8rement si l'on se fie \u00e0 la d\u00e9finition de la sant\u00e9 telle que propos\u00e9e par l'OMS : \u00ab La sant\u00e9 est un \u00e9tat de complet bien-\u00eatre physique, mental et social et ne consiste pas seulement en une absence de maladie ou d'infirmit\u00e9./La possession du meilleur \u00e9tat de sant\u00e9 qu'il est capable d'atteindre constitue l'un des droits fondamentaux de tout \u00eatre humain [. . .]/Les gouvernements ont la responsabilit\u00e9 de la sant\u00e9 de leurs peuples ; ils ne peuvent y faire face qu'en prenant les mesures sanitaires et sociales appropri\u00e9es \u00bb 37 .a b s t r a c t\u00ab Salus \u00bb et \u00ab salus populi \u00bb sont donc consubstantiels, en temps ordinaire la sant\u00e9 est un des moyens mobilis\u00e9s pour atteindre l'objectif de \u00ab bien-\u00eatre du peuple \u00bb, en temps de crise sanitaire elle deviendrait une fin en soi.", [["temps ordinaire la sant\u00e9 est un des moyens mobilis\u00e9s pour atteindre l'objectif de \u00ab bien-\u00eatre du peuple \u00bb, en temps de crise sanitaire elle deviendrait une fin en soi", "SPECIES", 734, 900], ["Salus", "TEST", 676, 681], ["en temps", "TREATMENT", 841, 849]]], ["Les plus perplexes pourront s'en 31 Vegece, Epitoma Rei Militaris : \u00ab Igitur qui desiderat pacem, praeparet bellum \u00bb (\u00ab Ainsi, celui qui d\u00e9sire la paix devrait pr\u00e9parer la guerre \u00bb).", [["Igitur qui desiderat pacem, praeparet bellum \u00bb (\u00ab Ainsi, celui qui d\u00e9sire la paix devrait pr\u00e9parer la guerre \u00bb", "SPECIES", 70, 180], ["Les", "TEST", 0, 3]]], ["32 convaincre en relisant le propos du Pr\u00e9sident de la R\u00e9publique : \u00ab Le 16 mars, nous avons fait le choix humaniste de placer la sant\u00e9 audessus de l'\u00e9conomie en vous demandant de rester chez vous \u00bb 38 .", [["sant\u00e9 audessus de l'\u00e9conomie en vous demandant de rester chez vous \u00bb 38", "SPECIES", 130, 201], ["16 mars", "OBSERVATION_MODIFIER", 73, 80]]], ["Faut-il rappeler que, pour l'Acad\u00e9mie fran\u00e7 aise, l'humanisme est ainsi d\u00e9fini : \u00ab Doctrine, attitude philosophique, mouvement de pens\u00e9e qui prend l'homme pour fin et valeur supr\u00eame, qui vise \u00e0 l'\u00e9panouissement de la personne humaine et au respect de sa dignit\u00e9 \u00bb 39 .", [["Faut-il", "CHEMICAL", 0, 7], ["Doctrine", "TREATMENT", 83, 91]]], ["Valeur absolue au plus fort du cataclysme sanitaire, elle prend le pas sur toutes autres consid\u00e9rations et justifie l'atteinte aux libert\u00e9s.", [["du cataclysme sanitaire", "TREATMENT", 28, 51]]], ["Valeur relative, une composante du \u00ab bien-\u00eatre du peuple \u00bb, au sortir de la crise o\u00f9 elle entre alors en concurrence avec d'autres d\u00e9terminants, comme par exemple les consid\u00e9rations \u00e9conomiques.a b s t r a c tLa pr\u00e9servation de la sant\u00e9 est donc au coeur des pr\u00e9occupations de l'action politique.", [["a c tLa pr\u00e9servation", "TREATMENT", 204, 224]]], ["Se pose alors la question de la l\u00e9gitimit\u00e9 dans l'exercice du pouvoir sur les questions de sant\u00e9.", [["Se", "CHEMICAL", 0, 2]]], ["Le pouvoir politique recherche alors l'autorit\u00e9 scientifique pour l\u00e9gitimer ses d\u00e9cisions et pour att\u00e9nuer sa responsabilit\u00e9.", [["Le pouvoir politique recherche alors l'autorit\u00e9", "TREATMENT", 0, 47]]], ["Le risque appara\u00eet d'un glissement insidieux vers une syst\u00e8me \u00e9pistocratique.", [["Le risque", "TEST", 0, 9]]], ["Les mois \u00e9coul\u00e9s ont cependant r\u00e9v\u00e9l\u00e9 que si les pouvoirs publics peuvent se r\u00e9v\u00e9ler fragilis\u00e9s du fait de leurs h\u00e9sitations et de leurs revirements, le monde scientifique n'est pas exempt de critiques, il n'est pour s'en convaincre que de rappeler le fiasco de la prestigieuse revue The Lancet dont la publication du 22 mai 40 a fait l'objet d'un retrait et a n\u00e9cessit\u00e9 la publication d'excuses le 4 juin 41 .a b s t r a c tAlors que le \u00ab d\u00e9confinement \u00bb se pr\u00e9cise il convient de tirer quelques enseignements des \u00ab combats \u00bb.a b s t r a c tNous ne nous livrerons pas pour notre part \u00e0 un sinistre d\u00e9compte des bless\u00e9s et des morts.", [["a fait l'objet d'un", "TREATMENT", 328, 347], ["a c tNous ne", "TREATMENT", 537, 549]]], ["Cette litanie quotidienne faisant insidieusement glisser sur la pente d'une certaine indiff\u00e9rence : \"Der Tod eines Menschen : das ist eine Katastrophe.", [["\"Der Tod eines Menschen : das ist eine Katastrophe", "SPECIES", 100, 150]]], ["Le principal enseignement des mois \u00e9coul\u00e9s nous semble conduire \u00e0 une le\u00e7 on d'humilit\u00e9.", [["d'humilit\u00e9", "TREATMENT", 77, 87], ["principal", "OBSERVATION_MODIFIER", 3, 12], ["enseignement", "OBSERVATION", 13, 25]]], ["Tous autant que nous sommes, citoyens et pouvoirs publics confondus, devons tirer les le\u00e7 ons de l'impasse o\u00f9 nous a conduit notre amn\u00e9sie.", [["conduit", "OBSERVATION", 117, 124]]], ["Si les diff\u00e9rents fronts ont tenu c'est ind\u00e9niablement gr\u00e2ce \u00e0 l'endurance et l'abn\u00e9gation des combattants, mais aussi \u00e0 la docilit\u00e9 des gaulois, soi-disant r\u00e9fractaires.", [["et l'abn\u00e9gation des", "TREATMENT", 75, 94]]], ["Si l'\u00e9pid\u00e9mie r\u00e9gresse, \u00ab Ce n'est pas la fin ni le commencement de la fin mais peut \u00eatre la fin du commencement \u00bb 46 .a b s t r a c tEnfin, il nous faut souligner que de nouveaux fronts se sont ouverts et que de nouvelles batailles nous attendent.", [["Ce", "CHEMICAL", 26, 28], ["Ce", "TEST", 26, 28], ["tEnfin", "TEST", 133, 139]]], ["Faut-il du pass\u00e9 faire table rase 48 , ne peut-on pas pr\u00e9f\u00e9rer dire avec Lampedusa : \u00ab Se vogliamo que tutto rimanga com'\u00e8, bisogna que tutto cambi \u00bb 49 .a b s t r a c tTout changer pour que rien ne change, pour que soient pr\u00e9serv\u00e9 l'essentiel, pour que soient pr\u00e9serv\u00e9es nos valeurs 50 , pour 44 https://www.elysee.fr/emmanuel-macron/2020/06/14/adresse-aux-francais-14-juin-2020 45 Nossiter (Adam),\u00abMacron Beat Back the Coronavirus.", [["cambi", "TEST", 142, 147], ["the Coronavirus", "PROBLEM", 417, 432], ["Coronavirus", "OBSERVATION", 421, 432]]], ["France Is Not Impressed\u00bb, New York Times 5 juin 2020 (\u00ab Macron a vaincu le coronavirus.", [["Macron a vaincu le coronavirus", "SPECIES", 56, 86], ["Macron a vaincu le coronavirus", "TREATMENT", 56, 86], ["Not", "UNCERTAINTY", 10, 13], ["le coronavirus", "ANATOMY", 72, 86]]], ["\u00ab Coronavirus in Frankreich : Die neue Maginot-Linie \u00bb: \u00ab L'une des premi\u00e8res cons\u00e9quences dramatiques de la crise corona a ind\u00e9niablement \u00e9t\u00e9 de jeter le discr\u00e9dit sur les capacit\u00e9s de l'\u00c9tat fran\u00e7 ais.", [["Coronavirus", "PROBLEM", 2, 13], ["Coronavirus", "OBSERVATION", 2, 13]]], ["De m\u00eame que la France s'\u00e9tait imagin\u00e9e en s\u00e9curit\u00e9 derri\u00e8re la ligne Maginot avant la seconde guerre mondiale, la majorit\u00e9 de ses citoyens a \u00e9t\u00e9 \u00e9duqu\u00e9e dans la croyance d'un pouvoir central protecteur.", [["central protecteur", "OBSERVATION", 183, 201]]], ["L'illusion est tomb\u00e9e.", [["L'illusion est tomb\u00e9e", "PROBLEM", 0, 21], ["illusion est", "OBSERVATION", 2, 14]]], ["R\u00e9former notre syst\u00e8me de sant\u00e9 pour que lors de la survenue possible-probable-d'une nouvelle pand\u00e9mie nous soyons, enfin et r\u00e9ellement, pr\u00eats, pour que nous n'ayons pas \u00e0 sacrifier nos libert\u00e9s sur l'autel de la \u00ab salus populi \u00bb en c\u00e9dant \u00e0 la tentation de l'\u00e9tat d'urgence : \u00ab Prospicere in pace oportet quod bellum iuvet \u00bb 51 .a b s t r a c tR\u00e9former pour ne plus se fourvoyer car \u00ab non licet bis in bello peccare \u00bb 52 .a b s t r a c tR\u00e9former pour que nous puissions acc\u00e9der \u00e0 l'invitation du Chef de l'\u00c9tat : \u00ab Face \u00e0 la menace, mes chers amis, nous ne renoncerons", [["peccare", "TEST", 409, 416]]]], "PMC7290074": [["The first reports about human-to-human transmission of a new severe acute respiratory syndrome (SARS) virus in Wuhan, China, which emerged in January 2020 met a relaxed sentiment among experts and the public in Austria who were reminiscent of similar reports on SARS1, H1N1 or H5N1.", [["acute respiratory syndrome (SARS) virus", "DISEASE", 68, 107], ["H5N1", "DISEASE", 277, 281], ["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 33, 38], ["SARS1", "GENE_OR_GENE_PRODUCT", 262, 267], ["H5N1", "ORGANISM", 277, 281], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 33, 38], ["H5N1", "SPECIES", 277, 281], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 33, 38], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 61, 107], ["a new severe acute respiratory syndrome", "PROBLEM", 55, 94], ["SARS) virus", "PROBLEM", 96, 107], ["SARS1", "TREATMENT", 262, 267], ["H1N1", "PROBLEM", 269, 273], ["H5N1", "PROBLEM", 277, 281], ["new", "OBSERVATION_MODIFIER", 57, 60], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94]]], ["Even warnings by the World Health Organization (WHO) of COVID-19 as a \u201chealth emergency of international concern\u201d [1], media coverage on the spread of the virus in Asia and on the situation on cruise ship Diamond Princess [2] and first reports and preprints about clinical courses and disease characteristics [3\u20136] did not lead to any particular precautions or change in sentiment.", [["media coverage", "TREATMENT", 119, 133], ["disease characteristics", "PROBLEM", 285, 308], ["virus", "OBSERVATION", 155, 160]]], ["It was widely assumed that containment of the disease would be accomplished in Asia like for SARS.", [["SARS", "DISEASE", 93, 97], ["the disease", "PROBLEM", 42, 53], ["SARS", "PROBLEM", 93, 97], ["containment", "OBSERVATION_MODIFIER", 27, 38], ["disease", "OBSERVATION", 46, 53]]], ["Increasing knowledge about non-symptomatic spreading and high case fatality rates in the older population, led to comparisons with influenza and the European Centre for Disease Prevention and Control (ECDC) risk assessment fourth update reported a \u201clow\u201d risk of COVID-19 for European member states on 14 February 2020 [7].", [["influenza", "DISEASE", 131, 140], ["non-symptomatic spreading", "PROBLEM", 27, 52], ["influenza", "PROBLEM", 131, 140], ["Disease Prevention", "TREATMENT", 169, 187]]]], "415e4e119a6be763781b87da73d6f5121c341561": [["IntroductionFractional calculus can provide a promising tool in modeling biological phenomena, as reviewed recently by Lonescu et al. [1] .", [["IntroductionFractional calculus", "PROBLEM", 0, 31], ["a promising tool in modeling biological phenomena", "PROBLEM", 44, 93], ["calculus", "OBSERVATION", 23, 31], ["biological phenomena", "OBSERVATION", 73, 93]]], ["For example, fractional-derivative equation (FDE) models have been applied to capture complex dynamics in biological tissues [2] , tumor growth [3] , DNA sequencing [4] , drug uptake [5] , and salmonella bacterial infection in animal herds [6] .", [["tissues", "ANATOMY", 117, 124], ["tumor", "ANATOMY", 131, 136], ["tumor", "DISEASE", 131, 136], ["salmonella bacterial infection", "DISEASE", 193, 223], ["tissues", "TISSUE", 117, 124], ["tumor", "CANCER", 131, 136], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["fractional-derivative equation (FDE) models", "TREATMENT", 13, 56], ["complex dynamics in biological tissues", "PROBLEM", 86, 124], ["tumor growth", "PROBLEM", 131, 143], ["DNA sequencing", "TEST", 150, 164], ["drug uptake", "TEST", 171, 182], ["salmonella bacterial infection", "PROBLEM", 193, 223], ["bacterial", "OBSERVATION_MODIFIER", 204, 213], ["infection", "OBSERVATION", 214, 223]]], ["Most recently, the FDE models have been applied to model the Pine Wilt Disease [7] , the human respiratory syncytial virus (HRSV) disease [8] , the harmonic oscillator with a position-dependent mass [9] , human liver using Caputo-Fabrizio fractional derivative [10, 11] , and tumor-immune surveillance [12] .", [["liver", "ANATOMY", 211, 216], ["tumor", "ANATOMY", 276, 281], ["respiratory syncytial virus (HRSV) disease", "DISEASE", 95, 137], ["tumor", "DISEASE", 276, 281], ["human", "ORGANISM", 89, 94], ["respiratory syncytial virus", "ORGANISM", 95, 122], ["human", "ORGANISM", 205, 210], ["liver", "ORGAN", 211, 216], ["tumor", "CANCER", 276, 281], ["human", "SPECIES", 89, 94], ["respiratory syncytial virus", "SPECIES", 95, 122], ["HRSV", "SPECIES", 124, 128], ["human", "SPECIES", 205, 210], ["human respiratory syncytial virus", "SPECIES", 89, 122], ["HRSV", "SPECIES", 124, 128], ["human", "SPECIES", 205, 210], ["the FDE models", "TREATMENT", 15, 29], ["the human respiratory syncytial virus (HRSV) disease", "PROBLEM", 85, 137], ["the harmonic oscillator", "TREATMENT", 144, 167], ["dependent mass", "PROBLEM", 184, 198], ["Caputo", "TEST", 223, 229], ["Fabrizio fractional derivative", "TREATMENT", 230, 260], ["tumor", "TEST", 276, 281], ["respiratory", "ANATOMY", 95, 106], ["syncytial virus", "OBSERVATION", 107, 122], ["dependent", "OBSERVATION_MODIFIER", 184, 193], ["mass", "OBSERVATION", 194, 198], ["liver", "ANATOMY", 211, 216]]], ["Motivated by these successful applications, this study tests whether the FDEs can be applied to model the dynamics and mitigation scenarios of coronavirus, an emerging and critical research area that has not been focused by the fractional calculus community before.IntroductionThe novel coronavirus disease 2019 (COVID-19) outbreak, a respiratory illness that started (first detected) in late December 2019, is a pandemic infecting >336,000 people in more than 140 countries with the average fatality rate of 4.4% globally (data up to 3/22/2020) [13] .", [["respiratory", "ANATOMY", 335, 346], ["coronavirus", "DISEASE", 143, 154], ["coronavirus disease", "DISEASE", 287, 306], ["COVID-19", "CHEMICAL", 313, 321], ["respiratory illness", "DISEASE", 335, 354], ["coronavirus", "ORGANISM", 143, 154], ["coronavirus", "ORGANISM", 287, 298], ["COVID-19", "ORGANISM", 313, 321], ["people", "ORGANISM", 441, 447], ["people", "SPECIES", 441, 447], ["coronavirus disease 2019 (COVID-19", "SPECIES", 287, 321], ["this study tests", "TEST", 44, 60], ["coronavirus", "PROBLEM", 143, 154], ["The novel coronavirus disease", "PROBLEM", 277, 306], ["COVID", "TEST", 313, 318], ["outbreak", "PROBLEM", 323, 331], ["a respiratory illness", "PROBLEM", 333, 354], ["a pandemic infecting", "PROBLEM", 411, 431], ["the average fatality rate", "TEST", 480, 505], ["coronavirus", "OBSERVATION", 143, 154], ["fractional", "OBSERVATION_MODIFIER", 228, 238], ["calculus", "OBSERVATION", 239, 247], ["coronavirus disease", "OBSERVATION", 287, 306], ["respiratory illness", "OBSERVATION", 335, 354]]], ["The COVID-19 pandemic is infiltrating almost every aspect of life, damaging global economy, and altering both man-made and natural environments.", [["The COVID", "TEST", 0, 9], ["infiltrating", "OBSERVATION", 25, 37], ["global economy", "OBSERVATION", 76, 90]]], ["Urgent actions have been taken but further effective and efficient strategies are promptly needed to confront this global challenge.", [["this global challenge", "TREATMENT", 110, 131]]], ["To address this challenge and promptly guide the next efforts, it is critical to model the COVID-19 outbreak.IntroductionMathematical models are among the necessary tools to quantify the COVID-19 and, therefore, testing the applicability of such FDE models under this new global pandemic is the primary objective motivating this study.IntroductionThis study aims to model the COVID-19 evolution dynamics (i.e., transmission, infection, recovery, and death evolution) for representative countries with apparent coronavirus cases, including China, the United States (U.S.), Italy, Japan, and South Korea using mathematical models, most specifically the FDE models described previously.", [["infection", "DISEASE", 425, 434], ["death", "DISEASE", 450, 455], ["coronavirus", "ORGANISM", 510, 521], ["the COVID", "TEST", 87, 96], ["the COVID", "TEST", 183, 192], ["such FDE models", "PROBLEM", 241, 256], ["this study", "TEST", 324, 334], ["This study", "TEST", 347, 357], ["the COVID", "TEST", 372, 381], ["infection", "PROBLEM", 425, 434], ["apparent coronavirus cases", "PROBLEM", 501, 527], ["infection", "OBSERVATION", 425, 434]]], ["It should be noted that the COVID-19 spread in these countries experienced different starting (initiation and detection) times, an important fact to consider when applying these models.", [["the COVID", "TEST", 24, 33]]], ["For example, China had passed the peak of the coronavirus outbreak, finally reaching a milestone with no new local infections on 3/19/2020 (79 days from the onset, 12/31/2019, in Wuhan, China), while the U.S. coronavirus cases soared past 10,000 on the same day.", [["coronavirus", "DISEASE", 46, 57], ["infections", "DISEASE", 115, 125], ["coronavirus", "DISEASE", 209, 220], ["coronavirus", "ORGANISM", 46, 57], ["coronavirus", "ORGANISM", 209, 220], ["coronavirus", "SPECIES", 209, 220], ["U.S. coronavirus", "SPECIES", 204, 220], ["the coronavirus outbreak", "PROBLEM", 42, 66], ["new local infections", "PROBLEM", 105, 125], ["coronavirus outbreak", "OBSERVATION", 46, 66], ["no", "UNCERTAINTY", 102, 104], ["new", "OBSERVATION_MODIFIER", 105, 108], ["local", "OBSERVATION_MODIFIER", 109, 114], ["infections", "OBSERVATION", 115, 125]]], ["This study will apply the core characteristics of the COVID-19 outbreak obtained in China to estimate the COVD-19 spread in the U.S., as well as other countries where the number of affected people has not yet reached its number of peak cases.IntroductionIn addition, this new pandemic may last for a relatively longer time than expected [14] .", [["people", "ORGANISM", 190, 196], ["people", "SPECIES", 190, 196], ["This study", "TEST", 0, 10], ["the COVID", "TEST", 50, 59]]], ["No vaccine against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is currently available [15] .", [["SARS", "DISEASE", 19, 23], ["acute respiratory syndrome coronavirus", "DISEASE", 38, 76], ["SARS-CoV-2", "ORGANISM", 19, 29], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 19, 76], ["vaccine", "TREATMENT", 3, 10], ["SARS", "PROBLEM", 19, 23], ["CoV", "TEST", 24, 27], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 31, 76], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["respiratory syndrome", "OBSERVATION", 44, 64]]], ["Indeed, a vaccine for prevention and infection control may not be ready beforeIntroductionMarch 2021 for the COVID-19, considering a minimum of 4~5 weeks for trials and at least 1 year for safety evaluation and final deployment.", [["infection", "DISEASE", 37, 46], ["a vaccine", "TREATMENT", 8, 17], ["infection control", "TREATMENT", 37, 54], ["trials", "TREATMENT", 158, 164], ["safety evaluation", "TEST", 189, 206], ["infection", "OBSERVATION", 37, 46]]], ["Efficient strategies are therefore needed to mitigate the COVID-19 outbreak.", [["the COVID", "TEST", 54, 63]]], ["Possible non-pharmaceutical scenarios, such as isolation of cases and contact tracing, can be evaluated using mathematical models [16] in order to identify the most efficient mitigation strategies going forward.", [["non-pharmaceutical scenarios", "PROBLEM", 9, 37], ["contact tracing", "TEST", 70, 85]]], ["This is another major motivation and the secondary task of this study using the FDE models.IntroductionTo address the questions mentioned above, this study is organized as follows.", [["this study", "TEST", 59, 69], ["this study", "TEST", 145, 155]]], ["Section 2 proposes an updated SEIR model with an FDE-based component for COVID-19, where \"S\", \"E\", \"I\", and \"R\" stand for Susceptible, Exposed, Infectious, and Recovered people, respectively [17] .IntroductionThis model is then applied to fit and predict the COVID-19 spread in various provinces and major cities in China, resulting in abundant datasets to derive the core characteristics of the COVID-19 6 dynamics in evolution.", [["people", "ORGANISM", 170, 176], ["COVID-19", "DNA", 259, 267], ["people", "SPECIES", 170, 176], ["COVID", "TEST", 73, 78], ["the COVID", "TEST", 255, 264], ["the COVID", "TEST", 392, 401], ["Infectious", "OBSERVATION", 144, 154]]], ["Section 3 predicts the spread of COVID-19 in the other countries using the knowledge that is gained from the China case study.", [["COVID", "TEST", 33, 38]]], ["Section 4 proposes a fully Lagrangian approach with the time FDE to model the spatiotemporal evolution of COVID-19, and then applies it to evaluate non-pharmaceutical scenarios to mitigate the virus spread.", [["COVID", "TEST", 106, 111], ["non-pharmaceutical scenarios", "PROBLEM", 148, 176], ["the virus spread", "PROBLEM", 189, 205], ["virus", "OBSERVATION", 193, 198]]], ["Section 5 reports the main conclusions, specifically the feasibility of FDEs for capturing COVID-19 evolution.", [["COVID", "DNA", 91, 96], ["COVID", "TEST", 91, 96]]], ["In the appendix, the impacts of the non-singular kernel and fractional derivative type on model results are further discussed for readers particularly interested in these fractional calculus techniques.", [["appendix", "ANATOMY", 7, 15], ["appendix", "ORGAN", 7, 15], ["the non-singular kernel", "TREATMENT", 32, 55], ["these fractional calculus techniques", "TREATMENT", 165, 201], ["appendix", "ANATOMY", 7, 15], ["impacts", "OBSERVATION_MODIFIER", 21, 28], ["calculus", "OBSERVATION", 182, 190]]], ["The main contributions of this work, therefore, include 1) the first application of FDEs in modeling the evolution of the COVID-19 death toll, 2) an updated SEIR model with a transient recovery rate to better capture the dynamics of COVID-19 pandemic within China and for other countries, and 3) a particle-tracking approach based on stochastic bimolecular reaction theory to evaluate the mitigation of the spread of the COVID-19 outbreak.A time-dependent SEIR model for the COVID-19 spread in ChinaSeveral mathematical models have been applied for epidemic analysis of COVID-19.", [["death", "DISEASE", 131, 136], ["COVID-19", "DNA", 475, 483], ["COVID", "TEST", 233, 238], ["a particle-tracking approach", "TREATMENT", 296, 324], ["stochastic bimolecular reaction", "PROBLEM", 334, 365], ["the COVID", "TEST", 417, 426], ["A time-dependent SEIR model", "TREATMENT", 439, 466], ["the COVID", "TEST", 471, 480], ["epidemic analysis", "TEST", 549, 566], ["COVID", "TEST", 570, 575], ["main", "OBSERVATION_MODIFIER", 4, 8], ["bimolecular reaction", "OBSERVATION", 345, 365]]], ["The most widely used one, to date, is the well-known SEIR model.", [["most widely", "OBSERVATION_MODIFIER", 4, 15]]], ["For example, Peng et al. [18] (using data up to 2/16/2020) proposed a generalized SEIR model to successfully estimate the key epidemic parameters of COVID-19 in China, and predicted the inflection point and ending time of confirmed COVID-19 cases.", [["a generalized SEIR model", "PROBLEM", 68, 92], ["COVID", "TEST", 149, 154], ["COVID", "TEST", 232, 237]]], ["The SEIR model was also applied by Li et al. [19] (using the observed data up to 2/6/2020) to compare the effect of city lockdowns on the transmission dynamics for different cities in China.", [["The SEIR model", "TREATMENT", 0, 14]]], ["The SIR model with time-dependent transmission and recovering rates was used by Chen et al. [20] (using data up to 2/20/2020) to analyze and predict the number of confirmed cases of COVID-19 in China.", [["COVID", "TEST", 182, 187]]], ["The SIR model was extended by Wang et al. [21] (using data up to 2/12/2020) to incorporate various time-varying quarantine protocols for assessing interventions on the COVID-19 epidemic in China.", [["varying quarantine protocols", "TREATMENT", 104, 132], ["assessing interventions", "TREATMENT", 137, 160], ["the COVID", "TEST", 164, 173]]], ["The SEIR model and its modifications were also successfully applied by others [22] [23] [24] [25] , mostly for assessing the early spreading of COVID-19 in China.", [["COVID-19", "CHEMICAL", 144, 152], ["COVID-19", "CHEMICAL", 144, 152], ["[22] [23] [24] [25]", "SIMPLE_CHEMICAL", 78, 97], ["The SEIR model", "TEST", 0, 14], ["COVID", "TEST", 144, 149]]], ["Previous applications of the popular SEIR model, however, may contain high uncertainty since they had limited data access for only a short period of the COVID-19 outbreak.", [["the COVID", "TEST", 149, 158], ["high", "OBSERVATION_MODIFIER", 70, 74]]], ["As will be shown below, the COVID-19 dynamics have changed dramatically in the last three months, likely due to the improvement/adjustment of screening/testing techniques, public hospital system capabilities, and the government's control policies for contagious diseases.", [["the COVID", "TEST", 24, 33], ["screening/testing techniques", "TEST", 142, 170], ["the government's control policies", "TREATMENT", 213, 246], ["contagious diseases", "PROBLEM", 251, 270], ["likely due to", "UNCERTAINTY", 98, 111]]], ["An updated, much better version of the SEIR model is therefore needed and can be reliably built now for China as more detailed and complete datasets are available that includes the coronavirus outbreak data (i.e., # of people infected) well beyond the peak in China.A time-dependent SEIR model for the COVID-19 spread in ChinaOther models have also been used for specific purposes related to COVID-19, including the global metapopulation disease transmission model to predict the impact of travel limitations on the epidemic spread [26] , the transmission model for risk assessment [27] , and the synthetic contact matrix model for quantifying reproductive ratios for COVID-19 [28] .", [["coronavirus", "ORGANISM", 181, 192], ["people", "ORGANISM", 219, 225], ["COVID-19", "DNA", 302, 310], ["people", "SPECIES", 219, 225], ["the SEIR model", "TEST", 35, 49], ["the coronavirus outbreak data", "PROBLEM", 177, 206], ["A time-dependent SEIR model", "TREATMENT", 266, 293], ["the COVID", "TEST", 298, 307], ["COVID", "TEST", 392, 397], ["the global metapopulation disease transmission model", "PROBLEM", 412, 464], ["risk assessment", "TEST", 566, 581], ["the synthetic contact matrix model", "TREATMENT", 593, 627], ["reproductive ratios", "TEST", 644, 663], ["COVID", "TEST", 668, 673], ["peak", "OBSERVATION_MODIFIER", 252, 256], ["metapopulation disease", "OBSERVATION", 423, 445]]], ["To the best of our knowledge, the classical stochastic epidemic models, such as the discrete or continuous time Markov chain model and the stochastic differential equation model, have not yet been applied for COVID-19 spread scenarios.", [["the stochastic differential equation model", "TEST", 135, 177], ["COVID", "TEST", 209, 214]]], ["A preliminary stochastic model built upon the FDE for evaluating COVID-19 spread in a city will be developed and applied in Section 4.A time-dependent SEIR model for the COVID-19 spread in ChinaThis section focuses on the deterministic model.", [["COVID", "DNA", 65, 70], ["COVID-19", "DNA", 170, 178], ["COVID", "TEST", 65, 70], ["the COVID", "TEST", 166, 175]]], ["The classical SEIR model considers constant parameters, which may not adequately capture time-dependent dynamics of epidemic (the COVID-19) spread.", [["epidemic", "PROBLEM", 116, 124], ["the COVID", "TEST", 126, 135]]], ["Hence, the SEIR model is updated in Section 2.1, and then tested in Section 2.2.SEIR model updateThe classical SEIR model containing four populations (S, E, I, and R) takes the form [29] :SEIR model updatewhere is the stock of susceptible population;SEIR model updateis the number of persons exposed to or in the latent period of the disease; is the stock of infected population; is the stock of recovered population; r denotes the number of susceptible people whom the infected people contact daily; N is the sum of all the four groups of people ( ( ) ( ) ( ) ( ) (which is a constant representing the constancy of population N); p is the constant rate of infection (i.e., representing the probability for the infected people to transform the susceptible people into infected ones); is the constant rate for the exposed person to be transformed into an infected one; and is the constant recovery rate (defining the speed for the infected person to be cured or expired).SEIR model updateTo allow for possible time-sensitive rates and time nonlocal-dependency for COVID-19SEIR model updateevolution, we revise model (1) as:SEIR model updatewhere represents the number of deaths (which is one component of I); is the rate for the healthy, susceptible person to be transferred to an infected one from exposed persons (note that COVID-19 patients in the incubation period might be contagious too); and is the number of healthy, susceptible people that are contacted by exposed people daily.", [["infection", "DISEASE", 657, 666], ["deaths", "DISEASE", 1170, 1176], ["persons", "ORGANISM", 284, 291], ["people", "ORGANISM", 454, 460], ["people", "ORGANISM", 479, 485], ["people", "ORGANISM", 540, 546], ["people", "ORGANISM", 720, 726], ["people", "ORGANISM", 756, 762], ["persons", "ORGANISM", 1306, 1313], ["patients", "ORGANISM", 1334, 1342], ["people", "ORGANISM", 1436, 1442], ["people", "ORGANISM", 1473, 1479], ["persons", "SPECIES", 284, 291], ["people", "SPECIES", 454, 460], ["people", "SPECIES", 479, 485], ["people", "SPECIES", 540, 546], ["people", "SPECIES", 720, 726], ["people", "SPECIES", 756, 762], ["person", "SPECIES", 821, 827], ["person", "SPECIES", 939, 945], ["person", "SPECIES", 1249, 1255], ["persons", "SPECIES", 1306, 1313], ["patients", "SPECIES", 1334, 1342], ["people", "SPECIES", 1436, 1442], ["people", "SPECIES", 1473, 1479], ["infection", "PROBLEM", 657, 666], ["time", "TEST", 1009, 1013], ["disease", "OBSERVATION", 334, 341], ["infection", "OBSERVATION", 657, 666], ["infected", "OBSERVATION", 854, 862]]], ["Now, the infection rates can change with time, and the infected persons are removed from the risk of infection via a time-dependent rate term of ( ).", [["infection", "DISEASE", 9, 18], ["infection", "DISEASE", 101, 110], ["persons", "ORGANISM", 64, 71], ["persons", "SPECIES", 64, 71], ["the infection rates", "PROBLEM", 5, 24], ["infection", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 9, 18], ["infected", "OBSERVATION", 55, 63], ["infection", "OBSERVATION", 101, 110]]], ["If the recovered individuals can return to a susceptible status due to, for example, a loss of immunity, then the partial differential equation (PDE) (2d) for the time rate of change of requires one more (sink) term: , where is the rate of the recovered individuals returning to a susceptible status.SEIR model updateWe replace the integer-order derivatives in the classical SEIR (1) by the fractional-order derivatives in (2) , to capture the possible nonlocal impact, such as the memory impact or any apparent delay, in the COVID-19 outbreak.", [["individuals", "ORGANISM", 17, 28], ["a loss of immunity", "PROBLEM", 85, 103], ["nonlocal impact", "PROBLEM", 453, 468], ["any apparent delay", "PROBLEM", 499, 517], ["the COVID", "TEST", 522, 531]]], ["Herein we use the death evolution (2e) as an example.SEIR model updateHence, the FDE (2e) containing the death probability of (while the other patients are cured) is modified as:SEIR model updatewhich is the Caputo fractional derivative [30, 31] with order ( ) (note that all the other indexes , , , and in model (2) are in the same range of (0, 1]).", [["death", "DISEASE", 18, 23], ["death", "DISEASE", 105, 110], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151]]], ["The Caputo fractional derivate was selected here because the initial condition for Caputo derivative takes the same form as that for the integer-order PDE.", [["Caputo", "CHEMICAL", 83, 89], ["Caputo", "SIMPLE_CHEMICAL", 4, 10], ["Caputo derivative", "SIMPLE_CHEMICAL", 83, 100], ["PDE", "PROTEIN", 151, 154], ["The Caputo fractional derivate", "TREATMENT", 0, 30], ["Caputo derivative", "TREATMENT", 83, 100]]], ["When the order =1, model (2e) reduces to the classical integer-order PDE for the death evolution.", [["death", "DISEASE", 81, 86], ["PDE", "PROTEIN", 69, 72], ["the death evolution", "PROBLEM", 77, 96]]], ["The fractional PDE (2e) is used here for two reasons.", [["The fractional PDE", "TREATMENT", 0, 18]]], ["First, the evolution of deaths and cures may be characterized by a random process, due to the fact that the exact time for the (recovered) person to be initially infected is unknown (i.e., the patient that died or was cured today may have been diagnosed yesterday or last week).", [["deaths", "DISEASE", 24, 30], ["patient", "ORGANISM", 193, 200], ["person", "SPECIES", 139, 145], ["patient", "SPECIES", 193, 200], ["deaths", "PROBLEM", 24, 30], ["infected", "OBSERVATION", 162, 170]]], ["Second, some patients may not be treated in time after being infected, making the death toll evolve with a time memory.", [["death", "DISEASE", 82, 87], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["infected", "OBSERVATION", 61, 69]]], ["Therefore, we extend the classical mass-balance equation of death cases using the FDE to characterize the random property and memory impact embedded in the temporal evolution of mortality.", [["death", "DISEASE", 60, 65], ["mass", "OBSERVATION", 35, 39], ["temporal", "OBSERVATION_MODIFIER", 156, 164], ["mortality", "OBSERVATION", 178, 187]]], ["The fractional PDE (2e) and its classical version will be compared below using real (observed) data.Result analysis for province and major cities in ChinaWe apply the SEIR model (2) does not exhibit any late-time tailing behavior, which supports the application of the integer-order, time-local model (2c).", [["The fractional PDE", "TEST", 0, 18], ["Result analysis", "TEST", 100, 115], ["fractional PDE", "OBSERVATION", 4, 18]]], ["The fast decline of the late time \"current infected population\" is most likely due to the improvement of health care facilities, which tends to accelerate the recovery of infected people and remove the possible memory impact on the disease recovery evolution.Comparison of different modelsOther complex SEIR models were also applied to model COVID-19 spread, such as the one proposed by Tang et al. [32] which has 12 rates/probabilities and 8 groups of people in SEIR.Comparison of different modelsNumerical results show that, compared with the SEIR model (2), the complex model proposed byComparison of different modelsTang et al. [32] (with solutions shown by the dotted lines in Fig. 1a ) accurately fits the observed data at the early stage, but then overpredicts the spread of COVID-19 observed after 2/12/2020.Comparison of different modelsThe dynamics of transmission for COVID-19, especially the recovery rate, therefore, changed over time in China, likely due to the time-dependent conditions (i.e. improvements/adjustment)s in medical care as mentioned above.", [["people", "ORGANISM", 180, 186], ["people", "ORGANISM", 453, 459], ["lines", "CELL", 673, 678], ["dotted lines", "CELL_LINE", 666, 678], ["people", "SPECIES", 180, 186], ["people", "SPECIES", 453, 459], ["The fast decline", "PROBLEM", 0, 16], ["the disease recovery evolution", "PROBLEM", 228, 258], ["Other complex SEIR models", "PROBLEM", 289, 314], ["model COVID", "TEST", 336, 347], ["solutions", "TREATMENT", 643, 652], ["COVID", "TEST", 782, 787], ["COVID", "TEST", 879, 884], ["the time-dependent conditions", "PROBLEM", 972, 1001], ["fast", "OBSERVATION_MODIFIER", 4, 8], ["decline", "OBSERVATION_MODIFIER", 9, 16], ["most likely due to", "UNCERTAINTY", 67, 85], ["possible", "UNCERTAINTY", 202, 210], ["disease", "OBSERVATION", 232, 239]]], ["A dynamic time-local SEIR model, therefore, may be preferred for modeling COVID-19 spread in China.Comparison of different modelsIn addition, compared to the FDE (2e), the best-fit solution using the classical PDE for death evolution (see the black, dotted line in Fig. 1a ) slightly overestimates the late-time growth of mortality.", [["death", "DISEASE", 218, 223], ["modeling COVID", "TEST", 65, 79], ["death evolution", "PROBLEM", 218, 233]]], ["The actual death toll in Hubei province grew slower than that estimated by a constant rate model, indicating that the memory impact may affect the late-time dynamics of death and can be better captured by the FDE (2e).Comparison of different regions in ChinaThe best-fit solutions using model (2) fit the evolution of the infected and recovered populations well for the data recorded from Hubei province and three large cities closely related (such as in transportation or economic cooperation) to Wuhan, China ( Fig. 1) .", [["death", "DISEASE", 11, 16], ["death", "DISEASE", 169, 174], ["the data", "TEST", 366, 374], ["infected", "OBSERVATION", 322, 330]]], ["The model was also shown to predict well the observed time series of COVID-19 spread from 3/8/2020 to 3/22/2020 for most places, except for Shanghai City (Fig. 1d) .", [["COVID", "TEST", 69, 74]]], ["This is likely due to the number of overseas COVID-19 cases imported into Shanghai, whereby the number of cases were observed to increase rapidly after 3/3/2020, causing inconsistency in the affected population and failure of the model.Comparison of different regions in ChinaShanghai Pudong International Airport, one of the two airports located in Shanghai City, is the eighth-busiest airport in the world and the busiest international gateway of mainland China.", [["the affected population", "PROBLEM", 187, 210], ["failure of the model", "PROBLEM", 215, 235], ["likely due to", "UNCERTAINTY", 8, 21], ["affected", "OBSERVATION_MODIFIER", 191, 199], ["population", "OBSERVATION", 200, 210], ["failure", "OBSERVATION", 215, 222]]], ["When excluding the coronavirus cases imported from overseas, model (2) predicts the COVID-19 spread evolution data in Shanghai (Fig. 2) .", [["coronavirus", "DISEASE", 19, 30], ["coronavirus", "ORGANISM", 19, 30], ["coronavirus", "SPECIES", 19, 30], ["the COVID", "TEST", 80, 89]]], ["Therefore, model (2) works well for various places in China that may not be experience a significant influx of imported cases, as external sources can easily break the internal evolution, especially the asymptotic status, of COVID-19 in China.Comparison of different regions in ChinaThe resultant time-dependent recovery rate ( ) is depicted in Fig. 3 , where the rate fitted by the latest observation data point within the fitting period (i.e., 3/7/2020) remains stable in the following prediction period.", [["COVID", "TEST", 225, 230], ["internal", "OBSERVATION_MODIFIER", 168, 176], ["stable", "OBSERVATION_MODIFIER", 464, 470]]], ["Contrarily, Hubei shows the lowest recovery rate, likely due to its delayed response and the relatively limited public health capability at the beginning of the outbreak compared with Shanghai.Comparison of different regions in ChinaWenzhou exhibits an impulse in the infection and recovery dynamics of coronavirus (Fig. 1b) , different from that observed for the other places studied herein.", [["infection", "DISEASE", 268, 277], ["coronavirus", "ORGANISM", 303, 314], ["its delayed response", "PROBLEM", 64, 84], ["the infection", "PROBLEM", 264, 277], ["coronavirus", "PROBLEM", 303, 314], ["likely due to", "UNCERTAINTY", 50, 63], ["impulse", "OBSERVATION_MODIFIER", 253, 260], ["infection", "OBSERVATION", 268, 277]]], ["On February 27, 2020, the number of Wenzhou's infected people suddenly declined, combined with the sudden increase of the number of people cured.", [["people", "ORGANISM", 55, 61], ["people", "ORGANISM", 132, 138], ["people", "SPECIES", 55, 61], ["people", "SPECIES", 132, 138]]], ["This abrupt change can be effectively captured by the SEIR model (2) with an impulse in the recovery rate ( ).", [["This abrupt change", "PROBLEM", 0, 18], ["the SEIR model", "TEST", 50, 64]]], ["This recovery impulse is most likely due to a new hospital, the No. 2 Affiliated Hospital of Wenzhou Medical University, recently built in this city in early February, which significantly improved the public health system.", [["most likely", "UNCERTAINTY", 25, 36]]], ["The first discharged cases of coronavirus from this hospital appeared in late February 2020, resulting in the sudden increase in the total recovery rate.", [["coronavirus", "DISEASE", 30, 41], ["coronavirus", "ORGANISM", 30, 41], ["coronavirus", "PROBLEM", 30, 41], ["sudden", "OBSERVATION_MODIFIER", 110, 116], ["increase", "OBSERVATION_MODIFIER", 117, 125]]], ["In addition, a relatively large number of people working in Wuhan returned to Wenzhou in late January, and it appears that the improved efficient screening process successfully identified the number of infected cases.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["relatively", "OBSERVATION_MODIFIER", 15, 25], ["large", "OBSERVATION_MODIFIER", 26, 31], ["number", "OBSERVATION_MODIFIER", 32, 38], ["infected", "OBSERVATION", 202, 210]]], ["The new cases were ~29,000 from 1/24/2020 to 1/31/2020 in Wenzhou (with an average of 3,600 new patients per day), who were then immediately centralized for treatment.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["treatment", "TREATMENT", 157, 166], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["It appears that this fast response helped to alleviate the spread of coronavirus in Wenzhou.Parameter analysisThe best-fit parameters of model (2) are listed in Table 1 , and the initial values for each group of people are listed in Table 2 .", [["coronavirus", "DISEASE", 69, 80], ["coronavirus", "ORGANISM", 69, 80], ["people", "ORGANISM", 212, 218], ["people", "SPECIES", 212, 218], ["coronavirus", "PROBLEM", 69, 80], ["Parameter analysis", "TEST", 92, 110], ["coronavirus", "OBSERVATION", 69, 80]]], ["First, the best-fit \"S\"-shaped recovery rate ( ) (Fig. 3) can be described by the sigmoid function ( ) ( ) (where a, b, and c are factors), showing that the recovery rate increases exponentially before reaching a stable condition.", [["sigmoid", "ANATOMY", 82, 89], ["stable", "OBSERVATION_MODIFIER", 213, 219]]], ["This increase is likely due to the fact that healthcare facility capabilities improved with time (with an accelerating rate) before reaching their asymptote or maximum capacity.Parameter analysisSecond, the rates and probabilities (r, , p, and ) affecting the COVID-19Parameter analysistransmission/infection evolution slightly change in space and remain stable for a given site ( Table 1 ).", [["infection", "DISEASE", 299, 308], ["Parameter analysisSecond", "TEST", 177, 201], ["the rates", "TEST", 203, 212], ["the COVID", "TEST", 256, 265], ["infection", "PROBLEM", 299, 308], ["slightly change in space", "PROBLEM", 319, 343], ["likely due to", "UNCERTAINTY", 17, 30], ["infection", "OBSERVATION", 299, 308], ["slightly", "OBSERVATION_MODIFIER", 319, 327], ["change", "OBSERVATION_MODIFIER", 328, 334], ["stable", "OBSERVATION_MODIFIER", 355, 361]]], ["The small spatial fluctuation of these rates may be due to the similar strategies implemented by We also introduce an index C to quantify the infection severity of COVID-19 at different places:Parameter analysiswhere is the maximum number of cumulative infected people at the given site.", [["infection", "DISEASE", 142, 151], ["people", "ORGANISM", 262, 268], ["people", "SPECIES", 262, 268], ["The small spatial fluctuation of these rates", "PROBLEM", 0, 44], ["an index C", "TEST", 115, 125], ["the infection severity", "PROBLEM", 138, 160], ["COVID", "TEST", 164, 169], ["small", "OBSERVATION_MODIFIER", 4, 9], ["spatial", "OBSERVATION_MODIFIER", 10, 17], ["fluctuation", "OBSERVATION_MODIFIER", 18, 29], ["infection", "OBSERVATION", 142, 151], ["maximum", "OBSERVATION_MODIFIER", 224, 231], ["number", "OBSERVATION_MODIFIER", 232, 238], ["cumulative", "OBSERVATION_MODIFIER", 242, 252], ["infected", "OBSERVATION", 253, 261]]], ["A smaller C represents a greater infection severity of coronavirus.", [["infection", "DISEASE", 33, 42], ["coronavirus", "DISEASE", 55, 66], ["coronavirus", "ORGANISM", 55, 66], ["A smaller C", "PROBLEM", 0, 11], ["a greater infection severity of coronavirus", "PROBLEM", 23, 66], ["smaller", "OBSERVATION_MODIFIER", 2, 9], ["greater", "OBSERVATION_MODIFIER", 25, 32], ["infection", "OBSERVATION", 33, 42], ["coronavirus", "OBSERVATION", 55, 66]]], ["There is a power-law relationship between the regional population N and the maximum cumulated number of infected people (Fig. 4) .Parameter analysisThis empirical formula may be used to approximate the largest cumulative number of infections, which will be applied in the subsequent section for predicting the COVID-19 evolution outside of China, where the coronavirus infection has not yet reached its peak number of cases.Prediction of spreading of COVID-19 in the worldDifferent countries are applying different modes to slow the the spread of the COVID-19.", [["infections", "DISEASE", 231, 241], ["coronavirus infection", "DISEASE", 357, 378], ["people", "ORGANISM", 113, 119], ["coronavirus", "ORGANISM", 357, 368], ["COVID-19", "DNA", 551, 559], ["people", "SPECIES", 113, 119], ["Parameter analysis", "TEST", 130, 148], ["This empirical formula", "TREATMENT", 148, 170], ["infections", "PROBLEM", 231, 241], ["the COVID", "TEST", 306, 315], ["the coronavirus infection", "PROBLEM", 353, 378], ["COVID", "TEST", 451, 456], ["the COVID", "TEST", 547, 556], ["regional", "OBSERVATION_MODIFIER", 46, 54], ["population", "OBSERVATION_MODIFIER", 55, 65], ["maximum", "OBSERVATION_MODIFIER", 76, 83], ["cumulated", "OBSERVATION_MODIFIER", 84, 93], ["number", "OBSERVATION_MODIFIER", 94, 100], ["infected", "OBSERVATION_MODIFIER", 104, 112], ["people", "OBSERVATION", 113, 119], ["Fig", "OBSERVATION_MODIFIER", 121, 124], ["largest", "OBSERVATION_MODIFIER", 202, 209], ["cumulative", "OBSERVATION_MODIFIER", 210, 220], ["number", "OBSERVATION_MODIFIER", 221, 227], ["infections", "OBSERVATION", 231, 241], ["coronavirus", "OBSERVATION_MODIFIER", 357, 368], ["infection", "OBSERVATION", 369, 378], ["spreading", "OBSERVATION_MODIFIER", 438, 447]]], ["In the next sub-sections, we discuss several representative countries and then fit/predict the virus spread there.United StatesToItalyTo decrease the acceleration of COVID-19 spread, Italy's mode is now similar to China:Italylockdown of the full population.", [["the virus spread", "PROBLEM", 91, 107], ["COVID", "TEST", 166, 171], ["decrease", "OBSERVATION_MODIFIER", 137, 145], ["acceleration", "OBSERVATION_MODIFIER", 150, 162]]], ["The predicted COVID-19 spread in Italy is plotted in Fig. 6a .ItalyAlthough Italy has followed China's mode of national isolation, the number of infected people increased rapidly from 3/14/2020 to 3/19/2020 (~495 new cases per day).", [["people", "ORGANISM", 154, 160], ["COVID-19", "DNA", 14, 22], ["people", "SPECIES", 154, 160], ["The predicted COVID", "TEST", 0, 19], ["national isolation", "TREATMENT", 111, 129], ["spread", "OBSERVATION_MODIFIER", 23, 29], ["Fig", "OBSERVATION_MODIFIER", 53, 56], ["infected", "OBSERVATION", 145, 153]]], ["To account for the delayed national quarantine compared with China, we decrease the C index (while also increasing the upper limit of the cumulative infection).", [["infection", "DISEASE", 149, 158], ["the delayed national quarantine", "PROBLEM", 15, 46], ["the C index", "TREATMENT", 80, 91], ["the cumulative infection", "PROBLEM", 134, 158], ["upper limit", "OBSERVATION_MODIFIER", 119, 130], ["infection", "OBSERVATION", 149, 158]]], ["The COVID-19 evolution prediction results show that there may be a turning point in the next two weeks when the current infected cases begin to decline.", [["The COVID", "TEST", 0, 9], ["the current infected cases", "PROBLEM", 108, 134], ["infected", "OBSERVATION", 120, 128]]], ["We also separate the death toll from the number of recovered cases.South KoreaSouth Korea's mode of combating the spread of COVID-19 is through fast detection and tracking of the disease.", [["death", "DISEASE", 21, 26], ["COVID-19", "CHEMICAL", 124, 132], ["COVID-19", "CHEMICAL", 124, 132], ["COVID", "TEST", 124, 129], ["the disease", "PROBLEM", 175, 186], ["disease", "OBSERVATION", 179, 186]]], ["South Korea is using efficient mobile diagnoses tests and accurate tracing of infected cases to maintain a low death rate even with a large infected population.", [["death", "DISEASE", 111, 116], ["diagnoses tests", "TEST", 38, 53], ["infected cases", "PROBLEM", 78, 92], ["a low death rate", "PROBLEM", 105, 121], ["a large infected population", "PROBLEM", 132, 159], ["large", "OBSERVATION_MODIFIER", 134, 139], ["infected", "OBSERVATION", 140, 148]]], ["The mobile method can test 20,000 people per day (the maximum capability on 3/12/2020), and apps for cell phones and/or credit cards can accurately track the routes of infected people with the help of local government (without an invasion of privacy), so that warnings can be immediately delivered to the general population to obviate the places with high risk.", [["cell", "ANATOMY", 101, 105], ["people", "ORGANISM", 34, 40], ["cell", "CELL", 101, 105], ["people", "ORGANISM", 177, 183], ["people", "SPECIES", 34, 40], ["people", "SPECIES", 177, 183]]], ["The current infected population may have passed its peak number of cases around 3/20/2020, and the prediction shows that the COVID-19South Koreaoutbreak may be well controlled in ~35 days from 3/22/2020 (Fig. 6b) .JapanJapan's mode of combating the spread of COVID-19 is compatible with that of the U.S., in addition to other changes such as enhanced education/outreach and rapid treatment of the infected cases.", [["the COVID", "TEST", 121, 130], ["JapanJapan", "TREATMENT", 214, 224], ["enhanced education/outreach", "TREATMENT", 342, 369], ["rapid treatment", "TREATMENT", 374, 389], ["the infected cases", "PROBLEM", 393, 411], ["infected", "OBSERVATION_MODIFIER", 12, 20], ["population", "OBSERVATION", 21, 31], ["peak", "OBSERVATION_MODIFIER", 52, 56], ["infected", "OBSERVATION", 397, 405]]], ["Specific policies include social distancing (which might be a key barrier to the spread of the novel coronavirus), personal hygiene, and quarantine of the infected cases.", [["coronavirus", "DISEASE", 101, 112], ["coronavirus", "ORGANISM", 101, 112]]], ["The current data and modeling results (Fig. 6c) show that Japan has an efficient way so far to limit the maximum population infected and slow the spread of COVID-19, while this outbreak may last for a while.Stochastic model to evaluate scenarios to mitigate the outbreak of COVID-19 in a cityThe model-predicted COVID-19 spread in the U.S., using the fitted infection and recovery rates from China (Fig. 5) , reveals the impact of one possible mitigation scenario for COVID-19:Stochastic model to evaluate scenarios to mitigate the outbreak of COVID-19 in a citycoronavirus lockdowns, which have now been implemented by some states in the U.S. such as California and New York.", [["COVID", "DISEASE", 274, 279], ["infection", "DISEASE", 358, 367], ["COVID-19", "CHEMICAL", 544, 552], ["COVID-19", "SPECIES", 156, 164], ["The current data", "TEST", 0, 16], ["the maximum population infected", "PROBLEM", 101, 132], ["COVID", "TEST", 156, 161], ["COVID", "TEST", 274, 279], ["The model-predicted COVID", "TEST", 292, 317], ["the fitted infection", "PROBLEM", 347, 367], ["COVID", "TEST", 468, 473], ["Stochastic model", "TREATMENT", 477, 493], ["COVID", "TEST", 544, 549], ["a citycoronavirus lockdowns", "TREATMENT", 556, 583], ["infected", "OBSERVATION", 124, 132], ["infection", "OBSERVATION", 358, 367]]], ["Other non-pharmaceutical options can and should also be evaluated using mathematical models, considering the recent surge of infected cases in the U.S.Stochastic model to evaluate scenarios to mitigate the outbreak of COVID-19 in a cityWhen the number of infected persons is initially small compared to that of susceptible people, the infected and susceptible people are not well mixed and hence the system is not homogeneous.Stochastic model to evaluate scenarios to mitigate the outbreak of COVID-19 in a cityUnder such conditions, a stochastic model is needed, as the deterministic, continuum models (such as the SEIR model) assume well-mixing of components for a homogeneous system [33, 34] .Stochastic model to evaluate scenarios to mitigate the outbreak of COVID-19 in a cityHence, this section develops and applies a stochastic model to evaluate non-pharmaceutical scenarios for mitigating the COVID-19 with a small number of initial infections.Stochastic model developmentThe random walk based stochastic model for COVID-19 spread is analogous to a mixing-limited bimolecular reaction-based mechanism/condition [35] .", [["COVID", "DISEASE", 218, 223], ["COVID", "DISEASE", 493, 498], ["infections", "DISEASE", 941, 951], ["COVID-19", "CHEMICAL", 1023, 1031], ["persons", "ORGANISM", 264, 271], ["people", "ORGANISM", 323, 329], ["people", "ORGANISM", 360, 366], ["persons", "SPECIES", 264, 271], ["people", "SPECIES", 323, 329], ["people", "SPECIES", 360, 366], ["Other non-pharmaceutical options", "TREATMENT", 0, 32], ["COVID", "TEST", 218, 223], ["the infected and susceptible people", "PROBLEM", 331, 366], ["COVID", "TEST", 493, 498], ["a stochastic model", "TREATMENT", 534, 552], ["the SEIR model", "TREATMENT", 612, 626], ["COVID", "TEST", 763, 768], ["this section", "TREATMENT", 788, 800], ["a stochastic model", "TREATMENT", 822, 840], ["non-pharmaceutical scenarios", "TREATMENT", 853, 881], ["the COVID", "TEST", 897, 906], ["initial infections", "PROBLEM", 933, 951], ["Stochastic model development", "PROBLEM", 952, 980], ["COVID", "TEST", 1023, 1028], ["infected", "OBSERVATION", 255, 263], ["small", "OBSERVATION_MODIFIER", 285, 290], ["infected", "OBSERVATION", 335, 343], ["susceptible", "OBSERVATION_MODIFIER", 348, 359], ["well mixed", "OBSERVATION_MODIFIER", 375, 385], ["not", "UNCERTAINTY", 410, 413], ["homogeneous", "OBSERVATION_MODIFIER", 414, 425], ["small", "OBSERVATION_MODIFIER", 917, 922], ["infections", "OBSERVATION", 941, 951]]], ["When a reactant A particle (representing a susceptible individual A) meets a reactant B particle (representing an infectious person B), a chemical reaction may occur if the collision energy is large enough to break the chemical bond (meaning that the susceptible person A may be infected if satisfying additional criteria such as A and B are close enough, and B touches his/her face after receiving coronavirus from A).", [["person", "SPECIES", 125, 131], ["person", "SPECIES", 263, 269], ["a reactant B particle", "PROBLEM", 75, 96], ["a chemical reaction", "PROBLEM", 136, 155], ["the collision energy", "PROBLEM", 169, 189], ["coronavirus", "PROBLEM", 399, 410], ["infectious", "OBSERVATION", 114, 124], ["large", "OBSERVATION_MODIFIER", 193, 198]]], ["Therefore, the condition of A being infected is not deterministic but rather a random, probability-controlled process.", [["A being infected", "PROBLEM", 28, 44], ["infected", "OBSERVATION", 36, 44]]], ["This probability is related to various factors, such as the duration that A and B are in contact, the infectivity rate, and the distance between the two people, which may be characterized parsimoniously by the interaction radius R that controls the number of reactant pairs (susceptible + infectious) in a potential reaction (infection) [35] .", [["infection", "DISEASE", 326, 335], ["B", "GENE_OR_GENE_PRODUCT", 80, 81], ["people", "ORGANISM", 153, 159], ["people", "SPECIES", 153, 159], ["the infectivity rate", "TEST", 98, 118], ["reactant pairs (susceptible + infectious)", "PROBLEM", 259, 300], ["a potential reaction (infection", "PROBLEM", 304, 335], ["infectious", "OBSERVATION_MODIFIER", 289, 299]]], ["Hence, the core of the random walk stochastic model to simulate COVID-19 spread is to define the interaction radiusR.The analogous development and similarities between bimolecular reactions and the SIR model can also be seen from their governing equations.", [["COVID-19", "CHEMICAL", 64, 72], ["COVID", "DNA", 64, 69], ["COVID", "TEST", 64, 69], ["bimolecular reactions", "PROBLEM", 168, 189], ["bimolecular reactions", "OBSERVATION", 168, 189]]], ["The time-dependent SIR model takes the form [36] :R.where ( ) and ( ) denote the transmission rate and recovery rate at time t, respectively.R.The rate equations for irreversible bimolecular reaction take the form [35] :R.where , , and denote the concentrations of A, B, and C, respectively; and ( ) is the forward kinetic coefficient of reaction.", [["A", "SIMPLE_CHEMICAL", 265, 266], ["B", "SIMPLE_CHEMICAL", 268, 269], ["C", "SIMPLE_CHEMICAL", 275, 276], ["the transmission rate", "TEST", 77, 98], ["The rate equations", "TEST", 143, 161], ["irreversible bimolecular reaction", "PROBLEM", 166, 199], ["the forward kinetic coefficient of reaction", "PROBLEM", 303, 346]]], ["Equations (5a) and (5b) are functionally similar to equations (4a) and (4b), respectively, if the recovery rate ( ) .", [["Equations", "TEST", 0, 9]]], ["Therefore, following the argument in Zhang et al. [35] and Lu et al. [37] , we derive analytically the interaction radius R for the SIR model (4):R.where V denotes the volume of the domain, is the time step in random walk particle tracking, is the mass (or weight) carried by each A particle, is the initial concentration of A (which can be assumed to be the normalized value 1 here), and denotes the initial number of susceptible people.R.The movement of A, B, and C can be described by the following time FDE [35] :R.where denotes A, B, and C, respectively; denotes the fractional capacity coefficient (which controls the ratio between the immobile and mobile population); denotes the mean moving speed; and denotes the macrodispersion coefficient.R.After defining the interaction radius R, the particle tracking scheme proposed by Zhang et al. [35] and Lu et al. [37] with particle trajectories defined by the time FDE (7) can be applied to model the transmission of coronavirus between the susceptible and infectious people.Scenario evaluation to mitigate the COVID-19 outbreak in a cityIn addition to pharmaceutical strategies including vaccine and therapeutic drug development, and herd immunity that may either take a while or have a high risk, non-pharmaceutical scenarios can be tested.", [["coronavirus", "DISEASE", 970, 981], ["people", "ORGANISM", 431, 437], ["B", "GENE_OR_GENE_PRODUCT", 459, 460], ["C", "GENE_OR_GENE_PRODUCT", 466, 467], ["R", "GENE_OR_GENE_PRODUCT", 750, 751], ["coronavirus", "ORGANISM", 970, 981], ["people", "ORGANISM", 1021, 1027], ["people", "SPECIES", 431, 437], ["people", "SPECIES", 1021, 1027], ["the mass", "PROBLEM", 244, 252], ["the fractional capacity coefficient", "PROBLEM", 568, 603], ["the macrodispersion coefficient", "PROBLEM", 718, 749], ["coronavirus", "PROBLEM", 970, 981], ["Scenario evaluation", "TEST", 1028, 1047], ["the COVID", "TEST", 1060, 1069], ["pharmaceutical strategies", "TREATMENT", 1106, 1131], ["vaccine", "TREATMENT", 1142, 1149], ["therapeutic drug development", "TREATMENT", 1154, 1182], ["non-pharmaceutical scenarios", "TREATMENT", 1252, 1280], ["mass", "OBSERVATION", 248, 252], ["movement", "OBSERVATION_MODIFIER", 444, 452], ["infectious", "OBSERVATION", 1010, 1020]]], ["Several particle-tracking based stochastic models were proposed recently [38] to evaluate non-pharmaceutical scenarios to mitigate coronavirus spreading in a city.", [["coronavirus", "DISEASE", 131, 142], ["coronavirus", "ORGANISM", 131, 142], ["Several particle-tracking based stochastic models", "PROBLEM", 0, 49], ["non-pharmaceutical scenarios", "PROBLEM", 90, 118], ["coronavirus", "PROBLEM", 131, 142], ["particle", "OBSERVATION_MODIFIER", 8, 16], ["coronavirus", "OBSERVATION", 131, 142]]], ["In the stochastic model, we assume that 10 days after being infected, the person will be removed because of being cured or expired (dead).", [["person", "ORGANISM", 74, 80], ["person", "SPECIES", 74, 80]]], ["This is because the median disease incubation period has been estimated to be 5.1 days [39] .", [["the median disease incubation", "PROBLEM", 16, 45]]], ["For simplicity purposes, the interaction radius R (6) remains constant, since the constant interaction radius was found to be able to efficiently capture the temporal variation of effective reaction rates in mixing controlled reaction experiments or simulations [35, 37] .", [["effective reaction rates", "PROBLEM", 180, 204]]], ["The initial number of A and B particles is 10,000 and 4, respectively.", [["A and B particles", "TEST", 22, 39]]], ["TheScenario evaluation to mitigate the COVID-19 outbreak in a cityLagrangian solutions of the COVID-19 outbreak for the three scenarios are depicted in Fig. 7 .Scenario evaluation to mitigate the COVID-19 outbreak in a cityModeling results for scenarios 1, 2, and 3 show a peak in the curve of newly infected people at time t=28, 65, and 32, respectively, demonstrating that the virus spreads the fastest for the scenario without mitigation constraints (i.e., scenario 1, where the number of the total infected people or cases increases by one order of magnitude every 10 days in the rising limb), as expected.", [["limb", "ANATOMY", 591, 595], ["infected", "DISEASE", 502, 510], ["people", "ORGANISM", 309, 315], ["people", "ORGANISM", 511, 517], ["limb", "ORGANISM_SUBDIVISION", 591, 595], ["people", "SPECIES", 309, 315], ["people", "SPECIES", 511, 517], ["TheScenario evaluation", "TEST", 0, 22], ["the COVID", "TEST", 35, 44], ["a cityLagrangian solutions", "TREATMENT", 60, 86], ["the COVID", "TEST", 90, 99], ["Scenario evaluation", "TEST", 160, 179], ["the COVID", "TEST", 192, 201], ["scenarios", "TEST", 244, 253], ["the virus", "PROBLEM", 375, 384], ["peak", "OBSERVATION_MODIFIER", 273, 277], ["newly", "OBSERVATION_MODIFIER", 294, 299], ["infected", "OBSERVATION", 300, 308], ["virus", "OBSERVATION", 379, 384], ["rising limb", "OBSERVATION_MODIFIER", 584, 595]]], ["However, the value for this peak (scenario 1, =198 people) is lower than that for scenario 3 (=267 people), although the total number of the infected people for scenario 1 (9,336) is slightly larger than scenario 3 (9,322).", [["people", "ORGANISM", 51, 57], ["people", "ORGANISM", 99, 105], ["people", "ORGANISM", 150, 156], ["people", "SPECIES", 51, 57], ["people", "SPECIES", 99, 105], ["people", "SPECIES", 150, 156], ["the value", "TEST", 9, 18], ["infected", "OBSERVATION", 141, 149], ["slightly", "OBSERVATION_MODIFIER", 183, 191], ["larger", "OBSERVATION_MODIFIER", 192, 198]]], ["This may be due to a greater separation of infection cases for the higher number of initial coronavirus carriers in scenario 1, which causes a lower and relatively flatter COVID-19Scenario evaluation to mitigate the COVID-19 outbreak in a cityevolution peak compared to that of scenario 3.", [["infection", "DISEASE", 43, 52], ["coronavirus", "DISEASE", 92, 103], ["coronavirus", "ORGANISM", 92, 103], ["infection cases", "PROBLEM", 43, 58], ["initial coronavirus carriers", "PROBLEM", 84, 112], ["19Scenario evaluation", "TEST", 178, 199], ["the COVID", "TEST", 212, 221], ["may be due to", "UNCERTAINTY", 5, 18], ["greater", "OBSERVATION_MODIFIER", 21, 28], ["separation", "OBSERVATION_MODIFIER", 29, 39], ["infection", "OBSERVATION", 43, 52], ["coronavirus", "OBSERVATION", 92, 103], ["lower", "ANATOMY_MODIFIER", 143, 148]]], ["Scenario 2 has the lowest peak value (=121 people) and the most-delayed peak in the curve for new cases, and the total infection time is almost doubled compared to the other two scenarios, indicating that people living with strict social distancing may also suffer from a much longer period of COVID-19 threat.", [["infection", "DISEASE", 119, 128], ["people", "ORGANISM", 205, 211], ["people", "SPECIES", 43, 49], ["people", "SPECIES", 205, 211], ["the total infection time", "PROBLEM", 109, 133], ["total", "OBSERVATION_MODIFIER", 113, 118], ["infection", "OBSERVATION", 119, 128]]], ["It is also noteworthy that the overall trend of the solution (simulation) of scenario 1 (initial surge without special constraints, Fig. 7a ) is similar to that for Italy which had a delayed response to the COVID-19Scenario evaluation to mitigate the COVID-19 outbreak in a cityoutbreak initially (Fig. 6a) , and scenario 3 solution (a lower peak value and a longer duration due to social distancing, Fig. 7b ) is similar to that observed in Japan where social distancing actions have been implemented (Fig. 6c) .Scenario evaluation to mitigate the COVID-19 outbreak in a cityThe simulated particle plumes plotted in Fig. 8 reveal the subtle discrepancy between the three mitigation scenarios.", [["19Scenario evaluation", "TEST", 213, 234], ["the COVID", "TEST", 247, 256], ["a lower peak value", "PROBLEM", 334, 352], ["Scenario evaluation", "TEST", 513, 532], ["the COVID", "TEST", 545, 554], ["the subtle discrepancy", "PROBLEM", 631, 653], ["particle", "OBSERVATION_MODIFIER", 590, 598], ["plumes", "OBSERVATION_MODIFIER", 599, 605], ["Fig", "OBSERVATION_MODIFIER", 617, 620], ["subtle", "OBSERVATION_MODIFIER", 635, 641], ["discrepancy", "OBSERVATION", 642, 653]]], ["Scenario 1 assumes that four initial cases were initially located on the right side of the city, while the whole population (10,000 susceptible persons) was distributed randomly in the 1\uf0b41 domain (Fig. 8a) .", [["persons", "ORGANISM", 144, 151], ["1\uf0b41 domain", "PROTEIN", 185, 195], ["persons", "SPECIES", 144, 151], ["right", "ANATOMY_MODIFIER", 73, 78]]], ["The trajectory of each person is assumed to follow (two-dimensional)Scenario evaluation to mitigate the COVID-19 outbreak in a cityBrownian motion with retention (described by Eq.", [["person", "SPECIES", 23, 29], ["Scenario evaluation", "TEST", 68, 87], ["the COVID", "TEST", 100, 109]]], ["(7)), to capture the random vector for each displacement and the random waiting time between two consecutive motions (described by the time fractional derivative term in Eq.", [["each displacement", "PROBLEM", 39, 56]]], ["The virus moved quickly from east to west (Figs.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["8b and 8c) , spreading over the entire city before all the infected people were cured or expired (dead) at time t=69 (Fig. 8d) .", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74]]], ["A total of 664 susceptible people (6.6% of the total population) distributed randomly around the city were never infected.Scenario evaluation to mitigate the COVID-19 outbreak in a cityScenario 2 assumes that social distancing can reduce the infection probability, which can be characterized by a smaller reaction rate or a smaller interaction radius in our Lagrangian approach.Scenario evaluation to mitigate the COVID-19 outbreak in a cityThe virus was spreading at a much lower rate from west to east than that in scenario 1 (Figs.", [["infection", "DISEASE", 242, 251], ["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["the total population)", "TREATMENT", 43, 64], ["Scenario evaluation", "TEST", 122, 141], ["the COVID", "TEST", 154, 163], ["the infection probability", "PROBLEM", 238, 263], ["a smaller reaction rate", "PROBLEM", 295, 318], ["a smaller interaction radius", "PROBLEM", 322, 350], ["Scenario evaluation", "TEST", 378, 397], ["the COVID", "TEST", 410, 419], ["The virus", "PROBLEM", 441, 450], ["infected", "OBSERVATION", 113, 121], ["infection", "OBSERVATION", 242, 251], ["smaller", "OBSERVATION_MODIFIER", 297, 304], ["reaction", "OBSERVATION", 305, 313], ["smaller", "OBSERVATION_MODIFIER", 324, 331], ["interaction radius", "OBSERVATION", 332, 350], ["virus", "OBSERVATION", 445, 450]]], ["8e~8g), reaching a stable condition (i.e., # of cases neither increasing or decreasing) at a later time (t=125) and leaving more susceptible people unaffected (2,734 total, which is 27.3% of the population).", [["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["stable", "OBSERVATION", 19, 25]]], ["Therefore, social distancing is effective in limiting the spread of coronavirus among people.", [["coronavirus", "DISEASE", 68, 79], ["coronavirus", "ORGANISM", 68, 79], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["Note, however, this scenario assumes that every person in this city strictly maintains social distancing; otherwise a surge of infections may occur the same way as that shown in scenario 1.Scenario evaluation to mitigate the COVID-19 outbreak in a cityScenario 3 assumes self-quarantine.", [["infections", "DISEASE", 127, 137], ["person", "SPECIES", 48, 54], ["infections", "PROBLEM", 127, 137], ["Scenario evaluation", "TEST", 189, 208], ["the COVID", "TEST", 221, 230], ["infections", "OBSERVATION", 127, 137]]], ["Notably, not all of the infected people can be effectively quarantined due to the following: 1) people can be infected without coronavirus symptoms; 2) people in the incubation period can transmit the infection; and 3) limited health care facilities and capabilities for the large influx of patients.", [["coronavirus", "DISEASE", 127, 138], ["infection", "DISEASE", 201, 210], ["people", "ORGANISM", 33, 39], ["people", "ORGANISM", 96, 102], ["coronavirus", "ORGANISM", 127, 138], ["people", "ORGANISM", 152, 158], ["patients", "ORGANISM", 291, 299], ["people", "SPECIES", 33, 39], ["people", "SPECIES", 96, 102], ["coronavirus", "SPECIES", 127, 138], ["people", "SPECIES", 152, 158], ["patients", "SPECIES", 291, 299], ["coronavirus symptoms", "PROBLEM", 127, 147], ["the infection", "PROBLEM", 197, 210], ["infected", "OBSERVATION", 24, 32], ["infection", "OBSERVATION", 201, 210]]], ["For example, according to Imai et al. [40] , many infected people could not be appropriately screened initially in Wuhan City, China.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["infected", "OBSERVATION", 50, 58]]], ["Under this condition, we assume that 50% of people infected and diagnosed are immediately quarantined, while the remaining infected people (Fig. 8i) can still cause the spread of coronavirus (Figs.Scenario evaluation to mitigate the COVID-19 outbreak in a city8j~8l).", [["coronavirus", "DISEASE", 179, 190], ["people", "ORGANISM", 44, 50], ["people", "ORGANISM", 132, 138], ["coronavirus", "ORGANISM", 179, 190], ["people", "SPECIES", 44, 50], ["people", "SPECIES", 132, 138], ["coronavirus", "PROBLEM", 179, 190], ["Scenario evaluation", "TEST", 197, 216], ["the COVID", "TEST", 229, 238], ["a city8j", "TREATMENT", 254, 262], ["coronavirus", "OBSERVATION", 179, 190]]], ["Self-quarantine, therefore, may not be as effective as maintained social distancing.ConclusionsFractional calculus provides a useful tool to modeling complex dynamics in biology, and this study extended the FDE for modeling the coronavirus outbreak.", [["coronavirus", "DISEASE", 228, 239], ["coronavirus", "ORGANISM", 228, 239], ["Fractional calculus", "PROBLEM", 95, 114], ["this study", "TEST", 183, 193], ["modeling the coronavirus outbreak", "PROBLEM", 215, 248], ["calculus", "OBSERVATION", 106, 114], ["coronavirus", "OBSERVATION", 228, 239]]], ["The COVID-19 is a pandemic Third, a stochastic model based on the Lagrangian scheme for the time FDEs, analogous to a mixing-limited reaction mechanism model, showed that self-quarantine may not be as effective as strict social distancing, since not all the infected people can be diagnosed and immediately quarantined.", [["people", "ORGANISM", 267, 273], ["COVID-19", "DNA", 4, 12], ["people", "SPECIES", 267, 273], ["The COVID", "TEST", 0, 9], ["a stochastic model", "TREATMENT", 34, 52]]], ["While strict social distancing can apparently slow COVID-19 spread, the pandemic may last longer.", [["slow COVID-19 spread", "PROBLEM", 46, 66]]], ["This is another case that fractional calculus may be used to explore COVID-19Conclusionsoutbreak.", [["fractional calculus", "PROBLEM", 26, 45], ["COVID", "TEST", 69, 74], ["calculus", "OBSERVATION", 37, 45]]], ["Therefore, one of the main contributions of this study is to extend the application of FDEs to model dynamics and mitigation scenarios of the coronavirus spread.Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultsThis appendix quantifies the potential impacts of the non-singular kernel and the type of the fractional derivative on the COVID-19 death toll simulation.", [["coronavirus", "DISEASE", 142, 153], ["death", "DISEASE", 389, 394], ["coronavirus", "ORGANISM", 142, 153], ["this study", "TEST", 44, 54], ["the coronavirus spread", "PROBLEM", 138, 160], ["the non-singular kernel", "TREATMENT", 182, 205], ["the non-singular kernel", "TREATMENT", 307, 330], ["the fractional derivative", "TREATMENT", 347, 372], ["the COVID", "TREATMENT", 376, 385], ["main", "OBSERVATION_MODIFIER", 22, 26], ["coronavirus spread", "OBSERVATION", 142, 160], ["appendix", "OBSERVATION", 262, 270], ["potential", "OBSERVATION_MODIFIER", 286, 295], ["impacts", "OBSERVATION_MODIFIER", 296, 303]]], ["For example, the Atagana-Baleanu fractional derivative is defined as [41] :Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultswhere ( ) \u2211 ( ) represents the single-parameter Mittag-Leffler function.Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultsWe employ this definition to extend the SEIR model and then use the finite difference method to simulate the evolution of the COVID-19 death toll, which leads to the following solver: (Fig. 9) , which is consistent with the conclusion in the previous study (see [42] ).Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultsThe resultant death roll peak is lower than that simulated by the conventional kernel function, but it does not mean that the kernel used in the Caputo fractional derivative is no longer valid.Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultsIndeed, the solution of the Caputo fractional derivative can capture well the obsvered death peak (Fig. 1a) .", [["death", "DISEASE", 474, 479], ["death", "DISEASE", 718, 723], ["death", "DISEASE", 1080, 1085], ["the Atagana", "TEST", 13, 24], ["the non-singular kernel", "TREATMENT", 96, 119], ["the non-singular kernel", "TREATMENT", 264, 287], ["the previous study", "TEST", 577, 595], ["the non-singular kernel", "TREATMENT", 629, 652], ["The resultant death roll peak", "TEST", 704, 733], ["the Caputo fractional derivative", "TREATMENT", 845, 877], ["the non-singular kernel", "TREATMENT", 918, 941], ["the Caputo fractional derivative", "TREATMENT", 1017, 1049], ["Appendix", "ANATOMY", 75, 83], ["consistent with", "UNCERTAINTY", 543, 558], ["resultant", "OBSERVATION_MODIFIER", 708, 717], ["death", "OBSERVATION_MODIFIER", 718, 723], ["roll", "OBSERVATION_MODIFIER", 724, 728], ["peak", "OBSERVATION_MODIFIER", 729, 733], ["lower", "OBSERVATION_MODIFIER", 737, 742], ["no longer", "UNCERTAINTY", 881, 890]]], ["Applications of the nonsingular kernel functions deserve further study in the future.Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultsSecond, the Riemann-Liouville fractional derivative is defined as [43] :Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultsThe Caputo fractional derivative listed in Section 2.1 and the Riemann-Liouville fractional derivative (9) are related by [44] :Appendix: Impacts of the non-singular kernel and the fractional derivative type on model resultswhere , and the operators and represent the Caputo andAppendix: Impacts of the non-singular kernel and the fractional derivative type on model resultsRiemann-Liouville fractional derivatives, respectively.Declaration of interests\u2612 The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Declaration of interestsCredit author statement:", [["Riemann-Liouville fractional derivatives", "SIMPLE_CHEMICAL", 723, 763], ["the nonsingular kernel functions", "TREATMENT", 16, 48], ["further study", "TEST", 57, 70], ["the non-singular kernel", "TREATMENT", 106, 129], ["the Riemann-Liouville fractional derivative", "TREATMENT", 189, 232], ["the non-singular kernel", "TREATMENT", 274, 297], ["The Caputo fractional derivative", "TREATMENT", 349, 381], ["the Riemann-Liouville fractional derivative", "TREATMENT", 408, 451], ["the non-singular kernel", "TREATMENT", 498, 521], ["the non-singular kernel", "TREATMENT", 648, 671], ["Riemann", "TREATMENT", 723, 730], ["Liouville fractional derivatives", "TREATMENT", 731, 763], ["Appendix", "ANATOMY", 253, 261], ["Appendix", "ANATOMY", 477, 485], ["Appendix", "ANATOMY", 627, 635]]]], "2e380520bdf1fec90bff0713dd7a8b6056d0dd0e": [["Abstract Purpose: Severe bronchiolitis is the leading cause of admission to the pediatric intensive care unit (PICU).", [["bronchiolitis", "DISEASE", 25, 38], ["Severe bronchiolitis", "PROBLEM", 18, 38], ["Severe", "OBSERVATION_MODIFIER", 18, 24], ["bronchiolitis", "OBSERVATION", 25, 38]]], ["Nasal continuous positive airway pressure (nCPAP) has become the primary respiratory support, replacing invasive mechanical ventilation (MV).", [["Nasal", "ANATOMY", 0, 5], ["airway", "ANATOMY", 26, 32], ["respiratory", "ANATOMY", 73, 84], ["Nasal", "MULTI-TISSUE_STRUCTURE", 0, 5], ["airway", "MULTI-TISSUE_STRUCTURE", 26, 32], ["MV", "SPECIES", 137, 139], ["Nasal continuous positive airway pressure (nCPAP", "TREATMENT", 0, 48], ["the primary respiratory support", "TREATMENT", 61, 92], ["invasive mechanical ventilation", "TREATMENT", 104, 135], ["airway pressure", "OBSERVATION", 26, 41], ["respiratory support", "OBSERVATION", 73, 92], ["mechanical ventilation", "OBSERVATION", 113, 135]]], ["Our objective was to evaluate the economic and clinical consequences following implementation of this respiratory strategy in our unit.", [["this respiratory strategy", "TREATMENT", 97, 122]]], ["Methods: This was a retrospective cohort analysis of 525 infants with bronchiolitis requiring respiratory support and successively treated during two distinct periods with invasive MV between 1996 and 2000, P1 (n = 193) and nCPAP between 2006 and 2010, P2 (n = 332).", [["respiratory", "ANATOMY", 94, 105], ["bronchiolitis", "DISEASE", 70, 83], ["infants", "ORGANISM", 57, 64], ["infants", "SPECIES", 57, 64], ["MV", "SPECIES", 181, 183], ["a retrospective cohort analysis", "TEST", 18, 49], ["bronchiolitis", "PROBLEM", 70, 83], ["respiratory support", "TREATMENT", 94, 113], ["invasive MV", "TEST", 172, 183], ["nCPAP", "TEST", 224, 229], ["bronchiolitis", "OBSERVATION", 70, 83], ["respiratory support", "OBSERVATION", 94, 113]]], ["Results: Patients' baseline characteristics were similar between the two periods.", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17]]], ["P2 is associated with a significant decrease in the length of ventilation (LOV) (4.1 \u00b1 3.5 versus 6.9 \u00b1 4.6 days, p \u00a00.001), PICU length of stay (LOS) (6.2 \u00b1 4.6 versus 9.7 \u00b1 5.5 days, p \u00a00.001) and hospital LOS. nCPAP was independently associated with a shorter duration of ventilatory support than MV (hazard ratio 1.8, 95 % CI 1.5-2.2, p \u00a00.001). nCPAP was also associated with a significant decrease in ventilation-associated complications, and less invasive management.", [["nCPAP", "CHEMICAL", 213, 218], ["nCPAP", "CHEMICAL", 350, 355], ["P2", "DNA", 0, 2], ["MV", "SPECIES", 300, 302], ["a significant decrease", "PROBLEM", 22, 44], ["LOS", "TEST", 146, 149], ["nCPAP", "TREATMENT", 213, 218], ["ventilatory support", "TREATMENT", 275, 294], ["MV", "TEST", 300, 302], ["hazard ratio", "TEST", 304, 316], ["CI", "TEST", 327, 329], ["nCPAP", "TREATMENT", 350, 355], ["a significant decrease in ventilation-associated complications", "PROBLEM", 381, 443], ["less invasive management", "TREATMENT", 449, 473], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["decrease", "OBSERVATION", 36, 44], ["length", "OBSERVATION_MODIFIER", 52, 58], ["significant", "OBSERVATION_MODIFIER", 383, 394], ["decrease", "OBSERVATION_MODIFIER", 395, 403], ["complications", "OBSERVATION", 430, 443]]], ["The mean cost of acute viral bronchiolitis-related PICU hospitalizations was significantly decreased, from 17,451 to 11,205 \u20ac (p \u00a00.001).", [["bronchiolitis", "DISEASE", 29, 42], ["acute viral bronchiolitis", "PROBLEM", 17, 42], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["viral", "OBSERVATION_MODIFIER", 23, 28], ["bronchiolitis", "OBSERVATION", 29, 42], ["decreased", "OBSERVATION_MODIFIER", 91, 100]]], ["Implementation of nCPAP led to a reduction of the total annual cost of acute viral bronchiolitis hospitalizations of 715,000 \u20ac.", [["bronchiolitis", "DISEASE", 83, 96], ["nCPAP", "TREATMENT", 18, 23], ["acute viral bronchiolitis hospitalizations", "PROBLEM", 71, 113], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["bronchiolitis", "OBSERVATION", 83, 96]]], ["Conclusion: nCPAP in severe bronchiolitis is associated with a significant improvement in patient management as shown by the reduction in invasive care, LOV, PICU LOS, hospital LOS, and economic burden.IntroductionAcute viral bronchiolitis is the most common cause of seasonal acute respiratory failure in infancy throughout the world and is responsible for approximately 600,000 deaths worldwide each year [1, 2] .", [["respiratory", "ANATOMY", 283, 294], ["bronchiolitis", "DISEASE", 28, 41], ["viral bronchiolitis", "DISEASE", 220, 239], ["acute respiratory failure", "DISEASE", 277, 302], ["deaths", "DISEASE", 380, 386], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["nCPAP", "TREATMENT", 12, 17], ["severe bronchiolitis", "PROBLEM", 21, 41], ["patient management", "TREATMENT", 90, 108], ["the reduction in invasive care", "TREATMENT", 121, 151], ["economic burden", "PROBLEM", 186, 201], ["Acute viral bronchiolitis", "PROBLEM", 214, 239], ["seasonal acute respiratory failure", "PROBLEM", 268, 302], ["nCPAP", "OBSERVATION", 12, 17], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["bronchiolitis", "OBSERVATION", 28, 41], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["improvement", "OBSERVATION_MODIFIER", 75, 86], ["invasive", "OBSERVATION_MODIFIER", 138, 146], ["Acute", "OBSERVATION_MODIFIER", 214, 219], ["viral bronchiolitis", "OBSERVATION", 220, 239], ["most common", "OBSERVATION_MODIFIER", 247, 258], ["seasonal", "OBSERVATION_MODIFIER", 268, 276], ["acute", "OBSERVATION_MODIFIER", 277, 282], ["respiratory failure", "OBSERVATION", 283, 302]]], ["In recent years, the hospitalization rate among infants with acute bronchiolitis has significantly increased in developed countries [3, 4] .", [["bronchiolitis", "DISEASE", 67, 80], ["infants", "ORGANISM", 48, 55], ["infants", "SPECIES", 48, 55], ["acute bronchiolitis", "PROBLEM", 61, 80], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["bronchiolitis", "OBSERVATION", 67, 80], ["significantly", "OBSERVATION_MODIFIER", 85, 98], ["increased", "OBSERVATION_MODIFIER", 99, 108]]], ["Up to 8 % of infants hospitalized with acute viral bronchiolitis required admission to a pediatric intensive care unit (PICU) owing to recurrent apnea or acute respiratory failure needing ventilatory support [5] .", [["respiratory", "ANATOMY", 160, 171], ["bronchiolitis", "DISEASE", 51, 64], ["apnea", "DISEASE", 145, 150], ["acute respiratory failure", "DISEASE", 154, 179], ["infants", "ORGANISM", 13, 20], ["infants", "SPECIES", 13, 20], ["acute viral bronchiolitis", "PROBLEM", 39, 64], ["recurrent apnea", "PROBLEM", 135, 150], ["acute respiratory failure", "PROBLEM", 154, 179], ["ventilatory support", "TREATMENT", 188, 207], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["viral bronchiolitis", "OBSERVATION", 45, 64], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["respiratory failure", "OBSERVATION", 160, 179]]], ["Currently, most PICU teams provide non-invasive nasal continuous positive airway pressure (nCPAP) ventilation as the first-line therapy when required.IntroductionTreatment of acute viral bronchiolitis-related hospitalization represents a significant seasonal healthcare burden in all developed countries.", [["nasal", "ANATOMY", 48, 53], ["airway", "ANATOMY", 74, 80], ["bronchiolitis", "DISEASE", 187, 200], ["airway", "MULTI-TISSUE_STRUCTURE", 74, 80], ["non-invasive nasal continuous positive airway pressure", "TREATMENT", 35, 89], ["nCPAP) ventilation", "TREATMENT", 91, 109], ["the first-line therapy", "TREATMENT", 113, 135], ["acute viral bronchiolitis", "PROBLEM", 175, 200], ["a significant seasonal healthcare burden", "PROBLEM", 236, 276], ["airway pressure", "OBSERVATION", 74, 89], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["viral bronchiolitis", "OBSERVATION", 181, 200], ["significant", "OBSERVATION_MODIFIER", 238, 249], ["seasonal", "OBSERVATION_MODIFIER", 250, 258]]], ["Even if representing a limited proportion of all acute viral bronchiolitis, the costeffectiveness of nCPAP in this setting is unknown.IntroductionThe main objective of our retrospective study was to compare the clinical evolution and economic impact of two different types of respiratory support: invasive mechanical ventilation and nCPAP-the new standard of care in our PICU.Study design and populationWe performed a large retrospective analysis of infants admitted to the PICU at the Kremlin-Bicetre tertiary care center for severe acute bronchiolitis needing any type of ventilatory support.", [["respiratory", "ANATOMY", 276, 287], ["bronchiolitis", "DISEASE", 61, 74], ["bronchiolitis", "DISEASE", 540, 553], ["infants", "ORGANISM", 450, 457], ["infants", "SPECIES", 450, 457], ["all acute viral bronchiolitis", "PROBLEM", 45, 74], ["nCPAP", "TREATMENT", 101, 106], ["our retrospective study", "TEST", 168, 191], ["respiratory support", "TREATMENT", 276, 295], ["invasive mechanical ventilation", "TREATMENT", 297, 328], ["nCPAP", "TREATMENT", 333, 338], ["a large retrospective analysis", "TEST", 416, 446], ["severe acute bronchiolitis", "PROBLEM", 527, 553], ["ventilatory support", "TREATMENT", 574, 593], ["all", "OBSERVATION_MODIFIER", 45, 48], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["bronchiolitis", "OBSERVATION", 61, 74], ["main", "OBSERVATION_MODIFIER", 150, 154], ["respiratory support", "OBSERVATION", 276, 295], ["invasive", "OBSERVATION_MODIFIER", 297, 305], ["mechanical ventilation", "OBSERVATION", 306, 328], ["severe", "OBSERVATION_MODIFIER", 527, 533], ["acute", "OBSERVATION_MODIFIER", 534, 539], ["bronchiolitis", "OBSERVATION", 540, 553], ["ventilatory support", "OBSERVATION", 574, 593]]], ["Medical records from all infants admitted for bronchiolitis between 1 January 1996 and 28 February 2000, and between 1 January 2006 and 28 February 2010, were obtained.", [["bronchiolitis", "DISEASE", 46, 59], ["infants", "ORGANISM", 25, 32], ["infants", "SPECIES", 25, 32], ["bronchiolitis", "PROBLEM", 46, 59], ["bronchiolitis", "OBSERVATION", 46, 59]]], ["During the first period (1996-2000, P1) , the only ventilatory support available was endotracheal mechanical ventilation.", [["endotracheal", "ANATOMY", 85, 97], ["ventilatory support", "TREATMENT", 51, 70], ["endotracheal mechanical ventilation", "TREATMENT", 85, 120], ["ventilatory support", "OBSERVATION", 51, 70], ["mechanical ventilation", "OBSERVATION", 98, 120]]], ["During the second period (2006-2010, P2) the primary ventilatory support was non-invasive nCPAP.", [["the primary ventilatory support", "TREATMENT", 41, 72], ["non-invasive nCPAP", "TREATMENT", 77, 95], ["ventilatory support", "OBSERVATION", 53, 72]]], ["Criteria for inclusion in the cohorts were admission in the PICU for severe acute bronchiolitis and acute respiratory failure or respiratory syncytial virus (RSV)-related apnea events requiring ventilatory support, either in invasive mechanical ventilation (MV) or nCPAP mode.", [["respiratory", "ANATOMY", 106, 117], ["bronchiolitis", "DISEASE", 82, 95], ["acute respiratory failure", "DISEASE", 100, 125], ["respiratory syncytial virus", "DISEASE", 129, 156], ["RSV", "DISEASE", 158, 161], ["apnea", "DISEASE", 171, 176], ["respiratory syncytial virus", "ORGANISM", 129, 156], ["RSV", "ORGANISM", 158, 161], ["respiratory syncytial virus", "SPECIES", 129, 156], ["RSV", "SPECIES", 158, 161], ["MV", "SPECIES", 258, 260], ["severe acute bronchiolitis", "PROBLEM", 69, 95], ["acute respiratory failure", "PROBLEM", 100, 125], ["respiratory syncytial virus (RSV)", "PROBLEM", 129, 162], ["apnea events", "PROBLEM", 171, 183], ["ventilatory support", "TREATMENT", 194, 213], ["invasive mechanical ventilation", "TREATMENT", 225, 256], ["MV)", "TREATMENT", 258, 261], ["nCPAP mode", "TREATMENT", 265, 275], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["bronchiolitis", "OBSERVATION", 82, 95], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory failure", "OBSERVATION", 106, 125], ["respiratory syncytial virus", "OBSERVATION", 129, 156]]], ["Exclusion criteria included acute bronchiolitis stabilized with nasal oxygen supplementation only and patients with missing data.", [["nasal", "ANATOMY", 64, 69], ["bronchiolitis", "DISEASE", 34, 47], ["oxygen", "CHEMICAL", 70, 76], ["oxygen", "CHEMICAL", 70, 76], ["nasal", "ORGANISM_SUBDIVISION", 64, 69], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["acute bronchiolitis", "PROBLEM", 28, 47], ["nasal oxygen supplementation", "TREATMENT", 64, 92], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["bronchiolitis", "OBSERVATION", 34, 47], ["nasal", "ANATOMY", 64, 69], ["oxygen supplementation", "OBSERVATION", 70, 92]]], ["The study was approved by Ethical Review Board of the French Speaking Society of Intensive Care, which waived the need for informed consent based on the retrospective design of the study (n\u00b012-390).Data collectionFor each patient, the demographic data collected included age, gender, weight, gestational age, and presence of congenital heart disease (CHD), bronchopulmonary dysplasia (BPD), airway obstruction, or any other underlying disease.", [["heart", "ANATOMY", 336, 341], ["bronchopulmonary dysplasia", "ANATOMY", 357, 383], ["airway", "ANATOMY", 391, 397], ["congenital heart disease", "DISEASE", 325, 349], ["CHD", "DISEASE", 351, 354], ["bronchopulmonary dysplasia", "DISEASE", 357, 383], ["BPD", "DISEASE", 385, 388], ["airway obstruction", "DISEASE", 391, 409], ["patient", "ORGANISM", 222, 229], ["heart", "ORGAN", 336, 341], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 357, 383], ["airway", "MULTI-TISSUE_STRUCTURE", 391, 397], ["patient", "SPECIES", 222, 229], ["The study", "TEST", 0, 9], ["the study", "TEST", 177, 186], ["Data collection", "TEST", 198, 213], ["the demographic data", "TEST", 231, 251], ["weight", "TEST", 284, 290], ["congenital heart disease", "PROBLEM", 325, 349], ["CHD)", "PROBLEM", 351, 355], ["bronchopulmonary dysplasia (BPD)", "PROBLEM", 357, 389], ["airway obstruction", "PROBLEM", 391, 409], ["any other underlying disease", "PROBLEM", 414, 442], ["congenital", "OBSERVATION_MODIFIER", 325, 335], ["heart", "ANATOMY", 336, 341], ["disease", "OBSERVATION", 342, 349], ["bronchopulmonary", "ANATOMY", 357, 373], ["dysplasia", "OBSERVATION", 374, 383], ["airway", "ANATOMY", 391, 397], ["obstruction", "OBSERVATION", 398, 409], ["disease", "OBSERVATION", 435, 442]]], ["BPD was defined in accordance with recognized criteria [6] .", [["BPD", "DISEASE", 0, 3], ["BPD", "PROBLEM", 0, 3]]], ["Because of the retrospective design, pre-PICU admission data illustrating disease severity prior to the initiation of ventilatory support was composed of objective measures such as respiratory rate (RR), capillary partial pressure of carbon dioxide (PCO 2 ), pulse oximetry (SpO 2 ), and inspired fraction of inspired O 2 (FiO 2 ).", [["capillary", "ANATOMY", 204, 213], ["carbon dioxide", "CHEMICAL", 234, 248], ["carbon dioxide", "CHEMICAL", 234, 248], ["PCO 2", "CHEMICAL", 250, 255], ["O 2", "CHEMICAL", 318, 321], ["FiO 2 )", "CHEMICAL", 323, 330], ["capillary", "TISSUE", 204, 213], ["carbon dioxide", "SIMPLE_CHEMICAL", 234, 248], ["O 2", "SIMPLE_CHEMICAL", 318, 321], ["illustrating disease severity", "PROBLEM", 61, 90], ["ventilatory support", "TREATMENT", 118, 137], ["objective measures", "TREATMENT", 154, 172], ["respiratory rate", "TEST", 181, 197], ["RR", "TEST", 199, 201], ["capillary partial pressure of carbon dioxide", "TREATMENT", 204, 248], ["PCO", "TEST", 250, 253], ["pulse oximetry", "TEST", 259, 273]]], ["The PCR viral status, use of antibiotics, and pulmonary radiologic abnormalities on chest X-ray were also included.", [["pulmonary", "ANATOMY", 46, 55], ["pulmonary", "ORGAN", 46, 55], ["The PCR", "TEST", 0, 7], ["antibiotics", "TREATMENT", 29, 40], ["pulmonary radiologic abnormalities", "PROBLEM", 46, 80], ["chest X-ray", "TEST", 84, 95], ["pulmonary", "ANATOMY", 46, 55], ["chest", "ANATOMY", 84, 89]]], ["PICU stay data included measurements of maximum PCO 2 and minimum SpO 2 /FiO 2 ratio on the first day of admission.", [["SpO 2", "CHEMICAL", 66, 71], ["FiO 2", "CHEMICAL", 73, 78], ["maximum PCO", "TEST", 40, 51], ["minimum SpO", "TEST", 58, 69], ["FiO", "TEST", 73, 76]]], ["All invasive studies and access were collected, such as number of labs and chest X-rays during the PICU stay, and the need of central venous lines.", [["central venous lines", "ANATOMY", 126, 146], ["central venous lines", "CELL", 126, 146], ["central venous lines", "CELL_LINE", 126, 146], ["All invasive studies", "TEST", 0, 20], ["labs", "TEST", 66, 70], ["chest X-rays", "TEST", 75, 87], ["central venous lines", "TREATMENT", 126, 146], ["chest", "ANATOMY", 75, 80], ["central venous lines", "OBSERVATION", 126, 146]]], ["Healthcare-associated pneumonia were based on Centers for Disease Control and Prevention(CDC) criteria and defined by new onset of fever (temperature [38.5\u00b0C), new infiltrate(s) on chest X-ray, and positive tracheal aspirate culture when available.", [["chest", "ANATOMY", 181, 186], ["tracheal aspirate", "ANATOMY", 207, 224], ["pneumonia", "DISEASE", 22, 31], ["fever", "DISEASE", 131, 136], ["pneumonia", "PROBLEM", 22, 31], ["Disease Control", "TREATMENT", 58, 73], ["fever", "PROBLEM", 131, 136], ["temperature", "TEST", 138, 149], ["new infiltrate", "PROBLEM", 160, 174], ["chest X-ray", "TEST", 181, 192], ["positive tracheal aspirate culture", "TEST", 198, 232], ["pneumonia", "OBSERVATION", 22, 31], ["fever", "OBSERVATION", 131, 136], ["new", "OBSERVATION_MODIFIER", 160, 163], ["infiltrate", "OBSERVATION", 164, 174], ["chest", "ANATOMY", 181, 186], ["tracheal", "ANATOMY", 207, 215], ["aspirate", "OBSERVATION", 216, 224]]], ["Total length of ventilatory support (invasive alone, invasive ? nCPAP, or nCPAP alone) and PICU length of stay (LOS), post-PICU general ward LOS, and PICU readmission were all collected.Costs assessmentTotal costs were assessed using the institutional billing database.", [["Total length of ventilatory support", "TREATMENT", 0, 35], ["nCPAP", "TREATMENT", 64, 69], ["nCPAP", "TREATMENT", 74, 79], ["Costs assessment", "TEST", 186, 202]]], ["This global data includes all the associated costs, staff salaries, equipment, procedures, and amortization of premises.", [["procedures", "TREATMENT", 79, 89]]], ["This value is calculated for each hospital unit on the basis of actual expenses paid the previous year.Costs assessmentThe cost burden for both periods was estimated using the median LOS in PICU and general ward for each period.", [["This value", "TEST", 0, 10], ["Costs assessment", "TEST", 103, 119], ["The cost burden", "PROBLEM", 119, 134]]], ["We used the cost accounting from 2009, the most recent year available to estimate total cost using the following formula: total cost (Euros) = [mean PICU LOS (day) 9 PICU cost accounting] ? [mean general ward LOS (day) 9 general ward cost accounting].Routine management during P1 (1996-2000)All patients were admitted to the PICU within the first 24 h following general pediatric ward admission.", [["patients", "ORGANISM", 295, 303], ["patients", "SPECIES", 295, 303], ["total cost (Euros)", "TREATMENT", 122, 140], ["Routine management", "TREATMENT", 251, 269]]], ["When ventilatory support was mandated, endotracheal intubation was performed using either a cuffed or uncuffed endotracheal tube (Mallinckrodt TM , Covidien, Dublin, Ireland).", [["endotracheal", "ANATOMY", 39, 51], ["ventilatory support", "TREATMENT", 5, 24], ["endotracheal intubation", "TREATMENT", 39, 62], ["a cuffed or uncuffed endotracheal tube", "TREATMENT", 90, 128], ["Mallinckrodt TM", "TREATMENT", 130, 145], ["Covidien", "TREATMENT", 148, 156], ["endotracheal tube", "OBSERVATION", 111, 128]]], ["All infants were ventilated in a time-cycled, pressure-limited ventilation mode (Babylog 8000, Draeger Medical, L\u00fcbeck, Germany) in order to achieve a normal range of tidal volume (6-8 ml/kg) with an infant dual-heated ventilator circuit (Fisher and Paykel Healthcare, Auckland, New Zealand).", [["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["pressure-limited ventilation mode", "TREATMENT", 46, 79], ["tidal volume", "TEST", 167, 179], ["an infant dual-heated ventilator circuit", "TREATMENT", 197, 237]]], ["Sedation and neuromuscular blockade were used at the discretion of the attending physician.Routine management during P2 (2006-2010)All patients were admitted to the PICU within 24 h of initial hospitalization. nCPAP was applied in the case of acute respiratory failure defined by tachypnea ([2 SD for age) associated with a transcutaneous carbon dioxide pressure (P tc CO 2 ) of at least 50 mmHg and marked chest wall retraction, irrespective of SaO 2 level and/or inspiratory oxygen fraction and for RSV-related apnea events.", [["neuromuscular", "ANATOMY", 13, 26], ["respiratory", "ANATOMY", 249, 260], ["chest wall", "ANATOMY", 407, 417], ["neuromuscular blockade", "DISEASE", 13, 35], ["respiratory failure", "DISEASE", 249, 268], ["tachypnea", "DISEASE", 280, 289], ["carbon dioxide", "CHEMICAL", 339, 353], ["oxygen", "CHEMICAL", 477, 483], ["apnea", "DISEASE", 513, 518], ["nCPAP", "CHEMICAL", 210, 215], ["carbon dioxide", "CHEMICAL", 339, 353], ["CO 2", "CHEMICAL", 369, 373], ["SaO 2", "CHEMICAL", 446, 451], ["oxygen", "CHEMICAL", 477, 483], ["patients", "ORGANISM", 135, 143], ["chest wall", "MULTI-TISSUE_STRUCTURE", 407, 417], ["SaO 2", "GENE_OR_GENE_PRODUCT", 446, 451], ["oxygen", "SIMPLE_CHEMICAL", 477, 483], ["RSV", "ORGANISM", 501, 504], ["patients", "SPECIES", 135, 143], ["RSV", "SPECIES", 501, 504], ["Sedation", "TREATMENT", 0, 8], ["neuromuscular blockade", "TREATMENT", 13, 35], ["Routine management", "TREATMENT", 91, 109], ["nCPAP", "TREATMENT", 210, 215], ["acute respiratory failure", "PROBLEM", 243, 268], ["tachypnea", "PROBLEM", 280, 289], ["a transcutaneous carbon dioxide pressure", "TREATMENT", 322, 362], ["P tc CO", "TEST", 364, 371], ["marked chest wall retraction", "PROBLEM", 400, 428], ["SaO 2 level", "TEST", 446, 457], ["inspiratory oxygen fraction", "TEST", 465, 492], ["RSV", "PROBLEM", 501, 504], ["apnea events", "PROBLEM", 513, 525], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["respiratory failure", "OBSERVATION", 249, 268], ["tachypnea", "OBSERVATION", 280, 289], ["marked", "OBSERVATION_MODIFIER", 400, 406], ["chest", "ANATOMY", 407, 412], ["wall", "ANATOMY_MODIFIER", 413, 417], ["retraction", "OBSERVATION", 418, 428], ["inspiratory", "ANATOMY", 465, 476], ["oxygen fraction", "OBSERVATION", 477, 492]]], ["However, clinical conditions leading to emergency endotracheal intubation were considered if any of the following were present: cardiac arrest or hemodynamic instability, major respiratory acidosis (defined by a pH \u00a07.2), refractory apnea to nCPAP and caffeine and major altered consciousness.Routine management during P2 (2006-2010)nCPAP was delivered through nasal prongs (Fisher and Paykel Healthcare, Auckland, New Zealand) using an ICU ventilator (Babylog 8000 or Evita 2 Dura Neoflow; Draeger Medical, L\u00fcbeck, Germany) and a standard heated humidifier chamber (MR 290 model, Fisher and Paykel Healthcare, Auckland, New Zealand).", [["endotracheal", "ANATOMY", 50, 62], ["cardiac", "ANATOMY", 128, 135], ["respiratory", "ANATOMY", 177, 188], ["nasal", "ANATOMY", 361, 366], ["cardiac arrest", "DISEASE", 128, 142], ["hemodynamic instability", "DISEASE", 146, 169], ["respiratory acidosis", "DISEASE", 177, 197], ["apnea", "DISEASE", 233, 238], ["caffeine", "CHEMICAL", 252, 260], ["caffeine", "CHEMICAL", 252, 260], ["caffeine", "SIMPLE_CHEMICAL", 252, 260], ["clinical conditions", "PROBLEM", 9, 28], ["emergency endotracheal intubation", "TREATMENT", 40, 73], ["cardiac arrest", "PROBLEM", 128, 142], ["hemodynamic instability", "PROBLEM", 146, 169], ["major respiratory acidosis", "PROBLEM", 171, 197], ["a pH", "TEST", 210, 214], ["refractory apnea", "PROBLEM", 222, 238], ["nCPAP", "TREATMENT", 242, 247], ["caffeine", "TREATMENT", 252, 260], ["major altered consciousness", "PROBLEM", 265, 292], ["Routine management", "TREATMENT", 293, 311], ["nCPAP", "TREATMENT", 333, 338], ["nasal prongs", "TREATMENT", 361, 373], ["an ICU ventilator", "TREATMENT", 434, 451], ["Babylog", "TREATMENT", 453, 460], ["Evita 2 Dura Neoflow", "TREATMENT", 469, 489], ["a standard heated humidifier chamber (MR", "TREATMENT", 529, 569], ["cardiac", "ANATOMY", 128, 135], ["arrest", "OBSERVATION", 136, 142], ["hemodynamic instability", "OBSERVATION", 146, 169], ["respiratory acidosis", "OBSERVATION", 177, 197]]], ["In all patients, initial PEEP level of nCPAP was set at 7 cmH 2 O, previously identified as the optimal PEEP in the setting of acute viral bronchiolitis [7] . nCPAP was first performed continuously, then switched to alternate spontaneous breathing and nCPAP support at the discretion of the attending nurse.", [["bronchiolitis", "DISEASE", 139, 152], ["nCPAP", "CHEMICAL", 159, 164], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["initial PEEP level of nCPAP", "TREATMENT", 17, 44], ["the optimal PEEP", "TREATMENT", 92, 108], ["acute viral bronchiolitis", "PROBLEM", 127, 152], ["nCPAP", "TREATMENT", 159, 164], ["alternate spontaneous breathing", "TREATMENT", 216, 247], ["nCPAP support", "TREATMENT", 252, 265], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["bronchiolitis", "OBSERVATION", 139, 152]]], ["Duration of ventilatory support encompassed time on both continuous and intermittent nCPAP.", [["ventilatory support", "TREATMENT", 12, 31], ["intermittent nCPAP", "TREATMENT", 72, 90], ["ventilatory support", "OBSERVATION", 12, 31]]], ["Routine sedation was prohibited; however, if necessary, oral hydroxyzine (1 mg/kg 9 3 per day) or codeine (0.5 mg/kg 9 3 per day) was used.Routine management during P2 (2006-2010)In both period P1 and P2, all infants underwent routinely chest physiotherapy including increased exhalation technique and were fed enterally using a nasoduodenal tube.", [["oral", "ANATOMY", 56, 60], ["chest", "ANATOMY", 237, 242], ["nasoduodenal tube", "ANATOMY", 329, 346], ["hydroxyzine", "CHEMICAL", 61, 72], ["codeine", "CHEMICAL", 98, 105], ["hydroxyzine", "CHEMICAL", 61, 72], ["codeine", "CHEMICAL", 98, 105], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["hydroxyzine", "SIMPLE_CHEMICAL", 61, 72], ["codeine", "SIMPLE_CHEMICAL", 98, 105], ["infants", "ORGANISM", 209, 216], ["nasoduodenal tube", "TISSUE", 329, 346], ["infants", "SPECIES", 209, 216], ["Routine sedation", "TREATMENT", 0, 16], ["oral hydroxyzine", "TREATMENT", 56, 72], ["codeine", "TREATMENT", 98, 105], ["Routine management", "TREATMENT", 139, 157], ["routinely chest physiotherapy", "TREATMENT", 227, 256], ["increased exhalation technique", "TREATMENT", 267, 297], ["a nasoduodenal tube", "TREATMENT", 327, 346], ["chest", "ANATOMY", 237, 242], ["tube", "OBSERVATION", 342, 346]]], ["The decision to start antimicrobial drugs was left at the discretion of the attending physician.", [["antimicrobial drugs", "TREATMENT", 22, 41]]], ["Corticosteroids were not used routinely during both periods.", [["Corticosteroids", "TREATMENT", 0, 15]]], ["Bronchodilators or adrenaline were used mainly before PICU admission, more often during P1.Statistical analysisBaseline demographic data were expressed as number and percentage for binary or ordinary data, and means (SD) for continuous data unless skewed, in which case median and interquartile range (IQR) were reported.", [["adrenaline", "CHEMICAL", 19, 29], ["adrenaline", "CHEMICAL", 19, 29], ["adrenaline", "SIMPLE_CHEMICAL", 19, 29], ["Bronchodilators", "TREATMENT", 0, 15], ["adrenaline", "TREATMENT", 19, 29]]], ["Continuous data were compared using the Wilcoxon test and dichotomic data using the Fischer exact test.", [["the Wilcoxon test", "TEST", 36, 53], ["dichotomic data", "TEST", 58, 73], ["the Fischer exact test", "TEST", 80, 102]]], ["Time failure data (length of ventilatory support and length of stay) were summarized as medians and 95 % confidence interval (95 % CI).Statistical analysisSurvival curves for length of ventilatory support and length of stay were estimated on the basis of the whole cohort using the Kaplan-Meier method, then compared across period groups by using the log-rank test.", [["Time failure data", "PROBLEM", 0, 17], ["ventilatory support", "TREATMENT", 29, 48], ["Statistical analysisSurvival curves", "TEST", 135, 170], ["ventilatory support", "TREATMENT", 185, 204], ["the log-rank test", "TEST", 347, 364]]], ["We additionally adjusted survival analyses for prognostic baseline covariates (age, gestational age, PRISM score, RSV infection, antibiotic use), using a Cox model.", [["RSV infection", "DISEASE", 114, 127], ["RSV", "ORGANISM", 114, 117], ["RSV", "SPECIES", 114, 117], ["survival analyses", "TEST", 25, 42], ["prognostic baseline covariates", "PROBLEM", 47, 77], ["PRISM score", "PROBLEM", 101, 112], ["RSV infection", "PROBLEM", 114, 127], ["antibiotic use", "TREATMENT", 129, 143], ["a Cox model", "TREATMENT", 152, 163], ["RSV", "ANATOMY", 114, 117], ["infection", "OBSERVATION", 118, 127]]], ["Measures of the period effect for survival data were hazard ratios (HR).Statistical analysisFor secondary outcomes, we compared the number of chest X-rays, blood check exams, antimicrobial therapy, nutritional support route (enteral vs parenteral), healthcare-associated pneumonia, ARDS, pneumothorax events, and mortality rate using the Fisher test.Statistical analysisAll tests were two-tailed, with p values of 0.05 or less considered as statistically significant.Statistical analysisStatistical analysis was carried out with Stata 12 (StataCorp.", [["blood", "ANATOMY", 156, 161], ["pneumonia", "DISEASE", 271, 280], ["ARDS", "DISEASE", 282, 286], ["pneumothorax", "DISEASE", 288, 300], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["survival data", "TEST", 34, 47], ["Statistical analysis", "TEST", 72, 92], ["chest X-rays", "TEST", 142, 154], ["blood check exams", "TEST", 156, 173], ["antimicrobial therapy", "TREATMENT", 175, 196], ["nutritional support route", "TREATMENT", 198, 223], ["enteral vs parenteral)", "TREATMENT", 225, 247], ["pneumonia", "PROBLEM", 271, 280], ["ARDS", "PROBLEM", 282, 286], ["pneumothorax events", "PROBLEM", 288, 307], ["mortality rate", "TEST", 313, 327], ["the Fisher test", "TEST", 334, 349], ["Statistical analysis", "TEST", 350, 370], ["All tests", "TEST", 370, 379], ["p values", "TEST", 402, 410], ["Statistical analysisStatistical analysis", "TEST", 467, 507], ["chest", "ANATOMY", 142, 147], ["pneumonia", "OBSERVATION", 271, 280], ["ARDS", "OBSERVATION", 282, 286], ["pneumothorax", "OBSERVATION", 288, 300], ["significant", "OBSERVATION_MODIFIER", 455, 466]]], ["LP).PatientsDuring the early period P1, there were 193 cases of severe acute viral bronchiolitis in 186 infants, and 332 bronchiolitis episodes in 325 infants during P2.", [["bronchiolitis", "DISEASE", 83, 96], ["bronchiolitis", "DISEASE", 121, 134], ["infants", "ORGANISM", 104, 111], ["infants", "ORGANISM", 151, 158], ["infants", "SPECIES", 104, 111], ["infants", "SPECIES", 151, 158], ["LP", "TEST", 0, 2], ["severe acute viral bronchiolitis", "PROBLEM", 64, 96], ["332 bronchiolitis episodes", "PROBLEM", 117, 143], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["bronchiolitis", "OBSERVATION", 83, 96], ["bronchiolitis", "OBSERVATION", 121, 134]]], ["Seventeen patients were excluded because of missing data during P1 and five during P2.", [["patients", "ORGANISM", 10, 18], ["P1", "DNA", 64, 66], ["P2", "DNA", 83, 85], ["patients", "SPECIES", 10, 18], ["missing data during P1 and five during P2", "PROBLEM", 44, 85]]], ["The percentage of invasive ventilation (IV) dramatically decreases from 2003 with a concomitant increase of the use of nCPAP.", [["invasive ventilation (IV)", "TREATMENT", 18, 43], ["nCPAP", "TREATMENT", 119, 124], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["invasive ventilation", "OBSERVATION", 18, 38], ["increase", "OBSERVATION_MODIFIER", 96, 104]]], ["The percentage of infants without any ventilatory support staying in spontaneous breath during all the PICU LOS remains stable over the whole period (Fig. 1) .PatientsBaseline characteristics were similar between the two periods, as summarized in Table 1 .", [["infants", "ORGANISM", 18, 25], ["Patients", "ORGANISM", 159, 167], ["infants", "SPECIES", 18, 25], ["Patients", "SPECIES", 159, 167], ["any ventilatory support", "TREATMENT", 34, 57], ["spontaneous breath", "PROBLEM", 69, 87], ["stable", "OBSERVATION_MODIFIER", 120, 126]]], ["Prematurity was the most frequent underlying disease, with 70 (37.6 \u00b1 3.4 %) affected infants during P1 and 111 (34.1 \u00b1 3.4 %) infants during P2.", [["Prematurity", "DISEASE", 0, 11], ["infants", "ORGANISM", 86, 93], ["infants", "ORGANISM", 127, 134], ["infants", "SPECIES", 86, 93], ["infants", "SPECIES", 127, 134], ["Prematurity", "PROBLEM", 0, 11], ["the most frequent underlying disease", "PROBLEM", 16, 52], ["P1", "TEST", 101, 103], ["most frequent", "OBSERVATION_MODIFIER", 20, 33], ["disease", "OBSERVATION", 45, 52]]], ["The number of infants with a history of any CHD was higher during P1 (12 versus 4).Respiratory managementMost infants were ventilated before PICU admission: during P1, 81 % were intubated before PICU admission and during P2, 67 % had ventilatory support with either nCPAP (55 %) or mechanical ventilation (12 %).", [["CHD", "DISEASE", 44, 47], ["infants", "ORGANISM", 14, 21], ["infants", "ORGANISM", 110, 117], ["infants", "SPECIES", 14, 21], ["infants", "SPECIES", 110, 117], ["any CHD", "PROBLEM", 40, 47], ["Respiratory management", "TREATMENT", 83, 105], ["intubated", "TREATMENT", 178, 187], ["ventilatory support", "TREATMENT", 234, 253], ["nCPAP", "TREATMENT", 266, 271], ["mechanical ventilation", "TREATMENT", 282, 304]]], ["All respiratory parameters are summarized in Table 2 .", [["respiratory", "ANATOMY", 4, 15]]], ["During P2, there was a significant decrease in the length of ventilatory support relative to P1: the median (95 % CI) length of ventilator support was respectively 6.0 (5.3-6.7) days for P1 and 3.0 (2.7-3.3) days for P2.", [["P2", "DNA", 7, 9], ["a significant decrease", "PROBLEM", 21, 43], ["ventilatory support", "TREATMENT", 61, 80], ["length", "TEST", 118, 124], ["ventilator support", "TEST", 128, 146], ["P1", "TEST", 187, 189], ["P2", "PROBLEM", 217, 219], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["decrease", "OBSERVATION_MODIFIER", 35, 43], ["length", "OBSERVATION_MODIFIER", 51, 57]]], ["This reduction was strongly associated with the period and nCPAP with an HR of 1.83 (1.53-2.19), p \u00a00.001 (Fig. 2a) .", [["nCPAP", "TREATMENT", 59, 64], ["an HR", "TEST", 70, 75]]], ["This effect remains significant after adjustment for prognostic baseline covariates: PRISM score, age, gestational age, RSV infection, and antibiotics [HR (95 % CI) = 1.76 (1.45-2.14), p \u00a00.001] (Fig. 2b) .Respiratory managementFurthermore, nCPAP was associated with a low rate of treatment failure between 15 and 3 % in the most recent year, illustrating the success of nCPAP implementation in clinical practice.", [["RSV infection", "DISEASE", 120, 133], ["RSV", "ORGANISM", 120, 123], ["RSV", "SPECIES", 120, 123], ["PRISM score", "TEST", 85, 96], ["RSV infection", "PROBLEM", 120, 133], ["antibiotics", "TREATMENT", 139, 150], ["HR", "TEST", 152, 154], ["CI", "TEST", 161, 163], ["Respiratory managementFurthermore", "TREATMENT", 206, 239], ["nCPAP", "TREATMENT", 241, 246], ["a low rate of treatment failure", "PROBLEM", 267, 298], ["nCPAP implementation", "TREATMENT", 371, 391], ["RSV infection", "OBSERVATION", 120, 133]]], ["Even in the case of nCPAP failure during P2, the length of invasive ventilatory support was shorter compared to P1 (Table 2) .Respiratory managementComplications and associated therapy during PICU stay A significant reduction in PICU LOS of 3 days was observed between P1 and P2.", [["P2", "DNA", 276, 278], ["nCPAP failure", "PROBLEM", 20, 33], ["invasive ventilatory support", "TREATMENT", 59, 87], ["Respiratory management", "TREATMENT", 126, 148], ["nCPAP failure", "OBSERVATION", 20, 33], ["invasive", "OBSERVATION_MODIFIER", 59, 67], ["ventilatory support", "OBSERVATION", 68, 87], ["significant", "OBSERVATION_MODIFIER", 204, 215], ["reduction", "OBSERVATION_MODIFIER", 216, 225]]], ["During P2, we observed a significant decrease in the total hospital LOS of 5.9 days.", [["P2", "DNA", 7, 9], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["decrease", "OBSERVATION_MODIFIER", 37, 45]]], ["Moreover, the reduction in PICU LOS was not associated with an increased number of readmissions to the PICU as demonstrated by similar rates of readmission between P1 and P2, (3.1 and 4 % respectively).Cost assessmentThe billing costs used in this study, obtained from the hospital cost accounting reports, were an average of 1,806 \u20ac ($2,408) per day of PICU care and 1,198 \u20ac ($1,597) per day of general ward care.", [["Cost assessment", "TEST", 202, 217], ["this study", "TEST", 243, 253], ["general ward care", "TREATMENT", 396, 413], ["reduction", "OBSERVATION_MODIFIER", 14, 23], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["We did not measure the individual costs.", [["individual", "OBSERVATION_MODIFIER", 23, 33], ["costs", "OBSERVATION", 34, 39]]], ["With the reduction in length of both PICU and general pediatric ward stay, we calculated a total cost reduction during P2 of 715,000 \u20ac ($950,000) per year and of 3,575,000 \u20ac ($4,750,000) for the whole 4-year period (Table 4 ).DiscussionThis study evaluated changes in the management of severe acute bronchiolitis in more than 500 infants over two distinct periods.", [["bronchiolitis", "DISEASE", 299, 312], ["infants", "SPECIES", 330, 337], ["a total cost reduction", "TREATMENT", 89, 111], ["DiscussionThis study", "TEST", 226, 246], ["the management", "TREATMENT", 268, 282], ["severe acute bronchiolitis", "PROBLEM", 286, 312], ["reduction", "OBSERVATION_MODIFIER", 9, 18], ["length", "OBSERVATION_MODIFIER", 22, 28], ["severe", "OBSERVATION_MODIFIER", 286, 292], ["acute", "OBSERVATION_MODIFIER", 293, 298], ["bronchiolitis", "OBSERVATION", 299, 312]]], ["There is a significant change in the global management of these infants and the major change in practice is the modification of ventilatory support with the use of a pre-emptive nCPAP strategy in severe bronchiolitis.", [["bronchiolitis", "DISEASE", 203, 216], ["infants", "ORGANISM", 64, 71], ["infants", "SPECIES", 64, 71], ["a significant change", "PROBLEM", 9, 29], ["ventilatory support", "TREATMENT", 128, 147], ["a pre-emptive nCPAP strategy", "TREATMENT", 164, 192], ["severe bronchiolitis", "PROBLEM", 196, 216], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["change", "OBSERVATION_MODIFIER", 23, 29], ["global", "OBSERVATION_MODIFIER", 37, 43], ["management", "OBSERVATION_MODIFIER", 44, 54], ["major", "OBSERVATION_MODIFIER", 80, 85], ["change", "OBSERVATION_MODIFIER", 86, 92], ["ventilatory support", "OBSERVATION", 128, 147], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["bronchiolitis", "OBSERVATION", 203, 216]]], ["This new management is associated with a significant improvement in supportive care as reflected by a dramatic reduction of the use of invasive mechanical ventilation, length of any respiratory support, PICU and hospital LOS, and economic burden.", [["respiratory", "ANATOMY", 182, 193], ["supportive care", "TREATMENT", 68, 83], ["invasive mechanical ventilation", "TREATMENT", 135, 166], ["any respiratory support", "TREATMENT", 178, 201], ["economic burden", "PROBLEM", 230, 245], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["improvement", "OBSERVATION", 53, 64], ["dramatic", "OBSERVATION_MODIFIER", 102, 110], ["reduction", "OBSERVATION_MODIFIER", 111, 120], ["mechanical ventilation", "OBSERVATION", 144, 166]]], ["Severe acute bronchiolitis is a potentially life-threatening respiratory condition that affects infants in predictable seasonal epidemics.", [["respiratory", "ANATOMY", 61, 72], ["bronchiolitis", "DISEASE", 13, 26], ["infants", "ORGANISM", 96, 103], ["infants", "SPECIES", 96, 103], ["Severe acute bronchiolitis", "PROBLEM", 0, 26], ["threatening respiratory condition", "PROBLEM", 49, 82], ["predictable seasonal epidemics", "PROBLEM", 107, 137], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["bronchiolitis", "OBSERVATION", 13, 26], ["respiratory condition", "OBSERVATION", 61, 82], ["predictable", "OBSERVATION_MODIFIER", 107, 118], ["seasonal", "OBSERVATION_MODIFIER", 119, 127], ["epidemics", "OBSERVATION", 128, 137]]], ["Hospital admission rates in the USA and Europe are reported to be between 20 and 30 per 1,000 for children under 1 year [8] [9] [10] .", [["children", "ORGANISM", 98, 106], ["children", "SPECIES", 98, 106]]], ["PICU admission rates range from 4 to 15 % for healthy infants and this percentage increases accordingly with the presence of comorbidities [11] .", [["infants", "ORGANISM", 54, 61], ["infants", "SPECIES", 54, 61], ["PICU admission rates", "TEST", 0, 20], ["comorbidities", "PROBLEM", 125, 138]]], ["The treatment of severe bronchiolitis is mainly supportive [12] .", [["bronchiolitis", "DISEASE", 24, 37], ["severe bronchiolitis", "PROBLEM", 17, 37], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["bronchiolitis", "OBSERVATION", 24, 37]]], ["Invasive ventilation is still frequently used to support these infants, but it is associated with significant airway and infectious adverse events [13] .", [["airway", "ANATOMY", 110, 116], ["infants", "ORGANISM", 63, 70], ["airway", "MULTI-TISSUE_STRUCTURE", 110, 116], ["infants", "SPECIES", 63, 70], ["Invasive ventilation", "TREATMENT", 0, 20], ["significant airway and infectious adverse events", "PROBLEM", 98, 146], ["ventilation", "OBSERVATION", 9, 20], ["airway", "ANATOMY", 110, 116], ["infectious", "OBSERVATION", 121, 131]]], ["In observational studies, early use of nCPAP was associated with a significant decrease in both RR and PCO 2 , suggesting that nCPAP might be an effective ventilation strategy in moderate to severe bronchiolitis with a low rate of failure [14] [15] [16] [17] [18] [19] [20] .", [["bronchiolitis", "DISEASE", 198, 211], ["[14] [15] [16] [17] [18] [19] [20]", "CHEMICAL", 239, 273], ["[14] [15] [16] [17] [18] [19] [20]", "SIMPLE_CHEMICAL", 239, 273], ["observational studies", "TEST", 3, 24], ["nCPAP", "TREATMENT", 39, 44], ["a significant decrease", "PROBLEM", 65, 87], ["PCO", "TEST", 103, 106], ["nCPAP", "TREATMENT", 127, 132], ["an effective ventilation strategy", "TREATMENT", 142, 175], ["moderate to severe bronchiolitis", "PROBLEM", 179, 211], ["a low rate of failure", "PROBLEM", 217, 238], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["decrease", "OBSERVATION_MODIFIER", 79, 87], ["moderate", "OBSERVATION_MODIFIER", 179, 187], ["severe", "OBSERVATION_MODIFIER", 191, 197], ["bronchiolitis", "OBSERVATION", 198, 211]]], ["In addition, nCPAP failure does not seem to be associated with a worse evolution.", [["nCPAP", "CHEMICAL", 13, 18], ["nCPAP failure", "PROBLEM", 13, 26], ["nCPAP failure", "OBSERVATION", 13, 26], ["does not seem to be", "UNCERTAINTY", 27, 46], ["worse", "OBSERVATION_MODIFIER", 65, 70], ["evolution", "OBSERVATION_MODIFIER", 71, 80]]], ["Moreover, recent physiological studies demonstrated that severe bronchiolitis is associated with increased work of breathing, as reflected by high levels of diaphragmatic and esophageal pressure-time products, and significantly improved with application of a continuous PEEP [7, 21, 22] .", [["diaphragmatic", "ANATOMY", 157, 170], ["esophageal", "ANATOMY", 175, 185], ["bronchiolitis", "DISEASE", 64, 77], ["diaphragmatic", "ORGAN", 157, 170], ["esophageal", "ORGAN", 175, 185], ["recent physiological studies", "TEST", 10, 38], ["severe bronchiolitis", "PROBLEM", 57, 77], ["increased work of breathing", "PROBLEM", 97, 124], ["diaphragmatic and esophageal pressure", "TREATMENT", 157, 194], ["a continuous PEEP", "TREATMENT", 257, 274], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["bronchiolitis", "OBSERVATION", 64, 77], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["work of breathing", "OBSERVATION", 107, 124], ["diaphragmatic", "ANATOMY", 157, 170], ["esophageal", "ANATOMY", 175, 185], ["pressure", "OBSERVATION_MODIFIER", 186, 194], ["significantly", "OBSERVATION_MODIFIER", 214, 227], ["improved", "OBSERVATION_MODIFIER", 228, 236]]], ["To our knowledge, this is the first study which clearly demonstrates the clinical and economic benefit of nCPAP in severe acute bronchiolitis.", [["bronchiolitis", "DISEASE", 128, 141], ["the first study", "TEST", 26, 41], ["nCPAP", "TREATMENT", 106, 111], ["severe acute bronchiolitis", "PROBLEM", 115, 141], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["bronchiolitis", "OBSERVATION", 128, 141]]], ["This large observational cohort study, with more than 300 cases of nCPAP, found that nCPAP is independently associated with a shorter duration of ventilatory support, PICU LOS, and hospital LOS.", [["This large observational cohort study", "TEST", 0, 37], ["nCPAP", "TREATMENT", 67, 72], ["nCPAP", "TREATMENT", 85, 90], ["ventilatory support", "TREATMENT", 146, 165], ["nCPAP", "OBSERVATION", 85, 90]]], ["These findings confirm previous observational studies which showed a similar reduction in time of ventilatory support of 2-3 days [17, 18, 23] .DiscussionThe second period is associated with significant changes in the overall clinical management of infants with acute bronchiolitis.", [["bronchiolitis", "DISEASE", 268, 281], ["infants", "ORGANISM", 249, 256], ["infants", "SPECIES", 249, 256], ["previous observational studies", "TEST", 23, 53], ["a similar reduction", "TREATMENT", 67, 86], ["ventilatory support", "TREATMENT", 98, 117], ["significant changes", "PROBLEM", 191, 210], ["acute bronchiolitis", "PROBLEM", 262, 281], ["similar", "OBSERVATION_MODIFIER", 69, 76], ["reduction", "OBSERVATION_MODIFIER", 77, 86], ["associated with", "UNCERTAINTY", 175, 190], ["significant", "OBSERVATION_MODIFIER", 191, 202], ["changes", "OBSERVATION", 203, 210], ["acute", "OBSERVATION_MODIFIER", 262, 267], ["bronchiolitis", "OBSERVATION", 268, 281]]], ["One of the most relevant changes was the significant decrease in the number of chest X-rays performed between the two periods.", [["chest X-rays", "TEST", 79, 91], ["most relevant", "OBSERVATION_MODIFIER", 11, 24], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["decrease", "OBSERVATION_MODIFIER", 53, 61], ["chest", "ANATOMY", 79, 84]]], ["Although current guidelines do not recommend its use for the diagnosis and follow-up of bronchiolitis, most emergency departments and PICUs are still performing systematic chest X-rays, particularly in the most critically ill patients.", [["bronchiolitis", "DISEASE", 88, 101], ["critically ill", "DISEASE", 211, 225], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["bronchiolitis", "PROBLEM", 88, 101], ["systematic chest X-rays", "TEST", 161, 184], ["bronchiolitis", "OBSERVATION", 88, 101], ["chest", "ANATOMY", 172, 177]]], ["Children are four times more sensitive than adults to the ionizing radiation with an accordingly elevated risk of delayed cancer, given their more active cell proliferation.", [["cancer", "ANATOMY", 122, 128], ["cell", "ANATOMY", 154, 158], ["cancer", "DISEASE", 122, 128], ["Children", "ORGANISM", 0, 8], ["cancer", "CANCER", 122, 128], ["cell", "CELL", 154, 158], ["Children", "SPECIES", 0, 8], ["the ionizing radiation", "TREATMENT", 54, 76], ["delayed cancer", "PROBLEM", 114, 128], ["their more active cell proliferation", "PROBLEM", 136, 172], ["delayed", "OBSERVATION_MODIFIER", 114, 121], ["cancer", "OBSERVATION", 122, 128], ["active", "OBSERVATION_MODIFIER", 147, 153], ["cell proliferation", "OBSERVATION", 154, 172]]], ["Shu et al. [24] reported that children with three or more postnatal X-rays had a 1.5-2 times higher risk of cancer compared to those who were never exposed.DiscussionApart from affecting PICU and hospital LOS, we noted that several associated therapies such antibiotics, chest X-rays, number of labs drawn, use of central venous catheters, blood transfusions, and parenteral nutrition were significantly reduced during the second period.", [["cancer", "ANATOMY", 108, 114], ["central venous", "ANATOMY", 314, 328], ["blood", "ANATOMY", 340, 345], ["parenteral", "ANATOMY", 364, 374], ["cancer", "DISEASE", 108, 114], ["children", "ORGANISM", 30, 38], ["cancer", "CANCER", 108, 114], ["central venous", "MULTI-TISSUE_STRUCTURE", 314, 328], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["children", "SPECIES", 30, 38], ["cancer", "PROBLEM", 108, 114], ["antibiotics", "TREATMENT", 258, 269], ["chest X-rays", "TEST", 271, 283], ["labs", "TEST", 295, 299], ["central venous catheters", "TREATMENT", 314, 338], ["blood transfusions", "TREATMENT", 340, 358], ["parenteral nutrition", "TREATMENT", 364, 384], ["cancer", "OBSERVATION", 108, 114], ["chest", "ANATOMY", 271, 276], ["central venous", "ANATOMY", 314, 328], ["catheters", "OBSERVATION", 329, 338]]], ["Bronchiolitis with fever has been associated with a lower risk of bacteremia (0.2 %) compared to children with a fever of unknown origin (2-7 %) [25] .", [["Bronchiolitis", "DISEASE", 0, 13], ["fever", "DISEASE", 19, 24], ["bacteremia", "DISEASE", 66, 76], ["fever", "DISEASE", 113, 118], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["Bronchiolitis", "PROBLEM", 0, 13], ["fever", "PROBLEM", 19, 24], ["bacteremia", "PROBLEM", 66, 76], ["a fever of unknown origin", "PROBLEM", 111, 136], ["fever", "OBSERVATION", 19, 24], ["lower", "OBSERVATION_MODIFIER", 52, 57], ["bacteremia", "OBSERVATION", 66, 76], ["fever", "OBSERVATION", 113, 118]]], ["Although antimicrobial therapy is no longer recommended for bronchiolitis, it is commonly used in hospitalized children, with a rate varying widely between 34 and 99 % For each PICU stay, the billing cost was assessed using the hospital cost accounting reports given per day of stay [26, 27] .", [["bronchiolitis", "DISEASE", 60, 73], ["children", "ORGANISM", 111, 119], ["children", "SPECIES", 111, 119], ["antimicrobial therapy", "TREATMENT", 9, 30], ["bronchiolitis", "PROBLEM", 60, 73], ["a rate", "TEST", 126, 132], ["no longer", "UNCERTAINTY", 34, 43], ["bronchiolitis", "OBSERVATION", 60, 73]]], ["In addition, infants with bronchiolitis requiring invasive mechanical ventilation have high rates of bacterial co-infection varying from 21 to 26 % [28, 29] and Kneyber et al. [29] reported antibiotic usage reaching 95 % in these setting.", [["bronchiolitis", "DISEASE", 26, 39], ["bacterial co-infection", "DISEASE", 101, 123], ["infants", "ORGANISM", 13, 20], ["infants", "SPECIES", 13, 20], ["bronchiolitis", "PROBLEM", 26, 39], ["invasive mechanical ventilation", "TREATMENT", 50, 81], ["bacterial co-infection", "PROBLEM", 101, 123], ["antibiotic usage", "TREATMENT", 190, 206], ["bronchiolitis", "OBSERVATION", 26, 39]]], ["In our series, the decrease in antibiotics use from 58 to 30 %, between the two periods, is partly due to increased physician awareness of the potential harmful effects of antibiotic selection pressure.", [["the decrease in antibiotics", "TREATMENT", 15, 42], ["antibiotic selection pressure", "TREATMENT", 172, 201], ["decrease", "OBSERVATION_MODIFIER", 19, 27], ["antibiotics", "OBSERVATION_MODIFIER", 31, 42]]], ["Nevertheless, we could not exclude a relationship between increasing use of nCPAP as a standard of care and the decrease in healthcare-associated pneumonia from 24 to 10 % [26] .", [["pneumonia", "DISEASE", 146, 155], ["nCPAP", "TREATMENT", 76, 81], ["a standard of care", "TREATMENT", 85, 103], ["pneumonia", "PROBLEM", 146, 155], ["decrease", "OBSERVATION_MODIFIER", 112, 120], ["pneumonia", "OBSERVATION", 146, 155]]], ["Similarly, in adults, non-invasive ventilation (NIV) was shown to decrease significantly the rate of nosocomial bacterial pneumonia from 20 to 8 % [30] .", [["pneumonia", "DISEASE", 122, 131], ["non-invasive ventilation (NIV", "TREATMENT", 22, 51], ["nosocomial bacterial pneumonia", "PROBLEM", 101, 131], ["nosocomial", "OBSERVATION_MODIFIER", 101, 111], ["bacterial", "OBSERVATION_MODIFIER", 112, 121], ["pneumonia", "OBSERVATION", 122, 131]]], ["This study highlights the fact that although there has been a change in the approach to ventilator support over time, there has also been a significant change in many aspects of the overall management of PICU patients between those two decades that can moderate the conclusion.DiscussionBronchiolitis is known to be the leading cause of hospitalization for infants less than 1 year old, but data on the economic burden of bronchiolitis hospitalizations are limited.", [["Bronchiolitis", "DISEASE", 287, 300], ["bronchiolitis", "DISEASE", 422, 435], ["patients", "ORGANISM", 209, 217], ["infants", "ORGANISM", 357, 364], ["patients", "SPECIES", 209, 217], ["infants", "SPECIES", 357, 364], ["This study", "TEST", 0, 10], ["ventilator support", "TREATMENT", 88, 106], ["Bronchiolitis", "PROBLEM", 287, 300], ["bronchiolitis hospitalizations", "PROBLEM", 422, 452], ["change", "OBSERVATION_MODIFIER", 62, 68], ["significant", "OBSERVATION_MODIFIER", 140, 151], ["change", "OBSERVATION_MODIFIER", 152, 158], ["many", "OBSERVATION_MODIFIER", 162, 166], ["moderate", "OBSERVATION_MODIFIER", 253, 261], ["Bronchiolitis", "OBSERVATION", 287, 300], ["bronchiolitis", "OBSERVATION", 422, 435]]], ["In 2002, in the USA, bronchiolitis hospitalizations accounted for 21.1 % of children less than 1 year old with an annual direct medical cost of approximately $543 million.", [["bronchiolitis", "DISEASE", 21, 34], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["bronchiolitis hospitalizations", "PROBLEM", 21, 51], ["bronchiolitis", "OBSERVATION", 21, 34]]], ["Younger age, male gender, mechanical ventilation, and co-diagnosis of pneumonia were all markers predictive of higher hospitalization cost and longer hospital LOS [31] .", [["pneumonia", "DISEASE", 70, 79], ["mechanical ventilation", "TREATMENT", 26, 48], ["pneumonia", "PROBLEM", 70, 79], ["mechanical ventilation", "OBSERVATION", 26, 48], ["pneumonia", "OBSERVATION", 70, 79]]], ["The use of NIV in adults with acute exacerbation of chronic obstructive disease significantly increased between 1998 and 2008 and was associated with clinical improvement and decrease in LOS [32] .", [["chronic obstructive disease", "DISEASE", 52, 79], ["NIV", "CHEMICAL", 11, 14], ["NIV", "TREATMENT", 11, 14], ["acute exacerbation", "PROBLEM", 30, 48], ["chronic obstructive disease", "PROBLEM", 52, 79], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["exacerbation", "OBSERVATION", 36, 48], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["obstructive", "OBSERVATION", 60, 71], ["increased", "OBSERVATION_MODIFIER", 94, 103], ["decrease", "OBSERVATION_MODIFIER", 175, 183]]], ["To our knowledge, our study is the first to evaluate the economic impact of nCPAP in children.", [["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93], ["our study", "TEST", 18, 27], ["nCPAP", "TREATMENT", 76, 81], ["nCPAP", "OBSERVATION", 76, 81]]], ["ICU admissions for severe bronchiolitis comprise only a small proportion of all bronchiolitis cases, but account for a larger proportion of all bronchiolitis-related hospitalization charges.", [["bronchiolitis", "DISEASE", 26, 39], ["bronchiolitis", "DISEASE", 80, 93], ["bronchiolitis", "DISEASE", 144, 157], ["severe bronchiolitis", "PROBLEM", 19, 39], ["all bronchiolitis cases", "PROBLEM", 76, 99], ["all bronchiolitis", "PROBLEM", 140, 157], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["bronchiolitis", "OBSERVATION", 26, 39], ["small", "OBSERVATION_MODIFIER", 56, 61], ["proportion", "OBSERVATION_MODIFIER", 62, 72], ["all", "OBSERVATION_MODIFIER", 76, 79], ["bronchiolitis", "OBSERVATION", 80, 93], ["larger", "OBSERVATION_MODIFIER", 119, 125], ["proportion", "OBSERVATION_MODIFIER", 126, 136], ["all", "OBSERVATION_MODIFIER", 140, 143], ["bronchiolitis", "OBSERVATION", 144, 157]]], ["In the USA, some authors demonstrate that bronchiolitis managed with invasive mechanical ventilation is associated with costs 6-9 times higher than when managed without any ventilatory support [33] [34] [35] .", [["bronchiolitis", "DISEASE", 42, 55], ["bronchiolitis", "PROBLEM", 42, 55], ["invasive mechanical ventilation", "TREATMENT", 69, 100], ["costs", "TEST", 120, 125], ["any ventilatory support", "TREATMENT", 169, 192], ["bronchiolitis", "OBSERVATION", 42, 55], ["invasive", "OBSERVATION_MODIFIER", 69, 77], ["mechanical ventilation", "OBSERVATION", 78, 100]]], ["In this study, we further demonstrate that nCPAP is a costeffective strategy with a trend to reduction of the total economic burden, mostly owing to a significant decrease in PICU and hospital LOS as actual individual costs could not be measured.DiscussionWe are aware that the before-after study design limits the ability to assess whether nCPAP as the first ventilatory support therapy is superior to invasive ventilation and it was not the objective.", [["nCPAP", "CHEMICAL", 43, 48], ["this study", "TEST", 3, 13], ["nCPAP", "TREATMENT", 43, 48], ["a costeffective strategy", "TREATMENT", 52, 76], ["the total economic burden", "PROBLEM", 106, 131], ["nCPAP", "TREATMENT", 341, 346], ["the first ventilatory support therapy", "TREATMENT", 350, 387], ["invasive ventilation", "TREATMENT", 403, 423], ["nCPAP", "OBSERVATION", 43, 48], ["total", "OBSERVATION_MODIFIER", 110, 115], ["economic", "OBSERVATION_MODIFIER", 116, 124], ["burden", "OBSERVATION", 125, 131], ["significant", "OBSERVATION_MODIFIER", 151, 162], ["decrease", "OBSERVATION_MODIFIER", 163, 171]]], ["Thus, this large descriptive study, even with some methodological limitations, highlights that nCPAP used as a pre-emptive treatment strategy is associated with significant reduction of the percentage of invasive ventilation requirement and treatment invasiveness.", [["this large descriptive study", "TEST", 6, 34], ["nCPAP", "TREATMENT", 95, 100], ["a pre-emptive treatment strategy", "TREATMENT", 109, 141], ["invasive ventilation requirement", "TREATMENT", 204, 236], ["treatment invasiveness", "TREATMENT", 241, 263], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["reduction", "OBSERVATION_MODIFIER", 173, 182], ["percentage", "OBSERVATION_MODIFIER", 190, 200], ["invasive", "OBSERVATION_MODIFIER", 204, 212], ["ventilation requirement", "OBSERVATION", 213, 236]]], ["The percentage of patients without any ventilatory support remains stable over the whole period, before the use of nCPAP and after the implementation of nCPAP as a pre-emptive ventilatory strategy in our unit (Fig. 1 ).", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["any ventilatory support", "TREATMENT", 35, 58], ["nCPAP", "TREATMENT", 115, 120], ["nCPAP", "TREATMENT", 153, 158], ["a pre-emptive ventilatory strategy", "TREATMENT", 162, 196], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["stable", "OBSERVATION", 67, 73]]], ["This suggests that the nCPAP was not used for infants who in fact did not require any ventilatory support and allowed us to suggest that nCPAP is associated with a reduction of the total economic burden of severe bronchiolitis.", [["bronchiolitis", "DISEASE", 213, 226], ["infants", "ORGANISM", 46, 53], ["infants", "SPECIES", 46, 53], ["the nCPAP", "TREATMENT", 19, 28], ["any ventilatory support", "TREATMENT", 82, 105], ["nCPAP", "TREATMENT", 137, 142], ["severe bronchiolitis", "PROBLEM", 206, 226], ["nCPAP", "OBSERVATION", 23, 28], ["nCPAP", "OBSERVATION", 137, 142], ["reduction", "OBSERVATION_MODIFIER", 164, 173], ["total", "OBSERVATION_MODIFIER", 181, 186], ["economic", "OBSERVATION_MODIFIER", 187, 195], ["severe", "OBSERVATION_MODIFIER", 206, 212], ["bronchiolitis", "OBSERVATION", 213, 226]]], ["We chose to analyze this effect in two different periods because, as shown in Fig. 1ConclusionThis is the first large study describing the cost-effectiveness of nCPAP in the management of severe acute bronchiolitis.", [["bronchiolitis", "DISEASE", 201, 214], ["nCPAP", "TREATMENT", 161, 166], ["the management", "TREATMENT", 170, 184], ["severe acute bronchiolitis", "PROBLEM", 188, 214], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["bronchiolitis", "OBSERVATION", 201, 214]]], ["Thus, it appears that the new global management with the early use of nCPAP is associated with a clear reduction in treatment invasiveness and complications, as well as a significant reduction in the economic burden of severe bronchiolitis.", [["bronchiolitis", "DISEASE", 226, 239], ["nCPAP", "TREATMENT", 70, 75], ["treatment invasiveness", "TREATMENT", 116, 138], ["complications", "PROBLEM", 143, 156], ["a significant reduction", "PROBLEM", 169, 192], ["severe bronchiolitis", "PROBLEM", 219, 239], ["new", "OBSERVATION_MODIFIER", 26, 29], ["global", "OBSERVATION_MODIFIER", 30, 36], ["reduction", "OBSERVATION_MODIFIER", 103, 112], ["significant", "OBSERVATION_MODIFIER", 171, 182], ["reduction", "OBSERVATION_MODIFIER", 183, 192], ["economic", "OBSERVATION_MODIFIER", 200, 208], ["burden", "OBSERVATION_MODIFIER", 209, 215], ["severe", "OBSERVATION_MODIFIER", 219, 225], ["bronchiolitis", "OBSERVATION", 226, 239]]], ["This descriptive study is a first step and highlights the need for further prospective controlled studies.", [["This descriptive study", "TEST", 0, 22], ["further prospective controlled studies", "TEST", 67, 105]]]]}